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ABSTRACT 
 
 
Cancer prevention and control programs rely on mortality data, from vital statistics, and 
incidence data, provided by population-based cancer registries. In this context, prediction 
models are valuable sources of information, not only to provide future estimates of the burden 
of cancer, but also to suppress the lag between data collection and their publication. 
Esophageal cancer is one of the most lethal cancers, and its public health relevance has 
increased in the last decades due to the steeply increasing incidence trends observed in Western 
countries. Esophageal cancer has two major histological types, squamous cell carcinoma (ESCC) 
and adenocarcinoma (EAC), which present various patterns of incidence trends, reflecting 
differences in their etiologies. Despite the extensive knowledge on the main risk factors for 
esophageal cancer, their joint contribution for the trends in the burden of disease associated 
with esophageal cancer has not been formally assessed. Therefore, we aimed to develop a 
model able to describe and predict the variation in its incidence at a population level, taking into 
account the variation in the exposure to the main modifiable risk factors. Five studies (Papers I-
V) were performed to accomplish the specific objectives necessary for the development of the 
model, which are mentioned below: 
 
Paper I – Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-
2011) and predictions to 2015. 
Paper II – Cancer incidence predictions in the North of Portugal: keeping population-based 
cancer registration up to date. 
Paper III – Trends in gastric and esophageal cancers incidence in Northern Portugal (1994-2009), 
by subsite and histology, and predictions for 2015. 
Paper IV – Modifiable factors and esophageal cancer: a systematic review of published meta-
analyses. 
Paper V – An explanatory and predictive model of the variation in esophageal cancer incidence, 
based on changes in the exposure to risk factors. 
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1. To describe the trends in esophageal cancer incidence, overall and by histological type, in 
different countries, including Portugal (Papers I-III); 
 
Cancer incidence data in Europe (Paper I) were obtained, by sex and age group, from Cancer 
Incidence in Five Continents (CI5) databases and analyzed by histological type. Annual data for 
the period 1980–2002 were derived from the CI5-plus database. Grouped data referring to the 
period 1998–2002 were retrieved from CI5-IX to describe the geographical distribution of 
esophageal cancer histological types across Europe. For countries with more than one cancer 
registry, data were aggregated to ensure the highest geographic coverage. In Northern Portugal 
(Papers II and III), data were retrieved from the North Region Cancer Registry (RORENO) for the 
period 1994-2009. 
Among men, increasing EAC incidence trends were observed in most European countries, while 
ESCC trends have been decreasing or stabilizing over the last few decades. In Northern Europe, 
the increases in male EAC trends were among the steepest observed, and EAC is now more 
frequent than ESCC. In central and southern Europe, smaller rises in EAC were observed and 
ESCC remains the predominant histological type among men. Trends were less stable among 
women, and ESCC was the predominant subtype in all settings. In Northern Portugal, men 
presented an upward trend for ESCC and a decline in EAC, while women had opposite trends; 
the proportion of cases of unspecified histological type was below 10%.  
 
2. To summarize the evidence on the exposure to the different risk factors of esophageal 
cancer in Northern Portugal over the past decades (Paper III); 
 
A review of literature published up to 2014 was performed to evaluate the prevalence of 
tobacco smoking, alcohol drinking, overweight and obesity, H. pylori infection, and fruit and 
vegetable consumption in Northern Portugal. For tobacco smoking, overweight/obesity and H. 
pylori infection, previously published systematic reviews of Portuguese studies were used as the 
primary source of published reports. For the other risk factors, data were collected from national 
health surveys and population-based studies conducted in the region.  
Among adults, the prevalence of smoking decreased for men and increased among women. The 
opposite was observed for alcohol drinking. The prevalence of overweight and obesity increased 
for both sexes, among children and among adults. The prevalence of H. pylori infection increased 
with age, but no clear trend was observed over time. The prevalence of daily consumption of 
fruit and vegetable showed relatively stable trends, with the consumption of fruits being higher 
than that of vegetables among adults. 
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3. To summarize the current scientific knowledge on modifiable risk factors for esophageal 
cancer, by histological type, through a systematic review of published meta-analyses (Paper 
IV); 
 
PubMed and ISI Web of Knowledge were searched up to September 2015 to identify meta-
analyses addressing the association between the main modifiable risk factors and esophageal 
cancer. Each meta-analysis was attributed a quality score, ranging from 0 to 11, based on the 
AMSTAR tool. 
We identified 95 meta-analyses, of which 47 focused on ESCC and 46 on EAC; half of the studies 
had a quality score of 7 or higher. Dose-response effects were found for ESCC regarding alcohol 
consumption and tobacco smoking, and cessation of either exposure significantly reduces the 
risk of ESCC. No significant associations were found between alcohol consumption and EAC. EAC 
risk was found decreasing by 50% in the presence of H. pylori infection, but it increased gradually 
with the increasing frequency and duration of GERD symptoms. A dose-response effect of BMI 
was found for EAC, while it was reported decreasing the risk of ESCC. Dietary aspects were 
extensively assessed in numerous meta-analyses. Increments of 100 g/day in fruit and vegetable 
intake were found decreasing ESCC risk by approximately 40% and 16%, respectively; for EAC, 
corresponding values were of 13% and 9%. Dose-response effects were also reported for red 
and processed meat, which increase the risk of both subtypes. 
 
4. To estimate the contribution of the variation in the exposure to the main risk factors for 
esophageal cancer to changes in its incidence rates between 1995 and 2005, in Northern 
Portugal and in selected countries (Paper V). 
 
We adapted an existing model (IMPACT) to calculate the expected variation in the number of 
esophageal cancer cases, between 1995 and 2005, due to changes in exposures to risk factors, 
taking into account the corresponding lag times. Analyses were based on country-specific data 
of cancer incidence (retrieved from CI5 and RORENO) and exposures to risk factors (collected 
from WHO databases, national health and nutrition surveys, and literature searches). Monte 
Carlo simulation methods were used to compute 95% credibility intervals. 
Absolute deviations between the number of cases predicted and those observed in 2005 ranged 
between 1.8% in Japan and 23.6% in the United Kingdom (UK) among men; 0.0% in Japan and 
18.0% in Australia among women. In Italy and Japan, deviations did not exceed 3%. The UK 
registered the worst model performance. The contribution of each risk factor to the observed 
changes in esophageal cancer incidence varied widely between countries, sexes and cancer 
subtypes. The major contributors to trends in esophageal cancer incidence were changes in fruit 
and red meat intake, and body mass index. For nearly half of the sex- and histological type-
specific predictions performed, the credibility intervals included the observed number of cases 
in 2005. 
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In conclusion, this thesis adds to previous research on this topic a framework for analysis of the 
contribution of the variation in the exposure to different factors known to be associated with 
esophageal cancer, as well as for long-term predictions of ESCC and EAC at a population level. 
The results obtained in this work show the potential of this model for the planning of 
interventions and to define cancer control policies, but future studies, taking into account a 
wider period of time between exposure assessments, while also using more accurate estimates 
of the variation in the exposure to the risk factors, are expected to improve the accuracy of 
predictions. 
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RESUMO 
 
 
Os programas de prevenção e controlo de cancro dependem de dados de mortalidade, 
provenientes de estatísticas oficais, e de dados de incidência, fornecidos por registos 
oncológicos de base populacional. Neste contexto, os modelos de projeção são uma fonte 
valiosa de informação, não só para fornecer estimativas futuras da incidência de cancro,  mas 
também para colmatar o tempo existente entre a colheita de dados e a sua publicação. 
O cancro do esófago é um dos cancros mais letais, e a sua relevância ao nível da saúde pública 
tem aumentado nas últimas décadas devido às tendências de aumento de incidência observadas 
nos países ocidentais. O cancro do esófago apresenta dois tipos histológicos principais, o 
carcinoma de células escamosas (CCEE) e o adenocarcinoma (ACE), que apresentam padrões de 
tendências de incidência distintos que refletem as diferenças das suas etiologias. Apesar do 
amplo conhecimento sobre os principais fatores de risco para o cancro do esófago, a sua 
contribuição conjunta para as tendências da carga da doença associada ao cancro do esófago 
não foi formalmente avaliada. Assim, procurou-se desenvolver um modelo capaz de descrever 
e prever a variação da incidência de cancro do esófago a nível populacional, tendo em conta a 
variação na exposição aos principais factores de risco modificáveis. Foram realizados cinco 
estudos (Artigos I-V) para responder aos objetivos específicos necessários ao desenvolvimento 
do modelo, descritos abaixo: 
 
Artigo I – Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-
2011) and predictions to 2015. 
Artigo II – Cancer incidence predictions in the North of Portugal: keeping population-based 
cancer registration up to date. 
Artigo III – Trends in gastric and esophageal cancers incidence in Northern Portugal (1994-2009), 
by subsite and histology, and predictions for 2015. 
Artigo IV – Modifiable factors and esophageal cancer: a systematic review of published meta-
analyses. 
Artigo V – An explanatory and predictive model of the variation in esophageal cancer incidence, 
based on changes in the exposure to risk factors. 
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1. Descrever as tendências na incidência de cancro do esófago, no global e por tipo histológico, 
em diferentes países, incluindo Portugal (Artigos I-III); 
Foram obtidos dados de incidência na Europa (Artigo I), por sexo e grupo etário, usando as bases 
de dados das publicações Cancer Incidence in Five Continents (CI5), que foram analisados por 
tipo histológico. A base de dados CI5-plus foi usada para a recolha de dados anuais para o 
período 1980-2002. Foram também recolhidos dados agregados relativos ao período 1998-
2002, usando a publicação CI5-IX, para descrever a distribuição geográfica dos tipos histológicos 
de cancro do esófago na Europa. Para os países com mais do que um registo oncológico, os 
dados foram agrupados para garantir a maior cobertura geográfica possível. No Norte de 
Portugal (Artigos II e III), os dados foram obtidos do Registo Oncológico Regional do Norte 
(RORENO), para o período 1994-2009. 
Nos homens, foram observadas tendências crescentes da incidência de ACE na maioria dos 
países europeus, enquanto as tendências do CCEE têm vindo a diminuir ou estabilizar ao longo 
das últimas décadas. No Norte da Europa, os aumentos nas tendências de ACE no sexo masculino 
foram dos mais marcados, e o ACE é atualmente mais frequente do que o CCEE. Na Europa 
Central e do Sul, foram observados aumentos menos marcados para o ACE, e o CCEE permanece 
o tipo histológico predominante no sexo masculino. As tendências foram menos estáveis entre 
as mulheres, sendo o CCEE o subtipo predominante em todos países. No Norte de Portugal, os 
homens apresentaram uma tendência crescente para o CCEE e decrescente para o ACE, 
enquanto que as mulheres apresentaram tendências opostas; a proporção de casos com tipo 
histológico não especificado foi inferior a 10%. 
 
2. Sumariar a evidência sobre a exposição a diferentes fatores de risco de cancro do esófago no 
Norte de Portugal nas últimas décadas (Artigo III); 
Foi realizada uma revisão da literatura publicada até 2014 para avaliar a prevalência de consumo 
de tabaco, consumo de álcool, excesso de peso e obesidade, infecção por H. pylori, e consumo 
de frutas e vegetais no Norte de Portugal. Para o consumo de tabaco, excesso de peso e 
obesidade e infecção por H. pylori, foram usadas revisões sistemáticas de estudos portugueses 
previamente publicadas como fonte primária de estudos elegíveis. Para os outros fatores de 
risco, os dados foram recolhidos a partir dos inquéritos nacionais de saúde e estudos de base 
populacional realizados na região. 
Nos adultos, a prevalência de consumo de tabaco diminuiu nos homens e aumentou nas 
mulheres. O oposto foi observado para a prevalência de consumo de álcool. A prevalência de 
excesso de peso e obesidade aumentou para ambos os sexos, nas crianças e nos adultos. A 
prevalência de infecção por H. pylori aumentou com a idade, mas foi detetada uma tendência 
clara ao longo do tempo. As prevalências de consumo diário de frutas e vegetais apresentaram 
uma tendência relativamente estável, sendo o consumo de frutas superior ao dos vegetais entre 
os adultos. 
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3. Sumariar o conhecimento científico atual sobre os fatores de risco modificáveis do cancro do 
esófago, por tipo histológico, através de uma revisão sistemática de meta-análises (Artigo IV); 
Foram utilizadas as bases da PubMed e ISI Web of Knowledge para identificar meta-análises 
publicadas até setembro de 2015, que avaliassem a associação entre os principais fatores de 
risco modificáveis e o cancro do esófago. Foi atribuído um score de qualidade a cada meta-
análise, entre 0 e 11, com base na ferramenta AMSTAR. 
Foram identificadas 95 meta-análises, das quais 47 avaliaram o CCEE e 46 o ACE; metade dos 
estudos tiveram um score de qualidade igual ou superior a 7. Foram encontrados efeitos dose-
resposta para o CCEE relativamente ao consumo de álcool e de tabaco, e a cessação de qualquer 
uma dessas exposições reduzia significativamente o risco de ESCC. Não foram encontradas 
associações significativas entre o consumo de álcool e o ACE. Foi detetada uma diminuição de 
50% no risco de ACE na presença de infecção por H. pylori, mas um aumento gradual  com a 
frequência e duração dos sintomas de refluxo gastroesofágico. Foi descrito um efeito dose-
resposta do índice de massa corporal em relação ao aumento do risco de ACE e, 
simultaneamente, de diminuição do risco de CCEE. Os aspetos ligados à alimentação foram 
amplamente avaliados em várias meta-análises. Foi estimado que um aumento de 100 g/dia na 
ingestão de frutas e vegetais diminuia o risco de CCEE em 40% e 16%, respetivamente; para o 
ACE, os valores correspondentes foram de 13% e 9%. Foram também descritos efeitos dose-
resposta de aumento do risco para ambos os subtipos em relação a carne vermelha e carne 
processada. 
 
4. Estimar a contribuição das mudanças na exposição aos principais fatores de risco para o 
cancro do esófago para as variações encontradas nas taxas de incidência entre 1995 e 2005, no 
Norte de Portugal e em países seleccionados (Artigo V). 
Foi adaptado um modelo previamente existente (IMPACT) para calcular a variação esperada no 
número de casos de cancro de esófago, entre 1995 e 2005, devida a mudanças na exposição a 
fatores de risco, tendo em conta o tempo que decorre entre a exposição e o outcome. A análise 
estatística foi baseada em dados específicos de cada país relativos à incidência de cancro 
(recolhidos do CI5 e do RORENO) e à exposição a fatores de risco (recolhidos de bases de dados 
da Organização Mundial de Saúde, inquéritos nacionais de saúde e de nutrição e pesquisas 
bibliográficas). Foram usados métodos de simulação de Monte Carlo para calcular intervalos de 
credibilidade a 95%. 
Os desvios, em módulo, entre o número de casos previsto e o observado em 2015 variaram 
entre 1,8% no Japão e 23,6% no Reino Unido no sexo masculino e entre 0,0% no Japão e 18,0% 
na Austrália no sexo feminino. Na Itália e no Japão, os desvios não excederam os 3%. O Reino 
Unido registrou o pior desempenho do modelo. A contribuição de cada fator de risco para as 
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alterações observadas na incidência de cancro do esófago variaram amplamente entre países, 
sexos e subtipos histológicos. Os fatores mais determinantes para as variações na incidência de 
cancro do esófago foram alterações no consumo de frutas e de carne vermelha, e variações no 
índice de massa corporal. Os intervalos de credibilidade incluiram o número de casos observados 
para quase metade das estimativas efetuadas por tipo histológico e por sexo. 
 
Em conclusão, esta tese apresenta uma metodologia para a análise da contribuição da variação 
da exposição a diferentes fatores de risco na variação da incidência de cancro do esófago, bem 
como para projeções a longo prazo para o CCEE e o ACE a nível populacional. Os resultados 
obtidos neste trabalho mostram o potencial deste modelo para o planeamento de intervenções 
e definição de políticas de controlo do cancro, mas espera-se que estudos futuros, efetuados 
para previsões a mais longo prazo, usando simultaneamente estimativas mais precisas da 
variação na exposição aos factores de risco, possam melhorar a validade das estimativas.   
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INTRODUCTION 
 
 
Prediction models are a valuable source of information for policies aiming to control and reduce 
the burden of disease in a given population. Since public health interventions heavily rely on 
adequate data supporting their need and cost-effectiveness, the collection of population-based 
information, along with scientific knowledge on the causes of a disease and their underlying 
mechanisms are of major importance. In the context of cancer research, several prediction 
methods have been developed, with a wide range of complexity regarding both the 
mathematical models involved and the level of detail of the data required. 
As cancer is a worldwide public health issue, many countries have national programs specifically 
targeting this disease. For their definition and evaluation, cancer prevention and control 
programs often rely on mortality data, from vital statistics, and incidence data, provided by 
regional or national population-based cancer registries, after the collection and treatment of the 
information on cancer cases occurring in their coverage area. Although there are no formal 
guidelines for the timeliness of cancer registry data, several North American agencies 
(particularly those providing funding via contracts) have set a two- to three-year standard for 
relevant registries, namely the Surveillance, Epidemiology, and End Results (SEER) Program, 
Centers for Disease Control and Prevention/National Program of Cancer Registries, and the 
North American Association of Central Cancer Registries[1]. However, worldwide there is a large 
heterogeneity between cancer registries regarding the most recent year of incidence data 
available[2], which enhances the usefulness of prediction models, not only for long-term 
predictions of the burden of cancer, but also to suppress the lag between data collection and 
their publications. 
Globally, cancer incidence has been rising over time, mainly due to the increase in life 
expectancy, the aging of the population and changes in the exposure to risk factors[3]. However, 
cancers occurring in different anatomical sites present diverse etiologies, as well as different 
rates of improvement in early detection and treatment, which leads to various patterns of 
incidence and mortality trends. Esophageal cancer is one of the most lethal cancers, with five-
year survival rates of 17% being reported in the United States of America (USA) and 12% in 
Europe[4, 5]. Furthermore, the public health relevance of this cancer has increased in the last 
decades due to the steeply increasing incidence trends observed in Western countries, which 
are usually considered to be of low-risk for esophageal cancer[6]. 
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EPIDEMIOLOGY OF ESOPHAGEAL CANCER 
 
PATHOLOGY AND NATURAL HISTORY 
Esophageal cancer presents with two major histological types, squamous cell carcinoma (ESCC) 
and adenocarcinoma (EAC). Sarcomas and small cell carcinomas rarely occur, comprising less 
than 1-2% of all esophageal cancer cases[4]. ESCC most often arises in the middle third of the 
esophagus, followed by the lower and the upper third, while EAC usually develops in the lower 
third. The etiology of the two subtypes appears to differ substantially, which translates into very 
diverse patterns regarding incidence rates and trends. Understanding the pathogenesis and 
biologic nature of their precursor lesions, which can be observed in the esophageal epithelium 
during neoplastic progression, is useful to avoid or treat esophageal malignancies. 
Although precursor lesions of ESCC are not particularly well defined, transition models, 
especially in high-risk populations, have described inflammation in squamous epithelium to 
cause dysplasia, ultimately leading to in situ or invasive tumors[7, 8]. 
It is well accepted that EAC develops through a multistep transformation of the epithelium of 
the esophagus (Figure 1). Barrett’s esophagus (BE), or columnar lined esophagus, is a 
premalignant condition that results from chronic gastroesophageal reflux (GERD) and 
predisposes to EAC. GERD occurs when the lower esophageal sphincter does not close properly, 
allowing acid to back up into the esophagus; when this reflux occurs frequently, it may lead to 
esophagitis, narrowing of the esophagus, bleeding, and dysphagia, which may cause BE; a 
greater duration and frequency of GERD symptoms, which include heartburn, regurgitation and 
dysphagia, have been found to further increase the risk of BE[9]. BE is usually diagnosed by 
biopsy, during upper gastrointestinal endoscopy for the assessment of GERD. Although some 
studies have suggested an upward trend in the population-based prevalence of BE, part of this 
increase likely reflects an increased detection through the wider use of upper gastrointestinal 
endoscopy in more recent years[10]. BE is characterized by the metaplastic replacement of the 
normal squamous epithelium of the lower esophagus by columnar epithelium, which may then 
progress through low- and high-grade dysplasia to the development of EAC[11]. 
 
 
 
Figure 1. Neoplastic progression from normal esophageal epithelium to esophageal adenocarcinoma (EAC) (adapted from Wild[11]). 
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Dysplasia is considered to be present when there are architectural and cytological changes 
severe enough to suggest neoplastic transformation. The definition of low- or high-grade 
dysplasia is based on the magnitude of changes, which are especially relevant if they involve the 
mucosal surface[12].Progression from BE to high-grade dysplasia and from high-grade dysplasia 
to EAC has been estimated to lag 9-13 years and 3-4 years, respectively[13]. 
The risk of EAC in BE patients has been estimated to be 30- to 60-fold higher than in the general 
population, and 0.5% to 1% are expected to progress to EAC per year[14-16]. These imprecise 
estimates are due to the fact that most studies have followed a small number of individuals, for 
short periods of time, finding few incident EAC cases; some cohort studies have also included 
patients referred to a specialist center, which may have led to the inclusion of more cases of 
high-grade dysplasia than would be observed in the general population[17]. The length of the 
esophagus showing metaplastic changes also influences the risk of EAC, with individuals with 
long-segment BE (LSBE) (≥ 3 cm in length) being at higher risk than the ones with the more 
common short-segment BE (SSBE)[9]. A systematic review of studies published up to 2008 
showed that GERD symptoms were not associated with SSBE, while increasing the odds of LSBE 
by five-fold[18]. This may contribute to explain the lower risk of EAC in SSBE patients. Other risk 
factors for BE include obesity, alcohol drinking and tobacco smoking, while a protective effect 
has been reported regarding Helicobacter pylori (H. pylori) infection[9]. 
Concomitantly to the metaplasia–dysplasia–adenocarcinoma sequence, several studies have 
showed the accumulation of genetic abnormalities in the transition from normal cells to 
malignant ones[19, 20]. Some of these genetic changes, namely variations in DNA ploidy, increased 
proliferation and alterations of the p53 gene, have been proposed as potentially helpful for 
screening and surveillance of patients with BE[12, 21]. However, to date none of the proposed 
biomarkers has been prospectively validated[9] and the most recent guidelines from the 
American Gastroenterological Association recommend against their usage for risk stratification 
of patients[22]. 
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GEOGRAPHIC VARIATION 
Esophageal cancer ranks as the eighth most common malignancy in the world and the sixth 
leading cause of death from cancer[6, 23]. However, the burden of esophageal cancer varies widely 
across geographical regions (Figure 2). According to the most recent estimates provided by the 
GLOBOCAN Project, esophageal cancer accounted for approximately 456 000 new cases, 
comprising 3.2% of all cancers (4.3% among men and 2.0% among women) and 400 000 deaths 
(6.0% of all cancer deaths among men and 3.4% among women) in 2012[23]. 
 
Figure 2. Worldwide age-standardized (World standard population) incidence and mortality rates per 100 000 of esophageal cancer 
in 2012 (source: Ferlay[23]). 
 
In 2012, among men, the age-standardized (World standard population) incidence rates (ASIR) 
per 100 000 varied between 6.4 in more developed countries and 10.1 in less developed 
countries, while among women rates varied between 1.2 and 4.1[23]; the male/female ratio 
ranged between 1.0 in Western Africa and 15.5 in Micronesia and Polynesia. Approximately 80% 
of esophageal cancer cases occurred in less developed countries, with ASIR being 1.6 and 3.4 
times higher than the ones observed in more developed countries, among men and women, 
respectively. 
The geographical area commonly referred to as the “esophageal cancer belt,” which extends 
from Northern Iran and Central Asia to Northern and Western China, has been described, 
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together with some areas of Southern Africa, as having the highest ASIR and age-standardized 
(World standard population) mortality rates (ASMR) worldwide[24]. In 2012, the countries with 
the highest ASIR were Malawi (24.2/100 000) and Turkmenistan (19.7/100 000), followed by 
Kenya and Mongolia (17.6/100 000)[23]. Among men, ASIR in Eastern Asia (17.0/100 000) were 
over 20-fold the ones estimated for Western Africa (0.8/100 000) and 10-fold the ones in Central 
America (1.7/100 000)[23]. Among women, the largest difference was observed between Eastern 
Africa (7.8/100 000), and Micronesia/Polynesia (0.2/100 000). 
In the so-called low-risk settings, there are also relevant variations in incidence and mortality 
rates. In the USA, where esophageal cancer is the seventh leading cause of death from cancer, 
and an ASIR of 3.2 was estimated for 2012[23], some notably high ASIR have been described in 
coastal areas of Southern Carolina, especially among black men[25]. In Europe, the highest ASIR 
among men have been reported in the United Kingdom (UK) and the Netherlands, whereas the 
lowest were observed in Georgia; among women, the highest ASIR have also been detected in 
the UK, while the lowest were found in Greece, Macedonia and the Republic of Moldova[26]. The 
UK also presented the highest ASMR in Europe for both sexes, followed by the Netherlands 
among men and Ireland among women[26, 27]. In Portugal, where some of the highest ASMR in 
Europe have been observed among men[26], esophageal cancer was the tenth most common 
cancer in 2010, with an ASIR of 5.5 and 0.7 per 100 000, among men and women, respectively[28]. 
However, there was a wide geographical distribution of cases within the country, with the 
highest ASIR being observed in the Northern Region (6.5 and 0.8 among men and women, 
respectively) (Figure 3). 
 
Men  Women 
 
 
 
 
Figure 3. Geographic distribution of age-standardized (World standard population) incidence rates (ASIR) of esophageal cancer in 
Portugal, by sex (source: RORENO[28]). 
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In the high-risk areas for esophageal cancer, the predominant histological type is ESCC, which 
comprises approximately 90% of all cases diagnosed[29]. In settings considered to be of low-risk 
for esophageal cancer, the most frequent histological type varies between countries. Although 
EAC used to account for less than 15% of esophageal cancer cases, and this is still the situation 
for most populations, EAC has recently become the most common subtype in some Western 
countries, after an increase greater than the observed for any other cancer[30]. In the USA, EAC 
incidence increased by seven-fold between 1975 and 2006, and it now represents over 60% of 
all esophageal cancer cases[31]. In Europe, the UK and Nordic countries have also observed a 
steep increase in EAC incidence and it has become the predominant subtype in those settings, 
unlike Southern Europe, where ESCC remained the most common subtype until 1998[27]. 
Most esophageal cancer patients are diagnosed at an advanced stage of the disease, and 
although improvements have been described in some settings, five-year relative survival rates 
are usually below 20%[32]. In the USA, using information from 18 SEER geographic areas, the five-
year relative survival in 2002-2008 was 16.9%, with higher rates being observed among white 
than black individuals, for both sexes[4]; however, a trend analysis by stage at diagnosis showed 
that survival increased from 33.5% to 47.8% for localized, from 9.4% to 20.7% for regional and 
from 1.9% to 2.9% for distant staged tumors, between 1992-1995 and 2000-2007[33]. In Europe, 
the EUROCARE-5 Project reported a five-year relative survival of 12.4% in 1999-2007, with an 
increase being reported between 1999-2001 and 2005-2007, from 9.9% to 12.6%[5]. Central 
Europe presented the highest survival in 1999-2007, while Eastern Europe had the lowest. These 
regions also had the biggest and smallest differences in five-year relative survival between the 
periods 1999-2001 and 2005-2007, of 4.3% and 0.8%, respectively[5]. 
Since esophageal cancer is a disease of poor prognosis, the measures of burden that evaluate 
disability show similar geographic and time patterns to the ones observed for mortality. Thus, 
the highest rates of disability-adjusted life years (DALYs) - computed based on the number of 
years of life lost (YLL) due to premature mortality in the population and the number of years lost 
due to disability (YLD) for people living with the disease or its consequences - are also observed 
in regions of high incidence[3]. Moreover, the Institute for Health Metrics and Evaluation 
estimated that the YLL component accounted for 98.7% of the DALYs worldwide, and that China 
alone contributed for 42.6% of the total DALYs related to esophageal cancer[34]. 
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RISK FACTORS 
Esophageal cancer risk is highly dependent on the age, sex and race of individuals. It is rarely 
diagnosed in children and young adults, becoming more frequent in the age groups above 45 
years; rates increase exponentially with age until approximately age 60, showing a more modest 
increase thereafter[25]. As it was previously described, this cancer occurs more frequently among 
men than women, with male/female ratios often surpassing three-fold and reaching values of 
8:1 for EAC, among white people[9]. The reasons for the gender disparity in EAC are not fully 
understood, but a greater proportion of abdominal fat or some unidentified influences of 
estrogen or testosterone on cancer development have been pointed out as possible 
explanations[35, 36]. Esophageal cancer also shows notorious racial and ethnic differences in 
incidence and mortality, which vary according to cancer subtype. In the USA, rates of EAC are 
higher among white than black men by more than three-fold, with white males also presenting 
a steeper increase in EAC incidence than black males[25], whereas for ESCC the rates among black 
men are over five-fold the ones observed among the white [37]. 
Regarding modifiable risk factors, several studies have assessed their effects on esophageal 
cancer incidence and mortality[6]. The contributions of each exposure to the occurrence of a 
specific outcome may be quantified using population attributable fractions (PAFs) which, by 
definition, constitute the proportional reduction in population disease or mortality that would 
occur if the exposure to a risk factor were reduced to a counterfactual scenario (e.g., no tobacco 
use). 
 
Table 1. Individual and joint contributions of risk factors to mortality and burden of disease from esophageal cancer (source: 
Ezzati[38]). 
Outcome Risk factor World 
Low- and middle-
income 
High-income 
Mortality 
Alcohol use 26% 24% 41% 
Smoking 42% 37% 71% 
Low F&V intake 18% 19% 12% 
Joint PAF 62% 58% 85% 
DALYs 
Alcohol use 27% 25% 43% 
Smoking 42% 39% 71% 
Low F&V intake 19% 20% 13% 
Joint PAF 63% 60% 86% 
F&V: fruit and vegetable; PAF: population attributable fraction; DALYs: disability-adjusted life 
years. 
 
Table 1 depicts the individual and joint PAFs for three of the most commonly mentioned risk 
factors for esophageal cancer, namely alcohol drinking, tobacco consumption, and low fruit and 
vegetable (F&V) intake, as provided by the Global Burden of Disease Project for the year 2001[38]. 
The outcomes represent the percentage of burden measured as DALYs and deaths from cancer. 
Since separate risk factors can interact in their effect on the overall risk of disease, the sum of 
18 | Defining predictive models of the variation in esophageal cancer incidence 
individual PAFs may exceed 100%. When considering each risk factor individually, the highest 
PAFs were observed for smoking, and the lowest for insufficient F&V intake. Once again, the 
burden of disease measured as the number of DALYs yielded similar results to that of mortality 
from esophageal cancer, because of the high lethality of the disease. According to these 
estimates, in high-income countries, if smoking were reduced to the theoretical minimum risk 
exposure (defined as a prevalence of 0%), the burden of esophageal cancer would be 71% lower, 
while in the low- and middle-income region that proportion would be 39%. For alcohol drinking, 
the corresponding values would be 43% and 25%, respectively. For F&V intake, which had 600 
grams/day as the theoretical minimum risk exposure, PAFs were higher for the low- and middle-
income region, which means that a higher proportion of esophageal cancer cases in that region 
could be prevented through an adequate consumption of F&V than in the high-income region. 
Although worldwide statistics of the burden of esophageal cancer attributable to modifiable risk 
factors are mainly, if not only, provided for esophageal cancer as a whole, the diverse etiologies 
of ESCC and EAC subtypes should be taken into consideration for a proper evaluation of the 
burden of disease in different settings. 
The main risk factors for ESCC occurrence are tobacco smoking and alcohol consumption[4, 39]. A 
collaborative, population-based study undertaken in 1997 has reported that the risk of 
developing ESCC is more than five times higher among current smokers and almost three times 
higher among ex-smokers, when compared to never smokers[40]. A more recent study showed 
that both the duration and intensity of smoking are independently associated with ESCC, and 
that the cancer risk among ex-smokers remains higher for up to 30 years after cessation, even 
though the magnitude of the risk reduction was approximately 15-20% for every 10 years post 
smoking cessation[41]. Regarding alcohol consumption, the International Agency for Research on 
Cancer (IARC) Monograph published in 2010 provided consistent epidemiologic evidence that it 
is causally related to ESCC, while there is little or no association with EAC[42]. For ESCC, several 
studies have shown a dose-response relationship[32, 43]. A meta-analysis conducted in 2011, 
including 40 retrospective case-control and 13 prospective studies, estimated the relative risk 
for the association between ESCC and light, moderate and heavy alcohol drinking as 1.31, 2.27 
and 4.89, respectively, although a significant publication bias was suggested by the results 
regarding heavy alcohol intake towards an overestimation of the results in this group[44]. The 
biologic effects of alcohol intake on the risk of digestive tract cancers depend on the individual’s 
genotype. Individuals with the ALDH2 (aldehyde dehydrogenase 2) Lys487 allele have a 
deficiency of ALDH2, leading to a higher risk of esophageal cancer than that observed in 
individuals with no deficiency and consuming the same amount of alcohol[6]. Regarding tobacco 
smoking, studies have shown a strong association between tobacco-specific N'-
nitrosonornicotine (NNN) and esophageal cancer risk, suggesting it as a causative agent for 
esophageal cancer among tobacco users[45]. In addition to the independent effects of smoking 
and alcohol drinking on ESCC, studies have also shown a synergistic effect of these 
determinants[46]. In the USA and other Western countries, more than 90% of ESCC cases have 
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been attributed to smoking and alcohol consumption[16, 39]. However, these factors seem to be 
less important for the burden of cancer in some high-risk areas of China and Iran[47, 48]. In these 
regions, the prevalence of exposure to smoking and alcohol is low[49], and other suggested risk 
factors include poor nutrition, the consumption of beverages at high temperatures and the use 
of opium[39, 48, 50, 51]. 
The consumption of fruits and vegetables has been described as a protective factor for the 
occurrence of ESCC[52]. This has led to trials evaluating the inhibitory effect of supplements or 
micronutrients on tumor growth, in areas with high incidence rates. One of the largest studies 
was conducted in Linxian, China, involving approximately 30 000 individuals, randomized to 
receive specific combinations of vitamins and minerals[53]. After five years of supplementation, 
mortality rates decreased by 13% among those receiving a combination of beta-carotene, 
vitamin E and selenium. Another trial in the same area, on 3 000 individuals with dysplasia, 
found a decrease in mortality from a supplementation using several vitamins and minerals[54]. 
Although other studies have found no reduction in the prevalence of esophagitis[55, 56], evidence 
suggests that improvements in nutrition may contribute to lower esophageal cancer incidence. 
Most studies on the association between socioeconomic status and esophageal cancer have 
been conducted in high-risk populations, and evidence shows that socioeconomic status is 
inversely associated with ESCC, while inconsistent results have been found for EAC[16, 57, 58]. 
A strong association between GERD symptoms and EAC has been described, with estimated 
odds ratios (OR) ranging from 5 to more than 40[15, 31, 59], a variability that reflects the increase 
in risk with the duration, frequency and severity of symptoms. Given the markedly increased risk 
of EAC among GERD patients, and the influence that GERD also has on the development of BE, 
some authors have suggested chemopreventive measures to hinder the transition from normal 
squamous epithelium to EAC. Although conflicting results have been found between some 
observational studies[60, 61], an inverse association between the use of nonsteroidal anti-
inflammatory drug (NSAID) and the risk of EAC has been found in several systematic reviews[62, 
63]. H2 receptor antagonists (H2 blockers), such as cimetidine and ranitidine, reduce acid 
production in the stomach, which may reduce the risk of EAC by decreasing the acid content in 
GERD. However, they may also increase risk by neutralizing the gastric pH, leading to the 
proliferation of bacteria in the stomach and an increasing production of carcinogens including 
nitrosamines and acetaldehyde. Several studies have evaluated the effect of H2 blockers on EAC 
risk, but results were inconclusive, with authors suggesting confounding by reflux[64-66]. More 
recently, studies focusing on proton pump inhibitors have suggested a decreasing risk of EAC 
with their use, although evidence on this association is still limited[60, 67]. Inconsistent results 
were also found regarding medications that relax the lower esophageal sphincter, such as 
calcium channel blockers and benzodiazepines, which might increase EAC risk[16]. 
Regarding obesity, a strong and dose dependent association with EAC has been observed, 
independent of GERD[14]. The systemic inflammatory state led by the altered metabolism of 
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obese patients, and the associated impact of adipocytokines and pro-coagulant factors released 
by adipocytes in central fat, has been proposed as an explanation for the association between 
obesity and EAC[68]. Parallel trends of the prevalence of overweight and obesity to those 
observed for EAC incidence further support the idea that obesity is a central driver of BE and 
EAC rates[68]. 
The association between smoking and EAC is much weaker than that of ESCC[69]. A meta-analysis 
conducted in 2011 on the relation between EAC and tobacco smoking yielded relative risks of 
1.8, 2.3 and 1.6, respectively for ever, current and ex-smokers, in comparison with never 
smokers[70]. Furthermore, the authors have found a direct association with dose and duration of 
cigarette consumption. A population-based case-control study assessed the effect of smoking 
cessation in EAC risk and showed that the risks among ex-smokers remained considerably high 
until 20 years after cessation, although no evidence was found that smoking intensity influenced 
the risk of EAC[41]. 
Reviews published in 2003 and 2007, respectively by IARC and by the World Cancer Research 
Fund and the American Institute for Cancer Research, found an inverse association between F&V 
intake and esophageal cancer risk, especially when considering case-control studies[71, 72]. Few 
prospective studies have investigated the effect of F&V intake on EAC and ESCC separately, and 
the association seemed weaker for EAC[73, 74]. On the other hand, consumption of meat and high-
fat meals has been found to be positively associated with EAC[72, 75]. 
H. pylori infection is also inversely associated with the occurrence of EAC, regardless of other 
environmental and genetic exposures[76], and the decline in the prevalence of this infection may 
have contributed to an increase in EAC incidence. The mechanism through which H. pylori 
infection reduces the risk of EAC is not clear, but studies have suggested that the bacteria could 
decrease gastric acid secretion by acting on parietal cells or through chronic inflammation[77]. 
Since tumors arising in the cardioesophageal junction are classified as cardia cancers, according 
to the International Classification of Diseases for Oncology[78-80], the increasing awareness of EAC 
may also have led to the increase in its incidence trends, through a misclassification of gastric 
cardia cancers[81]. However, in some settings, the incidence of cardia cancer is also increasing, 
and countries with the highest cardia rates present the highest EAC rates, so this 
misclassification should be further assessed for the clarification of observed trends[14, 81, 82]. 
The evidence summarized here suggests that there is room for lowering the worldwide burden 
of disease related to esophageal cancer through the implementation of public health strategies 
to reduce risk in specific populations. Once the most important modifiable risk factors are 
defined, the evaluation of potential interventions should take into account their joint effect on 
the current and future burden of disease in each setting. 
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METHODS FOR PREDICTION OF THE BURDEN OF CANCER 
 
Predictions of cancer incidence and mortality can be used to better inform decision-making 
policies, and aid in the efficient allocation of resources to meet short-term needs for cancer 
prevention, detection and treatment. However, since past trends will not necessarily persist in 
the future, a certain level of uncertainty is present in all projected values[83]. 
Several statistical methods have been used to predict the future burden of cancer. The simplest 
methods are usually applied in order to obtain short-term predictions (e.g., up to five years past 
diagnosis), by assuming the persistence of past rates or trends into the future. However, 
predictions over a longer term require more complex models, which aim to quantify the 
contribution of specific variables to the observed changes in the past, while making assumptions 
about the extent to which past changes are likely to influence the future. This increasing 
complexity in the models used for cancer prediction depends on the level of detail in data 
available for analyses (Figure 4). 
In this section, the rational for different types of prediction models is presented, discussing their 
advantages and shortcomings. 
 
 
Figure 4: Increasing complexity of prediction models depending on data availability (adapted from Bray[83]). 
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APPLICATION OF CURRENT INCIDENCE RATES TO FUTURE POPULATION ESTIMATES 
The simplest method to perform predictions, which is used by the GLOBOCAN Project[84], is the 
direct application of current incidence or mortality rates to the future expected population in 
the year of interest. Age is the most important time-related variable that influences cancer 
risk[83]. In GLOCOBAN 2012, the expected number of new cancer cases or deaths in a 
country/region in 2015-2035 was computed by multiplying the age-specific incidence and 
mortality rates estimated for 2012, by the expected population for 2015-2035. This expected 
population differs from that of the baseline year in terms of age structure and size. 
Although the assumption that past rates will remain in future years may hold true in short-term 
predictions and for specific cancer sites, it is arguable that this will remain accurate in the longer-
term ones. This method does not accommodate for changes in trends over time, leading to an 
underestimation of future incidence or mortality rates in cases of upward trends, and an 
overestimation in the opposite situation. However, since no reliable information regarding past 
trends is available for analysis in several regions in the world[85], it poses as the only solution for 
performing cancer incidence predictions worldwide. 
 
AGE-PERIOD-COHORT AND AGE-PERIOD MODELS 
Period effects relate to events that change incidence and mortality in a similar manner across 
all age groups. Examples of such events include changes in classification criteria, for incidence, 
or advances in treatment, for mortality. Cohort effects cause changes in incidence and mortality 
rates from one generation to another that are consistent across age groups. Many lifestyle 
factors, such as tobacco smoking, sexual and reproductive behaviors, are influenced by the date 
of birth, and cohort effects have an important role in the confirmation/refutation of putative 
etiological factors from other studies[83]. The application of an age-period-cohort (APC) model to 
perform predictions usually involves estimating the underlying age-, period- and cohort-specific 
trends and projecting them into the future using a Poisson regression model. Since the three 
components are codependent (e.g., for a given date of birth and age, the time period is locked), 
such models allow for the estimation of the average increase/decrease over time, but do not 
allow to disentangle the variations due to period effects from those of cohort effects. This 
average underlying trend, common to both period and cohort components, is named the 
“drift”[86]. 
From tabulated data using five-year age groups and five-year calendar periods, birth cohorts are 
obtained by subtracting age from period. The APC model can be written as: 
𝑅𝑎𝑝 = exp⁡(𝐴𝑎 + 𝐷. 𝑝 + 𝑃𝑝 + 𝐶𝑐), where 𝑅𝑎𝑝 is the incidence rate in age group 𝑎 and calendar 
period 𝑝; ⁡𝐴𝑎 is the age component for age group 𝑎; 𝐷 is the drift; 𝑃𝑝 is the non-linear period 
component of period 𝑝; and 𝐶𝑐 is the non-linear cohort component of cohort 𝑐. 
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A problem with this function of the APC model is that it yields exponentially growing predictions 
which are unrealistic for some cancer types. A proposed solution for this limitation, developed 
in Nordic European countries, was a power model which reduces the predicted rates growth by 
replacing the exponential x by the functional form x5. This method, called Nordpred, was found 
to improve predictions by a comparative study of different approaches[87], and has been widely 
used since[88, 89]. 
The Nordpred method has been used by the World Health Organization (WHO) Mortality 
Database to perform long-term predictions[90]. For each combination of country, cancer, sex and 
the latest year of observation, the model requires at least 15 consecutive years of data (in order 
to build three five-year periods), with a minimum of 100 deaths recorded per five-year period 
to allow for stability in the results, and predicts up to five five-year periods (25 years ahead). The 
results are presented by age group and for all ages combined. For each predicted period, the 
online tool then divides the number of predicted deaths in two parts: one due to changes in risk 
of dying from cancer, and another due to changes in the population size and structure[90]. 
For cancers with a small number of cases, a Bayesian approach has also been proposed for the 
application of an APC model[91]. With this methodology, the parameters of the usual APC model 
are assessed through their credibility intervals, instead of being considered as fixed values. 
When long-term data are not available for analysis, it is difficult to evaluate cohort patterns 
through an APC model[83]. For these situations, there are simpler models which have been 
derived by Dyba and Hakulinen, the so-called DH models, using only the age and period 
components[92, 93]. The underlying assumptions of the proposed models are as follows: future 
cancer trends can be modelled by extrapolating a historic trend; there are enough years of data 
available to allow for the estimation of models which incorporate age- and sex-specific trends; 
the numbers of cases/deaths in each age, sex and time period stratum follow a Poisson 
distribution. Additionally, when historic trends (of age-standardized rates) are decreasing, a log-
linear model is suitable to estimate the average rate; otherwise, a linear model is used to avoid 
exponential growth. Although these models do not include the cohort component, they have 
also shown a good performance when compared to other methods[87] and are used by the WHO 
Mortality Database to perform short-term predictions (up to five years past the year of 
death)[90]. 
Another example of an age-period model is the Joinpoint software, even though it has been 
mainly applied to detect significant changes in cancer trend analyses[94]. In this method, cancer 
incidence and mortality rates are modeled based on the least squares method as a function of 
time, which is composed of piecewise linear segments, connected at the so-called "joinpoints". 
The program starts by adjusting a straight line (e.g., 0 joinpoints) to the trend data and 
progressively tests the statistically significance of adding more joinpoints to the model, up to 
the maximum number defined by the user. The tests of significance use a Monte Carlo 
Permutation method[95]. The models may incorporate estimated variation for each point or use 
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a Poisson model of variation. Fitted models may be linear or log-linear, the latter being useful to 
calculate annual percentage rate changes. The software then provides the point and interval 
estimates of the slope parameters, allowing for the extrapolation of observed trends into the 
future. 
 
THE STATE-SPACE MODEL 
The State-Space model (SSM) has been used in the USA by the National Cancer 
Institute/American Cancer Society to predict cancer mortality three years ahead of the current 
calendar year since 2004[96]. It consists of two main steps: a measurement equation and the 
transition equation[97]. First, the model assumes that the number of deaths follows a linear 
model with time-varying coefficients, which also follow a linear model. This yields a quadratic 
trend over short segments of time. Second, a transition equation is used to model the year-to-
year variation of the parameters (or states). Random errors are incorporated in both equations, 
with error variances being estimated from the data[98]. The measurement and the transition 
equations are combined to obtain the full specification of the SSM. The model is then projected 
three years into the future, yielding the number of deaths and corresponding 95% prediction 
intervals. 
Due to the time-varying coefficients considered by the SSM, it can adjust to unexpected changes 
observed in the data, being more flexible than a standard regression model. However, the 
sensitivity of the SSM to these changes can be a limitation when they are due to random 
variations. To overcome this problem, two additional parameters – which are estimated by 
minimizing the sum of squares of the differences between the observed number of deaths and 
their three-year-ahead predictions – are included in the model, to refine the calculation of error 
variances[96]. 
 
MICRO-SIMULATION MODELS 
Mathematical models are powerful tools which can be used to perform predictions by 
systematically aggregating available data. However, a major criticism to this methodology is that 
independent modeling efforts frequently produce contrasting results. Generally, these 
differences are due to diverse model inputs and configurations, as well as to the lack of 
transparency in model assumptions. In the USA, the Cancer Intervention and Surveillance 
Modeling Network (CISNET), a National Cancer Institute funded consortium, aims to overcome 
these limitations by using a comparative modeling approach. The CISNET consortium focuses on 
five cancer sites: breast, colorectal, lung, prostate, and esophagus. Moreover, CISNET models 
have been used by the United States Preventive Services Task Force for breast and colorectal 
cancer screening guidelines[99, 100]. 
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Since 2011, three esophageal cancer modeling groups have been collaborating as part of CISNET, 
all focusing on EAC: the MSEAC model, from the Fred Hutchinson Cancer Research Center; the 
EACMo model, from the Massachusetts General Hospital; and the MISCAN-ESO model, from the 
University of Washington and Erasmus University Medical Center[101]. MSEAC is a biological 
model assuming that the accumulation of mutations and clonal expansion of altered cells forms 
the basis for carcinogenesis, and it is built on likelihood and micro-simulation methods[102]. 
EACMo is a Markov state transition simulation model, which simulates a cohort of individuals 
and does not allow for disease regression[103]. MISCAN-ESO is also a micro-simulation model, 
which allows for disease regression in the health states prior to cancer. The three models include 
the following health states: healthy, GERD, BE with and without dysplasia, preclinical cancer, 
clinically diagnosed cancer and death. The EACMo and the MISCAN-ESO models also classify 
dysplasia in BE as low- and high-grade. 
All models are calibrated to EAC incidence and mortality data collected from SEER, for all men 
and women aged 20-84 years, from 1975-2010. Moreover, the three groups use a generalization 
of APC[86, 104] to model EAC increase, in which age, period, and cohort trends are applied to rates 
within the natural history model. These models have recently been used to perform EAC 
incidence and mortality predictions for the year 2030[101]. Although the three groups differ in 
their modeling structure, they all yield predictions as a function of age and stage. 
 
THE PREVENT MODEL 
PREVENT was originally developed in 1988 and is defined as a multiple risk factor, multiple 
disease dynamic population model that allows the user to evaluate the effects of risk factor 
interventions. From observed changes in the exposure to a risk factor and the relative risk 
between that factor and the disease of interest, PREVENT estimates the proportional change in 
disease risk that would occur if the exposure reached a theoretical minimum value (e.g., smoking 
prevalence of 0)[105]. After the user specifies a change in risk factor prevalence due to an 
intervention, PREVENT calculates future incidence rates using observed and predicted changes 
in disease risk, and attributes the difference between the two to the intervention. Although 
some authors have performed cancer predictions using this method[106, 107], results are not easily 
reproducible since the software is not freely available and there is no full explicit formulation of 
the methods involved. Furthermore, such an approach requires a continuous update of the 
information regarding the relation between different modifiable risk factors and the different 
cancers, or their subtypes with distinct etiologies, to reflect the state of the art of the 
understanding of causes of different cancers. 
A conceptually similar approach underlies the IMPACT model, which was originally developed in 
the 1990s by Capewell and colleagues to explain the declining mortality from coronary heart 
disease, and to develop a comprehensive model of policy and prevention of the disease[108]. 
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After its first application to data from Scotland, it has henceforth been validated in 2001, 
gradually refined and widely used in more than 20 populations[109-111]. 
The main objective of the authors was to build a conceptually simple, although methodologically 
sophisticated model, with explicit assumptions that undergo multiway sensitivity analyses. The 
method takes into consideration the following components: 
• Major risk factors, including smoking, cholesterol, age and gender; 
• Patient groups, such as subjects with angina and heart failure; 
• Treatments, namely medication and surgery, and the cost-effectiveness of treatment; 
• Outcomes, measuring death, survival rates and life-years gained in adults. 
The model combines data from many sources on patient numbers, treatment uptake, treatment 
effectiveness and risk factor trends, measuring the consequent mortality effects, expressed as 
the number of deaths prevented or postponed (DPPs)[108]. 
Two approaches are used to calculate DPPs. A regression approach is used for continuous 
variables, for which DPPs are calculated as the product of three variables: the number of cases 
expected in the end year, the absolute reduction in the mean exposure between the two periods 
of interest and a regression coefficient quantifying the increase in risk of developing the disease 
by a unit increase in the mean exposure. Natural logarithms are used, assuming a log-linear 
relationship between changes in risk factor levels and mortality. 
For categorical variables, a PAF approach is used. The PAF is calculated conventionally as         
(𝑃 × (𝑅𝑅 − 1))/(1 + 𝑃(𝑅𝑅 − 1)), where P is the prevalence of the risk factor and RR is the 
relative risk associated with that risk factor. 
The number of DPPs is then estimated as the number of deaths expected in the end year (had 
rates in the first year persisted), multiplied by the difference between the PAF in both periods. 
The numbers of DPPs as a result of risk factor changes are quantified systematically for each age 
and sex group to account for potential differences in effect. Due to the uncertainty surrounding 
these estimates, sensitivity analyses are then performed using the analysis of extremes 
method[112], generating minimum and maximum estimates for DPPs. 
This method quantifies the contribution of each component to the observed variation in 
mortality, allowing for the assessment of potentially relevant interventions at a population level, 
in a similar way to that presented for the PREVENT model. Although the IMPACT model was not 
originally developed for cancer, the detailed description of the methods involved allow for their 
application in another context, had the proper and necessary adjustments been made to 
accommodate the disease under analysis. 
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DATA SOURCES FOR CANCER PREDICTIONS 
 
Cancer predictions rely, first and foremost, on the high quality of incidence and mortality data, 
and of population forecasts. While data on population forecasts are easily obtainable from 
international (such as the United Nations[113]) or local (national statistics offices in each country) 
sources of information, cancer incidence and mortality data require more careful attention. 
Reliable monitoring and surveillance of cancer is crucial for cancer control policies. Cancer 
registries are expected to accomplish this demand by collecting cancer incidence data for 
defined populations, including information on patient and tumor characteristics at diagnosis 
and, in some instances, stage at diagnosis, treatments provided and patient´s follow-up. 
However, the quality of incidence data provided by population-based cancer registries differs 
widely by geographic region, with many countries in Latin America, Asia and Africa presenting a 
poor quality or even total absence of information (Figure 5). Aiming at the development of 
cancer registration in such areas within the next decade, IARC has brought together diverse 
partners and created the Global Initiative for Cancer Registry Development[85]. This project has 
developed six Regional Hubs aimed at providing localized training and support for the 
development of cancer control plans and research networks. 
 
 
Figure 5. Quality of regional/national population-based cancer registries (source: Bray[85]). 
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The International Association of Cancer Registries (IACR), founded in 1966, represents 
population-based cancer registries worldwide. Every five years, IACR works in collaboration with 
IARC to gather incidence data from high-quality registries and to present data in a publication 
entitled Cancer Incidence in Five Continents (CI5). Information published in CI5 is then used for 
worldwide cancer incidence estimates provided by the GLOBOCAN Project[84]. For 
countries/regions where no cancer registry data are available, incidence is estimated from 
mortality information and/or from incidence data in adjacent areas. 
The number of registries with available data in CI5 has increased over time, from 32 (in 29 
countries) in Volume I to 290 (in 68 countries) in Volume X[114]. These publications present the 
absolute numbers of cancer cases by period, age group, sex, cancer site and the corresponding 
populations at risk. In addition, there is also an online database, CI5plus, containing updated 
annual incidence rates for 118 selected populations from 102 of the cancer registries included 
in CI5, for the longest period available up to 2007, for all cancers and 27 major types[115]. CI5plus 
can be used for time trends analyses, but these should be interpreted with caution because of 
differences in registration practices and coding over time, as well as the existence of missing 
data for specified cancer subsites or histological types[115]. 
In Europe, the first cancer registry was established in Hamburg, Germany, in 1927. In the 1940s 
and 1950s, regional registries were also developed in the UK and other countries. In Denmark, 
a national cancer registry was created in 1942. In Portugal, three regional cancer registries were 
established in 1988 on a legal framework (government decree 35/88 of January 16th), yielding a 
100% coverage of the national mainland territory. The North Region Cancer Registry (RORENO) 
covers a population of approximately 3.2 million people (nearly 30% of the Portuguese 
population) and is located in the Portuguese Oncology Institute of Porto. It constitutes the main 
source of information on cancer burden in Northern Portugal, publishing annual reports on 
cancer incidence and mortality/incidence ratios in the region. Incidence data from RORENO have 
been included in CI5 Volume IX[116], while survival data have been published in local and 
international studies such as EUROCARE-5[117] and CONCORD-2[118]. Apart from the initial years 
of operation, in which the completeness of registration is expected to be lower, the functioning 
and resources involved in cancer registration in the region have been fairly stable, and a 
quantitative study on the completeness of the registry yielded favorable quality results[119]. 
 
Regarding mortality, there is also great variation in the availability of information, as well as in 
the quality of data obtainable, with several countries of low and medium Human Development 
Index presenting low levels of quality and completeness of death certificate information (Table 
2). Although in some settings, as in the USA, registries have access to cancer mortality data from 
death certification, this is not the case for a large number of registries. However, there is an 
online tool (WHO Mortality Database) which compiles mortality data as reported annually by 
WHO Member States from their civil registration systems[90]. The WHO Mortality Database 
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provides access to the number of deaths and age-standardized mortality rates by country, year, 
cause of death and sex. Causes of death are coded according to the 9th and 10th editions of the 
International Classification of Disease (ICD-9, ICD-10), since 1979. More detailed information is 
available in raw data files for download, together with the necessary instructions, file structures 
and code reference tables, from 1950 onwards. 
 
Table 2. Proportion (%) of regional coverage by high quality cancer registration and high quality complete vital registration of death 
(source: Bray[85]). 
 High quality cancer  
registration data 
High quality complete vital 
registration of death 
Africa 2% 0% 
Asia 6% 3% 
Northern America 95% 100% 
Latin America and the Caribbean 8% 25% 
Oceania 78% 74% 
Europe 42% 18% 
 
In order to collect data on the prevalence of exposure to risk factors, one of the major sources 
of available information is the WHO Global InfoBase[120]. This online repository provides country-
level data on relevant risk factors for non-communicable diseases, for all WHO Member States. 
It gathers information collected from different surveys conducted in each country, covering 
eight major risk factors: tobacco use, alcohol consumption, F&V intake, overweight and obesity, 
raised blood pressure, raised cholesterol, physical inactivity and diabetes. All available 
information may be traced back to its original source. The WHO Global InfoBase collaborates 
with WHO Regional Offices to ensure the most up to date information possible. 
Furthermore, WHO provides worldwide relevant information on risk factors in dedicated 
databases and reports, which are freely available from the Global Health Observatory Data 
Repository[121]. The Global Information System on Alcohol and Health (GISAH)[122] provides 
information on levels (per capita availability) and patterns of alcohol consumption (prevalence 
of consumers and abstainers), by country and by year, as well as information on economic 
aspects, existing control policies and other key indicators for non-communicable diseases. The 
WHO Tobacco Free Initiative is composed by three units: National Capacity Building, 
Comprehensive Information Systems for Tobacco Control and Tobacco Control Economics. It 
aims to surveil the global tobacco epidemic and to assist countries in enhancing their ability to 
resist the epidemic of tobacco through the implementation of the WHO Framework Convention 
on Tobacco Control. The progress of WHO Member States towards the execution of suggested 
measures is routinely reported through the WHO Report on the Global Tobacco Epidemic[123]. 
Regarding overweight and obesity, information provided at the Global Health Observatory Data 
Repository concerns the prevalence of overweight and obesity and mean body mass index (BMI) 
by country, year and sex. For more detail, there is also information at the WHO Global Database 
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on BMI[124], which allows the user to obtain national and sub-national BMI data. Alcohol and 
tobacco consumption, and overweight and obesity are here presented as examples, but 
information on other risk factors is also attainable from WHO dedicated websites. 
Despite the existence of several worldwide sources of information for some of the most 
commonly evaluated risk factors, more detailed data regarding the same or other determinants 
(e.g., stratified results by age and sex) may be found in national/local sources, such as national 
health surveys or national statistics offices, as well as in scientific or technical publications of 
survey data, which should not be disregarded when looking for the most accurate information 
possible. 
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AIMS 
 
 
Despite the extensive knowledge on the main risk factors for esophageal cancer, their joint 
contribution for the trends in the burden of disease associated with esophageal cancer has not 
been formally assessed. 
This research aimed to translate the accumulated knowledge on the etiology of esophageal 
cancer into a model able to describe and predict the variation in its incidence at a population 
level, taking into account the variation in the exposure to the main modifiable risk factors. 
The development of such a model required the accomplishment of the following specific 
objectives: 
1. To describe the trends in esophageal cancer incidence, overall and by histological type, 
in different countries, including Portugal (Papers I-III); 
 
2. To summarize the evidence on the exposure to the different risk factors of esophageal 
cancer in Northern Portugal over the past decades (Paper III); 
 
3. To summarize the current scientific knowledge on modifiable risk factors for esophageal 
cancer, by histological type, through a systematic review of published meta-analyses 
(Paper IV); 
 
4. To estimate the contribution of the variation in the exposure to the main risk factors for 
esophageal cancer to changes in its incidence rates between 1995 and 2005, in Northern 
Portugal and in selected countries (Paper V). 
 
The accomplishment of these objectives was based on the collection of data from numerous 
sources of information. Cancer incidence data were retrieved from RORENO and from CI5 
publications. The levels of exposure to risk factors were derived from online databases provided 
by WHO, national health and nutrition surveys and literature searches. The strength of 
association between each risk factor and esophageal cancer was obtained from a systematic 
review of meta-analyses. The methods are described in detail in each of the papers that 
constitute this thesis. 
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Paper I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. 
PATTERNS AND TRENDS IN ESOPHAGEAL CANCER MORTALITY AND INCIDENCE IN EUROPE (1980-2011) 
AND PREDICTIONS TO 2015. 
Ann Oncol. 2014 Jan;25(1):283-90. 
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Supplementary Figure 1: Trends in age-standardized (world population) incidence rates per 100,000 women for esophageal cancer 
by histological types in selected European countries, 1980-2002.   
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Supplementary Figure 2: Proportion of cases of the four esophageal cancer subtypes, i.e., squamous cell carcinoma (ESCC), 
adenocarcinoma (EAC), other esophageal cancers and unspecified esophageal cancers, among men, across Europe. 
 
  
Supplementary Figure 3: Proportion of cases of the four esophageal cancer subtypes, i.e., squamous cell carcinoma (ESCC), 
adenocarcinoma (EAC), other esophageal cancers and unspecified esophageal cancers, among women, across Europe.
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Supplementary Table S1: Joinpoint analysis for esophageal cancer mortality in men and women (at all ages and 25-49 and 35-64 years) for the European Union and selected European countries, from 1980 to 2011. 
  Men Women 
Country Age group Years APC 1 Years APC 2 Years APC 3 Years APC 4 AAPC Years APC 1 Years APC 2 Years APC 3 Years APC 4 AAPC 
Austria All ages 1980-2011 -0.1       -0.1 1980-1993 -0.6 1993-1999 7.5 1999-2011 -2a   0.4 
 25-49 years 1980-2011 -1.6a       -1.6a 1980-2011 0.2       0.2 
 35-64 years 1980-2007 0.4 2007-2011 -6.1     -0.5 1980-2003 3.1a 2003-2011 -4.8     1 
Bulgaria All ages 1980-1988 7.6a 1988-1991 31.4 1991-2002 -6.5a 2002-2011 2.2 2.8 1980-1986 1.4 1986-1991 33.6a 1991-2000 -12.4a 2000-2011 -1.8 0.5 
 25-49 years 1980-1995 11.5a 1995-2001 -16.4a 2001-2011 1.8   2.4 1980-1991 23.8a 1991-2011 -7.6a     2.5 
 35-64 years 1980-1991 16.4a 1991-2011 -2.8a     3.7a 1980-1991 25.8a 1991-2000 -13.1a 2000-2011 0.4   4.3 
Czech Republic All ages 1986-1995 4a 1995-2011 -0.8a     0.9a 1986-2011 1.4a       1.4a 
 25-49 years 1986-1994 7.2a 1994-2011 -4.7a     -1.1 1986-2011 1.8       1.8 
 35-64 years 1986-1993 7.3a 1993-2011 -1a     1.3a 1986-2011 3.9a       3.9a 
Denmark All ages 1980-2002 2.6a 2002-2008 -5.4a 2008-2011 5.5   1.3a 1980-2005 2.2a 2005-2011 -6.4a     0.5 
 25-49 years 1980-2000 3.5a 2000-2011 -6.6a     -0.2 1980-2011 0.6       0.6 
 35-64 years 1980-2000 2.9a 2000-2011 -3.3a     0.6 1980-2006 2a 2006-2011 -9.4     0.1 
Finland All ages 1980-2011 -0.2       -0.2 1980-2001 -4.4a 2001-2011 0.8     -2.8a 
 25-49 years 1980-2011 1.5       1.5 1980-2011 -0.8       -0.8 
 35-64 years 1980-2011 1.3a       1.3a 1980-2011 -1.8a       -1.8a 
France All ages 1980-1989 -1.6a 1989-2009 -3.5a     -3a 1980-2009 -0.1       -0.1 
 25-49 years 1980-2000 -2.4a 2000-2009 -10.1a     -4.9a 1980-2000 1.5a 2000-2009 -6a     -0.9 
 35-64 years 1980-1989 -1.4a 1989-2009 -4.1a     -3.3a 1980-2009 0       0 
Germany All ages 1980-1991 2.9a 1991-2011 -0.5a     0.7a 1980-1985 -0.3 1985-1995 3a 1995-2011 0.7a   1.3a 
 25-49 years 1980-1991 3.5a 1991-2011 -3.9a     -1.4a 1980-1993 5.8a 1993-2011 -2.9a     0.6 
 35-64 years 1980-1985 7.2a 1985-1992 3a 1992-2011 -1.6a   0.8a 1980-1993 4.8a 1993-2008 1.3a 2008-2011 -5.1   2.1a 
Greece All ages 1980-1992 -2.5a 1992-2010 -0.1     -1.1a 1980-2010 -2.6a       -2.6a 
 25-49 years 1980-2010 0.1       0.1 1980-2010 -2.7a       -2.7a 
 35-64 years 1980-1992 -3.7a 1992-2010 2a     -0.3 1980-2010 -2.4a       -2.4a 
Hungary All ages 1980-1990 5.9a 1990-1997 3.1a 1997-2011 -2.7a   1.3a 1980-2000 4.5a 2000-2011 -1.2     2.4a 
 25-49 years 1980-1995 6.9a 1995-2003 -4a 2003-2011 -10.8a   -0.8 1980-1998 6a 1998-2011 -4.4     1.5 
 35-64 years 1980-1990 7.7a 1990-1997 3.5a 1997-2011 -3.3a   1.7a 1980-2000 6.2a 2000-2011 -1.5     3.4a 
Ireland All ages 1980-1994 2.3a 1994-2010 -0.7     0.7a 1980-2010 -1.3a       -1.3a 
 25-49 years 1980-2010 0.2       0.2 1980-2010 -1.6       -1.6 
 35-64 years 1980-2010 0       0 1980-2010 -2.5a       -2.5a 
Italy All ages 1980-1986 0.2 1986-2001 -3a 2001-2006 -5.9 2006-2010 0 -2.5a 1980-2010 -1.9a       -1.9a 
 25-49 years 1980-1986 0.5 1986-2010 -4.6a     -3.6a 1980-2010 -1.6a       -1.6a 
 35-64 years 1980-1987 1 1987-2008 -4.1a 2008-2010 3.1   -2.5a 1980-2010 -1.3a       -1.3a 
Latvia All ages 1980-2010 1.6a       1.6a 1980-1992 4.3a 1992-1995 -20.5 1995-2010 3.5a   1.1 
 25-49 years 1980-2010 0.3       0.3 1980-2010 -0.5       -0.5 
 35-64 years 1980-1989 7.4a 1989-2010 0.7     2.7a 1980-2010 1.2       1.2 
Lithuania All ages 1981-2010 2.3a       2.3a 1981-2010 1.3a       1.3a 
 25-49 years 1981-2010 0.1       0.1 1981-2010 2.5       2.5 
 35-64 years 1981-1990 7.5a 1990-2010 1.5a     3.3a 1981-2010 1.8a       1.8a 
Netherlands All ages 1980-1995 4.5a 1995-2011 1.4a     2.8a 1980-1994 4a 1994-2011 0.8a     2.2a 
 25-49 years 1980-1992 10.6a 1992-2011 -0.5     3.7a 1980-1996 5.9a 1996-2011 -4.9a     0.5 
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  Men Women 
Country Age group Years APC 1 Years APC 2 Years APC 3 Years APC 4 AAPC Years APC 1 Years APC 2 Years APC 3 Years APC 4 AAPC 
 35-64 years 1980-1992 6.7a 1992-2011 1.6a     3.5a 1980-1995 6.3a 1995-2011 0.3     3.2a 
Norway All ages 1980-2011 1a       1a 1980-2011 1.4a       1.4a 
 25-49 years 1980-2011 0.7       0.7 1980-2011 -0.6       -0.6 
 35-64 years 1980-1989 5.6a 1989-2011 -0.3     1.4 1980-2011 2.3a       2.3a 
Poland All ages 1980-1983 7a 1983-2004 0 2004-2011 -3.2a   -0.1 1980-2011 -0.5a       -0.5a 
 25-49 years 1980-1991 2.2 1991-2011 -3.2a     -1.3a 1980-2011 -0.5       -0.5 
 35-64 years 1980-1983 12.1a 1983-2002 0.5 2002-2011 -3.6a   0.3 1980-2011 0.5a       0.5a 
Portugal All ages 1980-2011 -0.3a       -0.3a 1980-2011 -4a       -4a 
 25-49 years 1980-2005 2.9a 2005-2011 -5.7     1.2 1980-2011 -4.7a       -4.7a 
 35-64 years 1980-2011 0.7a       0.7a 1980-2011 -4.1a       -4.1a 
Romania All ages 1980-1990 1.1 1990-1993 10 1993-2011 3.1a   3.1a 1980-2011 0.3       0.3 
 25-49 years 1980-1999 6.3a 1999-2011 -0.3     3.7a 1980-2011 0.1       0.1 
 35-64 years 1980-2005 4.8a 2005-2011 0.4     3.9a 1980-2011 0.8a       0.8a 
Russian Federation All ages 1980-1982 -2 1982-1992 1.6a 1992-2000 -3.4a 2000-2010 -1.4a -1a 1980-1993 -2.8a 1993-1996 -7.2 1996-2010 -3.4a   -3.5a 
 25-49 years 1980-1990 3.7a 1990-2010 -4.7a     -1.9a 1980-2010 -2.8a       -2.8a 
 35-64 years 1980-1992 2.7a 1992-1999 -4.1a 1999-2010 -1.7a   -0.5a 1980-1992 -2.5a 1992-1997 -8.6a 1997-2010 -1.7a   -3.2a 
Spain All ages 1980-1995 0.4a 1995-2011 -2.5a     -1.1a 1980-1995 -3.7a 1995-2011 0.1     -1.7a 
 25-49 years 1980-1995 0.9 1995-2011 -5.8a     -2.6a 1980-2011 0.1       0.1 
 35-64 years 1980-1995 1.3a 1995-2011 -3.5a     -1.2a 1980-2011 0.4       0.4 
Sweden All ages 1980-2010 0.3       0.3 1980-2010 0.6a       0.6a 
 25-49 years 1980-2010 0       0 1980-2010 1.5       1.5 
 35-64 years 1980-2010 0.5a       0.5a 1980-2010 1.4a       1.4a 
Switzerland All ages 1980-2010 -1.2a       -1.2a 1980-2010 0.4       0.4 
 25-49 years 1980-1994 1.7 1994-2010 -6.6a     -2.8a 1980-2010 -1.4       -1.4 
 35-64 years 1980-2010 -1.3a       -1.3a 1980-2010 1.1a       1.1a 
Ukraine All ages 1981-1992 4.7a 1992-2003 -2.7a 2003-2011 -0.5   0.5a 1981-1992 -0.4 1992-2011 -3.8a     -2.5a 
 25-49 years 1981-1990 6.7a 1990-2011 -3.6a     -0.6 1981-2011 -2a       -2a 
 35-64 years 1981-1992 5.7a 1992-2002 -2.8a 2002-2011 -0.5   0.9a 1981-2011 -1.7a       -1.7a 
United Kingdom All ages 1980-1994 2.5a 1994-2010 0.1     1.2a 1980-1995 1.1a 1995-2010 -1a     0 
 25-49 years 1980-1995 2.4a 1995-2010 -0.7     0.8a 1980-2010 -1a       -1a 
 35-64 years 1980-1994 2.2a 1994-2010 0.1     1.1a 1980-1992 0.4 1992-2010 -0.9a     -0.4 
European Union (27) All ages 1980-1985 1.3a 1985-1994 0.2 1994-2009 -1.2a   -0.3a 1980-1995 0.3a 1995-2009 -0.6a     -0.2a 
 25-49 years 1980-1985 2.3a 1985-1994 0.8a 1994-2002 -2.5a 2002-2009 -5.4a -1.4a 1980-1996 1.9a 1996-2009 -2.9a     -0.2 
 35-64 years 1980-1990 1.5a 1990-2003 -1a 2003-2009 -2.2a   -0.4a 1980-2009 0.5a       0.5a 
a significantly different from 0 (p < 0.05) 
APC, estimated annual percent change 
AAPC, estimated average annual percent change 
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Supplementary Table S2: Number of esophageal cancer incident cases in men and women, by histological type, and age-
standardized rate ratio ESCC/EAC, by European country with available data in the Cancer Incidence in Five Continents volume IX 
(national data are provided unless if otherwise specified). 
 
Country 
Men  Women 
ESCC EAC Other Unspecified ESCC/EAC  ESCC EAC Other Unspecified ESCC/EAC 
Austria 632 339 164 162 2.0  141 62 66 71 2.5 
Belarus  1109 158 43 432 7.2  85 35 9 80 2.1 
Belgium a 698 754 101 83 1.8  255 163 30 33 1.0 
Bulgaria  146 78 19 459 1.9  22 23 8 152 1.0 
Croatia  495 55 88 305 9.1  90 17 18 88 4.8 
Czech Republic  929 420 117 314 2.2  150 61 19 89 2.7 
Denmark  503 610 97 119 0.9  284 150 33 51 2.2 
Estonia  175 11 15 23 16.8  37 1 2 8 41.0 
Finland  362 243 38 57 1.5  281 61 23 34 4.3 
France b 2178 581 136 64 6.5  386 92 26 23 4.3 
Germany c 2396 791 270 762 4.4  608 178 71 285 3.3 
Iceland  21 26 2 0 0.7  5 8 3 0 0.6 
Ireland  295 489 69 88 0.6  329 132 39 97 2.7 
Italy d 1680 560 200 345 4.7  503 127 83 178 3.5 
Latvia  259 37 16 123 7.2  23 10 5 38 2.0 
Lithuania  429 59 45 174 7.5  53 13 4 33 4.6 
Malta  11 16 2 10 0.7  4 5 0 2 1.0 
Norway  277 260 38 25 1.2  140 85 16 11 2.0 
Poland e 187 28 25 251 5.9  40 9 7 79 6.8 
Portugal f 915 199 71 133 3.3  197 57 12 43 5.3 
Russia g 560 90 148 279 6.4  174 26 69 177 6.3 
Serbia  283 83 35 148 3.6  83 31 14 37 3.1 
Slovakia  847 121 52 233 7.2  56 32 6 34 2.0 
Slovenia  268 39 28 36 7.1  47 19 10 17 3.2 
Spain h 1416 403 111 151 3.2  168 56 17 59 4.3 
Sweden  614 621 97 13 1.0  407 147 37 5 3.0 
Switzerland i 402 243 38 23 4.4  144 43 17 12 1.9 
Netherlands  1441 2523 268 74 0.6  903 720 135 38 1.6 
United Kingdom j 4936 12169 1492 2622 1.9  6179 3801 1128 2206 0.4 
ESCC: squamous cell carcinoma; EAC: esophageal adenocarcinoma 
a Antwerp and Flanders 
b Bas-Rhin, Calvados, Doubs, Haut-Rhin, Herault, Isere, Loire-Atlantique, Manche, Somme, Tarn, Vendee 
c Brandenburg, Free State of Saxony, Hamburg, Mecklenburg-Western Pomerania, Munich, Northrhine-Westphalia: Munster, 
Saarland 
d Biella, Brescia, Ferrara, Florence and Prato, Genoa, Macerata, Milan, Modena, Naples, North East Cancer Surveillance Network, 
Parma, Ragusa, Reggio Emilia, Romagna, Salerno, Sassari, Syracuse, Sondrio, Torino, Umbria, Varese, Veneto 
e Cracow, Kielce, Warsaw 
f Northern and Southern Regions 
g St Petersburg 
h Albacete, Asturias, Basque Country, Canary Islands, Cuenca, Girona, Granada, Murcia, Navarra, Tarragona, Zaragoza 
I Geneva, Graubunden and Glarus, Neuchatel, St Gall-Appenzell, Ticino, Valais, Vaud 
j East of England Region, England (Merseyside and Cheshire, North Western, Northern and Yorkshire, Oxford, South and Western, 
Thames, Trent, West Midlands), Northern Ireland, Scotland 
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Supplementary Table 1: Number of cases (n), age-standardized incidence rates (ASIR) and corresponding 95% confidence intervals (95%CI), for 2015 and 2020, by cancer site and by sex. 
Cancer site (ICD-10) 
Men - 2015 Men - 2020  Women - 2015 Women - 2020 
n (95% CI) ASIR (95% CI) n (95% CI) ASIR (95% CI)  n (95% CI) ASIR (95% CI) n (95% CI) ASIR (95% CI) 
All cancers (except skin non-melanoma) 9057 (8541 - 9573) 473.1 (446.0 - 500.2) 10236 (9379 - 11094) 500.8 (458.9 - 542.6)  8243 (7978 - 8507) 373.5 (361.0 - 385.9) 9820 (9463 - 10178) 422.4 (406.4 - 438.3) 
Esophagus (C15) 186 (151 - 220) 10.2 (8.3 - 12.1) 202 (160 - 243) 10.7 (8.5 - 12.9)  32 (18 - 47) 1.2 (0.6 - 1.7) 32 (16 - 48) 1.0 (0.5 - 1.6) 
Stomach (C16) 729 (655 - 803) 37.3 (33.5 - 41.0) 743 (653 - 833) 35.4 (31.2 - 39.7)  497 (441 - 554) 18.8 (16.6 - 21.0) 514 (446 - 584) 17.7 (15.3 - 20.0) 
Colorectum (C18-C21) 1939 (1783 - 2094) 97.8 (89.8 - 105.7) 2421 (2194 - 2647) 113.1 (102.4 - 123.8)  1234 (1148 - 1319) 47.7 (44.2 - 51.2) 1464 (1359 - 1569) 52.0 (48.0 - 56.0) 
Pancreas (C25) 141 (111 - 171) 7.3 (5.7 - 8.9) 175 (138 - 213) 8.4 (6.6 - 10.2)  135 (106 - 164) 5.0 (3.9 - 6.2) 170 (133 - 206) 5.8 (4.5 - 7.2) 
Lung (C33-C34) 1151 (1063 - 1239) 59.4 (54.8 - 64.0) 1360 (1251 - 1469) 65.2 (59.9 - 70.5)  338 (293 - 384) 14.0 (12.0 - 16.0) 420 (364 - 476) 16.1 (13.9 - 18.4) 
Melanoma of the skin (C43) 116 (91 - 141) 6.2 (4.7 - 7.6) 141 (111 - 171) 7.7 (6.0 - 9.3)  176 (144 - 208) 8.5 (6.8 - 10.0) 212 (172 - 251) 9.7 (7.9 - 11.6) 
Female breast (C50) NA NA NA NA  2177 (2060 - 2294) 107.2 (101.3 - 113.2) 2541 (2398 - 2682) 120.6 (113.7 - 127.5) 
Cervix uteri (C53) NA NA NA NA  195 (161 - 229) 10.3 (8.5 - 12.2) 179 (143 - 215) 9.4 (7.4 - 11.4) 
Corpus uteri (C54) NA NA NA NA  398 (338 - 458) 16.6 (14.0 - 19.2) 501 (417 - 585) 19.3 (15.9 - 22.8) 
Prostate (C61) 2351 (2009 - 2695) 119.1 (102.1 - 136.3) 3016 (2567 - 3471) 140.6 (120.1 - 161.5)  NA NA NA NA 
Kidney (C64) 248 (212 - 285) 13.3 (11.3 - 15.3) 307 (263 - 351) 15.4 (13.2 - 17.7)  116 (89 - 143) 5.2 (3.9 - 6.4) 138 (104 - 170) 5.8 (4.4 - 7.3) 
Bladder (C67) 724 (659 - 789) 35.9 (32.7 - 39.2) 873 (794 - 953) 40.0 (36.3 - 43.7)  168 (128 - 208) 6.1 (4.5 - 7.6) 194 (138 - 250) 6.4 (4.4 - 8.4) 
Brain and CNS (C70-C72) 153 (124 - 183) 8.8 (7.1 - 10.5) 177 (142 - 212) 9.7 (7.7 - 11.7)  133 (102 - 164) 6.8 (5.1 - 8.4) 155 (117 - 194) 7.6 (5.6 - 9.5) 
Thyroid (C73) 149 (121 - 178) 8.9 (7.2 - 10.7) 186 (152 - 220) 10.9 (8.9 - 12.8)  934 (870 - 997) 52.6 (45.3 - 59.9) 1055 (980 - 1130) 59.3 (50.7 - 67.9) 
Non-Hodgkin Lymphoma (C82-C85, C96) 305 (263 - 347) 16.9 (14.5 - 19.2) 356 (306 - 407) 18.7 (16.1 - 21.4)  250 (212 - 289) 11.1 (9.3 - 12.8) 292 (246 - 338) 12.2 (10.2 - 14.2) 
NA: Not applicable; CNS: central nervous system 
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Supplemental Figure 1: Trends in 3-year moving averages of the number of cases and age-standardized (all ages, direct method, European standard population) incidence rates in 1994-2009 (in grey and black, 
respectively) and predictions for 2015 and 2020, by cancer site, among men. 
  
    
    
    
*we assumed that the increasing rate observed up to 2006 would become apparent again in future years, after the decline observed in the most recent years 
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Supplemental Figure 2: Trends in 3-year moving averages of the number of cases and age-standardized (all ages, direct method, European standard population) incidence rates in 1994-2009 (in grey and black, 
respectively) and predictions for 2015 and 2020, by cancer site, among women. 
    
    
    
  
  
*we assumed that the increasing rate observed up to 2006 would hold in future years, instead of the steep increase observed onwards. 
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TRENDS IN GASTRIC AND ESOPHAGEAL CANCERS INCIDENCE IN 
NORTHERN PORTUGAL (1994-2009), BY SUBSITE AND HISTOLOGY, AND 
PREDICTIONS FOR 2015 
 
Clara Castro1,2, Bárbara Peleteiro2,3, Maria José Bento1, Nuno Lunet2,3 
1 North Region Cancer Registry (RORENO) – Portuguese Oncology Institute, Porto, Portugal 
2 EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal 
3 Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of 
Porto Medical School, Porto, Portugal 
 
ABSTRACT 
Introduction: Gastric (GC) and esophageal (EC) cancers share risk factors, and incidence trends 
reflect differences in etiology according to their subtypes. We aimed to describe GC (by 
topography) and EC (by histological type) incidence trends in Northern Portugal for 1994-2009, 
and estimate incidence in 2015. We further analyzed exposure to the main risk factors for these 
cancers in the region over the last decades.  
Methods: GC and EC data were obtained from North Region Cancer Registry of Portugal 
(RORENO). Joinpoint regression was used to compute annual percent changes (APC) in incidence 
trends. Poisson regression yielded estimates for 2015. A literature review up to 2014 provided 
data on exposure to risk factors. 
Results: GC rates decreased in 1994-2009 (men, APC=-1.3; women, APC=-1.6); GC unspecified 
subtype had the steepest decline, since the early 2000s (men, APC=-4.9; women, APC=-6.3). 
Incidence for 2015 will increase for EC in men (up to ≈190 cases) and stabilize in women (≈30) 
and for GC (≈730 men, ≈500 women). Increasing prevalences of tobacco smoking among women 
and overweight/obesity, fairly stable prevalences of alcohol, fruit and vegetable consumptions, 
and no trend for Helicobacter pylori infection were observed. 
Conclusion: The declining incidence of GC unspecified subtype showed improvements in cancer 
registration, but precluded a sound assessment of trends by subtype. Variations in the 
prevalence of exposure to some risk factors were consistent with observed incidence trends, 
and future studies should aim to quantify their contribution to GC and EC burden in the region. 
 
KEYWORDS 
Esophageal neoplasms; Incidence; Stomach neoplasms; Trends.  
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INTRODUCTION 
Gastric and esophageal cancers are among the ten most common worldwide, jointly accounting 
for 10% of the overall number of incident cases[1]. Both tumors present a low survival: in Europe, 
a recent study yielded 5-year relative survival rates of 25% and 12% for gastric and esophageal 
cancer, respectively[2]. 
Stomach cancer incidence and mortality have been decreasing for several decades, which is 
mainly attributable to the decrease in the frequency of Helicobacter pylori (H. pylori) infection, 
smoking, salt intake, and low consumption of fruits and vegetables[3, 4]. However, trends are not 
homogeneous across gastric cancer subtypes, as the decline has been greater for non-cardia 
gastric tumors, while for cardia tumors, in many settings, the pattern of variation resembles 
more closely the observed for esophageal cancer[3, 5]. 
Esophageal cancer is much less frequent than gastric cancer in more developed countries. There 
is a heterogeneous distribution of its main histological types, esophageal adenocarcinoma (EAC) 
and esophageal squamous cell carcinoma (ESCC), across countries, reflecting differences in the 
etiology of these subtypes. Overall, the incidence of esophageal cancer has been increasing in 
many of the most developed countries, mainly due to upward trends in EAC, possibly on account 
of higher prevalences of obesity and gastro-esophageal reflux[6]. The main risk factors for ESCC 
are smoking and alcohol consumption, and studies have shown their independent and 
synergistic effects[7]. H. pylori infection is negatively associated with EAC[8] and decreases in the 
prevalence of infection are expected to translate into a higher esophageal cancer morbidity[9]. 
Low fruit and vegetable intake increases the risk of both EAC and ESCC, and variations in their 
consumption are also expected to influence the trends in esophageal cancer incidence and 
mortality. 
This study aimed to describe subtype-specific incidence trends in stomach (cardia and non-
cardia) and esophageal cancers (squamous cell carcinoma (ESCC) and EAC) in Northern Portugal 
between 1994 and 2009, and to estimate the number of incident cases and age-standardized 
rates for 2015. It further analyzed the exposure to the main risk factors for these cancers in the 
region over the last decades. 
 
METHODS 
Incidence data on stomach and esophagus cancers for the period 1994-2009 were retrieved 
from the North Region Cancer Registry of Portugal (RORENO); this  is a population-based cancer 
registry, set up in 1988, which covers approximately 3.2 million people who live in the five 
districts of Northern Portugal (Braga, Bragança, Porto, Viana do Castelo and Vila Real). For the 
same period, population figures based on official censuses were obtained from Statistics 
Portugal[10]. 
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Sex-specific incidence rates were computed for each 5-year age group and calendar period, and 
age-standardized rates were calculated by the direct method, using the European standard 
population[11], for all ages and the age groups <65 and ≥65 years. Poisson regression analyses 
were performed using Joinpoint software[12], in order to identify significant changes in incidence 
trends (allowing for up to two joinpoints). For each of the segments obtained in the best model, 
the estimated annual percent change (APC) and corresponding confidence intervals (CI) were 
computed by fitting a regression line to the natural logarithm of the rates using calendar year as 
a regressor variable. 
Stomach cancer incidence trends were analyzed overall and by sub-location according to the 
International Classification of Diseases for Oncology, 3rd edition (ICD-O-3), i.e., cardia (C16.0), 
non-cardia (C16.1-C16.6) and unspecified topography (C16.8-C16.9). Esophageal cancer 
incidence trends were analyzed overall and by histological type: ESCC (M8050/3-M8084/3), EAC 
(M8140/3-M8384/3), and other and unspecified esophageal cancers (all other morphology 
codes). 
Population predictions up to 2015 were computed by RORENO, using a scenario of the evolution 
of resident population based on a constant fertility rate and on migration rates derived from 
available population figures from Statistics Portugal up to 2012. Predicted absolute numbers of 
cases of stomach and esophageal cancers for the year 2015, and the corresponding 95% 
prediction intervals[13, 14], were computed through linear (for increasing or stabilizing trends) or 
log-linear (for decreasing trends) Poisson regression analyses, by age group (0-34, 35-44, 45-54, 
55-64, 65-74, 75-84 and ≥85 years). The last periods of time obtained in sex- and site-specific 
joinpoint models were used as a basis for the predictions. Age-standardized incidence rates were 
computed using the projected absolute number of cases and corresponding population 
estimates. The year 2015 was chosen as prediction limit to allow for international comparisons, 
using data from GLOBOCAN[1]. 
The variation in the prevalence of exposure to major determinants of gastric and/or esophageal 
cancers (tobacco smoking, alcohol drinking, overweight/obesity, H. pylori infection, and fruit and 
vegetable consumption) was evaluated by reviewing studies, published up to 2014, providing 
data from Northern Portugal. For tobacco smoking, overweight/obesity and H. pylori infection, 
previously published systematic reviews of Portuguese studies[15-17] were used as the primary 
source of published reports. For H. pylori infection, the systematic review was based on searches 
in PubMed and in the online database of the publications in Portuguese medical journals, from 
inception to July 2014. For smoking and overweight/obesity, PubMed was searched from 
inception up to 2011. Data obtained in these reviews were complemented by information from 
National Health Surveys. For alcohol drinking, and fruit and vegetable consumption, information 
was collected from National Health Surveys and from studies using the population-based 
cohorts EPIPorto (adults), EPITeen (adolescents) and Geração XXI (children) from Porto, the 
largest city in the region. Overall, sex- and age-group specific estimates were collected, 
whenever available. To describe the variation in exposure to the risk factors, only the overall- 
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and sex-specific estimates were used. For a graphical display of results, when two studies 
described the prevalence of exposure to the same risk factor in the same period of time, the 
estimate used was the one with the most similar selection criteria to the remaining studies on 
that risk factor. 
 
RESULTS 
In Northern Portugal, gastric cancer standardized rates significantly decreased since 1994, both 
among men (APC=-1.3, 95%CI: -1.6 to -0.9) and women (APC=-1.6, 95%CI: -2.3 to -1.0), while for 
the incidence of esophageal cancer, no significant variation was observed in the same period 
(Figure 1). The age groups <65 and ≥65 years presented similar trends, both for gastric (men: 
<65 years, APC=-0.6, 95%CI: -1.4 to 0.2, ≥65 years, APC=-0.3, 95%CI: -0.9 to 0.3; women: <65 
years, APC=-1.3, 95%CI: -2.1 to -0.5, ≥65 years, APC=-0.2, 95%CI: -1.0 to 0.7), and esophageal 
(men: <65 years, APC=2.1, 95%CI: 0.2 to 3.9, ≥65 years, APC=0.8, 95%CI: -0.8 to 2.4; women: <65 
years, APC=-1.5, 95%CI: -3.4 to 0.5, ≥65 years, APC=-1.5, 95%CI: -4.7 to 1.9) cancers. 
The estimated number of cases in Northern Portugal for 2015 was 1224 (men, 728; women, 496) 
for gastric and 218 (men, 184; women, 34) for esophageal cancers. In relation to the estimated 
overall number of incident cancer cases in the region[18] these corresponded to 8.0% and 2.1% 
among men, respectively, and to 6.0% and 0.4% among women, respectively (Figure 1 and Table 
1). 
Figure 1: Sex-specific trends* in the absolute number of cases and age-standardized (all ages, direct method, European standard 
population) incidence rates for stomach and esophageal cancers in 1994-2009, and predictions to 2015. 
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Table 1: Absolute number of new cases (n) of gastric and esophageal cancers expected for 2015 and corresponding proportion in 
relation to the total number of cases, in Northern Portugal and selected countries (source: GLOBOCAN[1]), by sex. 
 Sex Country/Region 
All cancers* Gastric cancer Esophageal cancer 
n n % of all cancers n % of all cancers 
Men 
RORENO 9057† 729 8.0 186 2.1 
Portugal 29397 1898 6.5 550 1.9 
Spain 135954 5147 3.8 1865 1.4 
Germany 286424 10845 3.8 5816 2.0 
Italy 200137 7915 4.0 1395 0.7 
Sweden 29128 524 1.8 356 1.2 
Ukraine  69649 6877 9.9 1647 2.4 
Australia 75377 1457 1.9 1127 1.5 
USA 903319 14408 1.6 14799 1.6 
Japan 441132 79350 18.0 17468 4.0 
Women 
RORENO 8243† 497 6.0 32 0.4 
Portugal 21241 1223 5.8 77 0.4 
Spain 91122 3100 3.4 353 0.4 
Germany 232229 6231 2.7 1485 0.6 
Italy 167768 5654 3.4 490 0.3 
Sweden 23486 327 1.4 126 0.5 
Ukraine 71980 4547 6.3 260 0.4 
Australia 56096 765 1.4 450 0.8 
USA 827542 8473 1.0 3744 0.5 
Japan 308370 36217 11.7 3333 1.1 
*except non-melanoma skin cancer 
†source: Castro et al.[18] 
 
Figure 2 depicts the trends between 1994 and 2009 according to gastric cancer sub-location and 
esophageal cancer histological type. For gastric cancer, the steepest variation was a decline since 
the early 2000s in rates of tumors with unspecified location within the stomach, both among 
men (APC=-4.9, 95%CI: -7.6 to -2.0) and women (APC=-6.3, 95%CI: -10.6 to -1.7), along with 
increasing trends of a similar magnitude in non-cardia cancers in the same period (APC=5.2, 
95%CI: 2.1 to 8.3 for men and APC=5.4, 95%CI: 3.0 to 7.9 for women). The incidence of cardia 
cancer decreased since 1994, though the variation was only statistically significant among 
women. In 2003-2007, gastric cancer with unspecified location accounted for more than two-
thirds of all gastric cancer cases registered by RORENO, while the ratio non-cardia/cardia was 
3.4 in men and 5.4 in women (Table 2).  
For esophageal cancers, no significant variation was observed for any subtype among men, 
despite an upward trend for ESCC and a decline in EAC and unspecified/other tumors. Among 
women, there was a significant downward trend in ESCC (APC=-3.1) and non-significant 
increases for EAC and unspecified/other tumors (Figure 2). In 2003-2007, the overall proportion 
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Figure 2: Number of cancer cases (n) diagnosed in 2003-2007 in Northern Portugal and selected geographical areas* (source: Cancer 
Incidence in Five Continents, volume X[50]) and corresponding proportion of cancer subtypes (%), by cancer site and by sex. 
 
of esophageal cancers with other/unspecified histological type was less than 10%, and the ratio 
ESCC/EAC was 6.0 in men and 3.6 in women (Table 2). 
Figure 3 depicts the variation in the prevalence of exposure to tobacco smoking, alcohol 
drinking, overweight/obesity, H. pylori infection, and fruit and vegetable consumption in 
Northern Portugal. Overall, sex- and age-group specific estimates are presented in 
Supplementary Table 1. Among adults, the prevalence of tobacco smoking[19-29] decreased for 
men, from 35% in 1987 to 25% in 2007, while for women it increased from 4% to 19%. The 
prevalence of alcohol drinking[22-25, 30-34] slightly increased for adult men, from 81% in 1987 to 
86% in 2011, and decreased among adult women, from 58% to 53%. Among adults, the 
prevalence of overweight varied from 18% to 40% for men and from 16% to 33% for women; 
the prevalence of obesity varied from 8% to 15% for men and from 11% to 15% for women. 
Among children/adolescents aged 6-13 years, overweight increased from 21% to 23% for boys 
and from 19% to 22% for girls between 2003 and 2008, while obesity increased from 7% to 9% 
for boys and from 6% to 10% for girls in the same period[23-25, 35-37]. For H. pylori infection[38-44], 
seven studies were conducted in Northern Portugal, which targeted population at different age 
ranges, and no clear trends were observed among adults or children. The consumption of fruits 
and vegetables[23, 24, 32, 45-48] showed relatively stable trends, with the consumption of fruits being 
higher than that of vegetables, except among children, reflecting a high consumption of 
vegetable soup in this age group.
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Table 2: Number of cancer cases (n) diagnosed in 2003-2007 in Northern Portugal and selected geographical areas* (source: Cancer Incidence in Five Continents, volume X[50]) and corresponding proportion of cancer 
subtypes (%), by cancer site and by sex. 
Sex Country/Region 
Gastric cancer† Esophageal cancer‡ 
n % unspecified % cardia % non-cardia 
ratio 
non-cardia/cardia 
n % unspecified % ESCC % EAC ratio ESCC/EAC 
Men 
RORENO 3525 68.1 7.3 24.7 3.4 748 7.4 79.4 13.2 6.0 
Spain (13 registries) 5914 50.3 14.7 35.0 2.4 2373 11.6 62.2 26.2 2.4 
Germany (9 registries) 13411 40.4 21.9 37.7 1.7 6336 16.7 56.1 27.2 2.1 
Italy (33 registries) 16148 50.6 12.3 37.1 3.0 3247 18.6 57.1 24.3 2.3 
Ukraine (national) 39350 38.1 12.4 49.5 4.0 8078 36.5 52.9 10.6 5.0 
Sweden (national) 2909 71.8 28.2 0.0 - 1486 6.5 38.8 54.7 0.7 
Australia (national) 6165 42.9 34.1 23.1 0.7 4088 13.0 31.1 55.9 0.6 
USA (42 states) 56113 36.6 36.0 27.4 0.8 52617 11.8 26.0 62.2 0.4 
Japan (8 registries) 56165 39.8 6.5 53.7 8.2 11756 18.9 78.0 3.2 24.6 
Women 
RORENO 2390 67.8 5.0 27.2 5.4 168 13.1 67.9 19.0 3.6 
Spain (13 registries) 3424 52.5 6.9 40.6 5.9 375 16.5 60.0 23.5 2.6 
Germany (9 registries) 10202 45.8 10.6 43.5 4.1 1693 22.5 59.3 18.2 3.3 
Italy (33 registries) 11623 51.6 5.8 42.5 7.3 1093 28.6 57.0 14.4 4.0 
Ukraine (national) 26720 39.2 8.9 51.9 5.8 1256 51.2 31.6 17.2 1.8 
Sweden (national) 1839 86.0 14.0 0.0 - 535 7.1 59.3 33.6 1.8 
Australia (national) 3317 55.1 17.7 27.2 1.5 1913 17.3 58.3 24.4 2.4 
USA (42 states) 36044 46.8 16.5 36.7 2.2 15211 14.3 49.1 36.6 1.3 
Japan (8 registries) 27069 42.9 4.6 52.5 11.4 2209 26.3 70.1 3.6 19.6 
*when data from more than one cancer registry were available in the same country, we added the number of incident cases from all registries 
†includes ICD-O-3 codes C16.0 as cardia, C16.1-C16.4 as non-cardia and C16.5-C16.9 as unspecified location in the stomach 
‡unspecified tumors include ICD-O-3 morphologies other than squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) 
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Figure 3: Variation in the exposure to major gastric and/or esophageal cancer determinants in Northern Portugal.  
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DISCUSSION 
In Northern Portugal, the incidence of gastric cancer has been declining, but it remains the 4th 
most frequent cancer, whereas for esophageal cancer, there was no statistically significant 
variation, and it currently accounts for a much smaller proportion of all cancers registered, 
especially among women, ranking below 10th[49]. 
A wide variation between populations was observed, especially among men, regarding the 
proportion of gastric and esophageal cancers in the total number of expected cancers for 2015[1, 
50]. Among the regions/countries considered in our study, male gastric cancer was estimated to 
account for between 1.6% (in the USA) and 18.0% (in Japan) of all cancers diagnosed in 2015, 
while male esophageal cancer represented between 0.7% (in Italy) and 4.0% (in Japan) of all 
cancers. For gastric cancer, the variability in the proportions found followed the patterns 
observed in cancer incidence, with countries with the highest incidence rates also presenting 
the highest proportions in relation to all cancers diagnosed; Northern Portugal had the third 
highest values, after Japan and Ukraine, and represented approximately double of the expected 
for Spain (8.0 vs. 3.8% for men and 6.0 vs. 3.4% for women). Portugal as a whole presented lower 
values, which was expected since gastric cancer is more frequent in the Northern region than in 
the rest of the country[51]. 
In relation to the proportion of cases of cardia and non-cardia subtypes, the differences 
observed are in accordance with a recent study showing that countries with high gastric cancer 
mortality rates present the lowest proportions of cardia cancers[3]. Regarding trends by subtype, 
the steep decline in the rates of tumors with unspecified location within the stomach is 
noteworthy. However, since unspecified gastric cancer still comprise the majority of stomach 
cancer cases in Northern Portugal, this precludes a sound interpretation of the trends in the 
rates of cardia and non-cardia cancers; the increasing rates observed for non-cardia cancers are 
unexpected, and most likely explained by a reduction in tumors with unspecified location mostly 
among the non-cardia cancers, which in Northern Portugal are much more frequent than those 
located in the cardia. The decreasing trends in rates of tumors with unspecified location within 
the stomach reflect improvements in cancer registration accuracy in RORENO, although there is 
still margin for improvement at this level[52]. 
For esophageal cancer, the proportion of unspecified tumors was among the lowest when 
compared with other European countries[5] and with the USA, Australia and Japan. The only 
significant change in trends regarding esophageal cancer subtypes in Northern Portugal was 
observed for ESCC among women, which was found declining. This pattern has also been 
observed in European countries such as France or Poland[5], although it is difficult to interpret in 
terms of changes in exposure to risk factors, on account of the much lower rates observed for 
women, in comparison with men. Among men, Joinpoint analyses were unable to detect 
significant changes in trends, although a peak and a minimum were observed for ESCC in 2003 
and 2006, respectively. These variations may be due to random fluctuations, but overdispersion 
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in data could also be present. For both sexes, the majority of the esophageal cancers in Northern 
Portugal were ESCC, as observed in most European countries[5]. 
The prevalence of smoking in Northern Portugal steadily increased among women and 
decreased among men over the last decades, which is in accordance with the previously 
observed for Portugal as a whole[15]. The patterns of alcohol consumption found in the region 
seemed different from the ones previously described for the country, for which a long-term and 
marked decrease in overall alcohol consumption had been portrayed in international 
evaluations[53]. However, these comparisons are not straightforward: in international studies, 
data usually is related to availability, estimated from production, import, export and sales data 
in each country [54]; in our study, we described the prevalence of alcohol consumption, rather 
than dose, since such data were not available at a regional level. Our results suggest that, in 
Northern Portugal, alcohol drinking is an important contributor to ESCC risk (the trends in the 
prevalence of alcohol consumption and in ESCC incidence rates are both upwards among men 
and downwards among women); for EAC, tobacco was more important (the trends in the 
prevalence of tobacco consumption and in EAC incidence rates are both downwards among men 
and upwards among women), which was expected given that alcohol intake influences ESCC risk 
but it has no association with EAC[55, 56]. Further studies should be performed in the region to 
quantify the contribution of each risk factor to the observed cancer trends, also taking into 
account the lag times between exposures and outcomes. 
The increasing prevalence of overweight and obesity previously described for Portugal was also 
found in the Northern Region[16], although the interpretation of these figures is limited by the 
fact that no data could be obtained for the region in the years preceding 1995. Since a lag of 10 
years has been described for the association between excess body mass index and EAC[57], this 
increasing prevalence may contribute to an increase in EAC incidence in the next few years, 
which has not yet been observed in the area.  
H. pylori infection is a risk factor for both gastric and esophageal cancers. Worldwide, the steady 
decline in gastric cancer incidence and mortality trends over the last five decades has been 
mainly attributed to an increase in socioeconomic status, namely through a reduction in H. pylori 
infection[3] and better nutrition and food preservation practices[4]. However, the prevalence of 
H. pylori infection in Northern Portugal was found persistently high, with no clear trend 
detected, showing that there is a margin for further reducing the burden of gastric cancer, by 
lowering the prevalence of infection[17]. 
Regarding nutrition, we were only able to evaluate the consumption of fruits and vegetables 
and alcohol intake, since information on the consumption of salt, and of smoked and pickled 
foods in the region is scarce, not allowing for a trend evaluation. 
Although this study is based on data from a relatively small country, Portugal presents the 
highest gastric cancer mortality rates in Western Europe, along with some of the highest 
prevalences of H. pylori infection in the most recent years; within Portugal, the North Region 
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has the highest gastric cancer incidence and mortality rates. Nevertheless, we have recently 
described different patterns of variation in gastric cancer mortality[3], showing that Portugal, 
Japan, Chile or Ukraine, among others, share the same pattern, characterized by some of the 
highest rates in the world, and declines around 2.5% per year over the last three decades. For 
esophageal cancer, Portugal is also among a group of countries including, for example, Russia, 
France and Italy, which have ESCC as the predominant histological type and decreasing mortality 
rates[5]. Finally, our extensive review provides an easy access to data on the main risk factors for 
these cancers, which may be useful for understanding the observed trends and for international 
comparisons with this objective. 
In conclusion, the declining incidence of cancers with unspecified subtypes suggest an 
improvement in cancer registration in Northern Portugal, but limit, to a certain extent, the 
interpretation of trends according to cancer subtypes, mainly regarding gastric tumors. Further 
studies should be performed in the region to quantify the individual and joint contribution of 
risk factors to the observed cancer trends, to yield more informed predicted estimates. 
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Supplementary Table 1: Exposure to the main determinants of esophageal and gastric cancers in Northern Portugal. 
Reference Year of data 
collection 
Sample size Age range 
(years) 
Exposure Exposure 
measurement 
Results 
INE, 1988 1987 6056 men, 
6584 
women 
All ages Tobacco Prevalence of 
current 
consumption 
Men 
≥15 years: 34.9% 
15-19 years: 15.5% 
20-39 years: 48.9% 
40-59 years: 37.0% 
≥60 years: 23.8% 
<20 cig/day: 34.0% 
≥21 cig/day: 58.8% 
  
Women 
≥15 years: 4.1% 
15-19 years: 3.2% 
20-39 years: 10.0% 
40-59 years: 1.8% 
≥60 years: 0.4% 
<20 cig/day: 64.0% 
≥21 cig/day: 30.8% 
 
        Alcohol Prevalence of 
consumption the 
week before the 
survey 
  
  
  
  
  
  
  
  
Men 
All ages: 66.8% 
≥15 years: 81.1% 
<15 years: 20.8% 
15-19 years: 55.7% 
20-39 years: 83.7% 
40-59 years: 89.3% 
≥60 years: 82.0% 
Wine: 63.6% 
Beer: 16.6% 
Brandy: 11.6% 
  
Women 
All ages: 53.7% 
≥15 years: 57.8% 
<15 years: 18.2% 
15-19 years: 37.9% 
20-39 years: 60.7% 
40-59 years: 61.8% 
≥60 years: 59.1% 
Wine: 48.0% 
Beer: 3.1%  
Brandy: 0.9% 
 
EUROGAST, 
1993 
1993 3194 25-34, 55-
64 
H. pylori Prevalence of 
infection (ELISA) 
Both sexes, 25-34 years: 
55.0% 
Both sexes, 55-64 years: 
70.0% 
 
da Costa, 
1997 
1994 1825 men, 
1704 
women 
Mean age: 
36.4 (men), 
32.1 
(women) 
Tobacco Prevalence of 
current 
consumption 
Men: 21.6% 
Women: 3.1% 
INE, 1998 1995-1996 6909 men, 
7603 
women 
All ages Tobacco Prevalence of 
current 
consumption 
Men 
All ages: 30.4% 
≥15 years: 31.7% 
15-24 years: 27.0% 
25-34 years: 51.8% 
35-44 years: 47.1% 
45-54 years: 36.3% 
55-64 years: 24.1% 
64-74 years: 17.7% 
≥75 years: 8.7% 
<20 cig/day: 28.7% 
≥21 cig/day: 70.7% 
  
Women 
All ages: 5.0% 
≥15 years: 5.4% 
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15-24 years: 6.7% 
25-34 years: 13.2% 
35-44 years: 8.7% 
45-54 years: 3.4% 
55-64 years: 0.6% 
64-74 years:0.6% 
≥75 years: 0.0% 
<20 cig/day: 61.9% 
≥21 cig/day: 37.0% 
 
        Alcohol Prevalence of 
consumption the 
year before the 
survey 
  
  
  
  
  
  
Men 
All ages: 66.9% 
≥15 years: 81.8% 
<15 years: 6.0% 
15-17 years: 33.6% 
18-24 years: 67.0% 
25-34 years: 87.7% 
35-44 years: 92.2% 
45-54 years: 94.0% 
55-64 years: 88.5% 
65-74 years: 84.7% 
≥75 years: 76.6% 
Wine: 62.1% 
Beer: 47.2% 
  
Women 
All ages: 46.9% 
≥15 years: 55.4% 
<15 years: 6.0% 
15-17 years: 20.8% 
18-24 years: 38.8% 
25-34 years: 59.9% 
35-44 years: 67.0% 
45-54 years: 66.0% 
55-64 years: 61.0% 
65-74 years: 56.4% 
≥75 years: 49.3% 
Wine: 44.2% 
Beer: 13.6% 
 
        Fruits Prevalence of 
consumption the 
day before the 
survey 
  
  
  
  
  
Both sexes 
All ages: 89.9% 
≥15 years: 89.4% 
0-4 years: 86.6% 
5-14 years: 94.0% 
15-17 years: 94.7% 
18-24 years: 93.9% 
25-34 years: 91.1% 
35-44 years: 89.1% 
45-54 years: 88.0% 
55-64 years: 87.4% 
65-74 years: 86.2% 
≥75 years: 85.3% 
 
        Vegetables Prevalence of 
consumption the 
day before the 
survey 
  
  
  
Both sexes 
All ages: 85.5% 
≥15 years: 86.5% 
0-4 years: 71.6% 
5-14 years: 84.6% 
15-17 years: 85.5% 
18-24 years: 86.2% 
25-34 years: 86.2% 
35-44 years: 86.8% 
45-54 years: 87.6% 
55-64 years: 87.8% 
65-74 years: 85.9% 
≥75 years: 83.5% 
 
        Obesity 
(BMI ≥ 30) 
Prevalence Men 
≥18 years: 8.4% 
18-24 years: 1.0% 
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25-34 years: 5.1% 
35-44 years: 8.0% 
45-54 years: 12.0% 
55-64 years: 14.0% 
65-74 years: 12.1% 
≥75 years: 9.6% 
  
Women 
≥18 years: 10.5% 
18-24 years: 1.9% 
25-34 years: 4.6% 
35-44 years: 10.1% 
45-54 years: 15.6% 
55-64 years: 15.5% 
65-74 years: 16.9% 
≥75 years: 8.3% 
 
        Overweight  
(27 ≤ BMI < 30) 
Prevalence Men 
≥18 years: 18.2% 
18-24 years: 7.4% 
25-34 years: 16.2% 
35-44 years: 19.3% 
45-54 years: 24.4% 
55-64 years: 23.1% 
65-74 years: 19.9% 
≥75 years: 18.9% 
  
      Women 
≥18 years: 16.3% 
18-24 years: 3.8% 
25-34 years: 10.5% 
35-44 years: 16.1% 
45-54 years: 23.3% 
55-64 years: 15.5% 
65-74 years: 16.9% 
≥75 years: 8.3% 
 
Marques-
Vidal, 2005 
1995-1996 5553 men, 
6296 
women 
  
≥15 Alcohol Prevalence of 
consumption the 
week before the 
survey 
Men 
Drinker: 73.1% 
Wine: 95.1% 
Beer: 72.3% 
Whiskey: 34.0% 
Port wine: 41.8% 
  
Women 
Drinker: 22.6% 
Wine: 92.0% 
Beer: 51.2% 
Whiskey: 27.7 % 
Port wine: 47.3 % 
  
1998-1999 5802 men, 
6546 
women 
≥15 Alcohol Prevalence of 
consumption the 
week before the 
survey 
Men 
Drinker: 69.1% 
Wine: 93.4% 
Beer: 74.3% 
Whiskey: 35.5% 
Port wine: 35.9% 
  
Women 
Drinker: 22.5% 
Wine: 92.5% 
Beer: 48.4% 
Whiskey: 24.3% 
Port wine: 41.0% 
 
Sallmen, 
2008  
1997 406 women 15-39 Tobacco Prevalence of 
current 
consumption 
Women, 15-39 years: 11.6% 
 
 
Amaral, 1998 1998 211 men, 
135 women 
18-65 H. pylori Prevalence of 
infection (ELISA) 
Both sexes 
18-65 years: 76.6% 
18-25 years: 58.9% 
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26-40 years: 74.5% 
41-65 years: 87.6% 
 
Pinho, 1998 1998 299 men, 
162 women 
≥11 H. pylori Prevalence of 
infection (ELISA) 
≥11 years: 82.9% 
11-20 years: 58% 
21-30 years: 71% 
31-40 years: 91% 
41-50 years: 90% 
≥51+ years: 91% 
 
Silva, 1999 1998 47 boys, 57 
girls 
6-11 H. pylori Prevalence of 
infection (UBT) 
Both sexes 
6-11 years: 52.9% 
6-8 years: 45.9% 
9-11 years: 56.3% 
Boys, 6-11 years: 57.4% 
Girls, 6-11 years: 49.1% 
 
INSA, 2001 1998-1999 5802 men, 
6546 
women 
All ages Tobacco Prevalence of 
current 
consumption 
Men 
≥15 years: 34.1% 
15-24 years: 27.7% 
25-34 years: 49.4% 
35-44 years: 47.7% 
45-54 years: 32.5% 
55-64 years: 23.3% 
64-74 years: 16.9% 
≥75 years: 9.0% 
<20 cig/day: 71.7% 
≥21 cig/day: 25.9% 
  
Women 
≥15 years: 8.0% 
15-24 years: 10.3% 
25-34 years: 16.2% 
35-44 years: 11.1% 
45-54 years: 5.1% 
55-64 years: 1.7% 
64-74 years: 0.5% 
≥75 years: 0.7% 
<20 cig/day: 91.6% 
≥21 cig/day: 6.3% 
 
        Alcohol Prevalence of 
consumption the 
year before the 
survey 
  
  
  
  
  
  
  
  
  
  
  
Men 
≥15 years: 79.2% 
<15 years: 1.6% 
15-24 years: 47.9% 
25-34 years: 85.2% 
35-44 years: 91.3% 
45-54 years: 90.6% 
55-64 years: 88.3% 
65-74 years: 82.6% 
≥75 years: 75.3% 
Wine: 89.9% 
Beer: 74.9% 
Brandy: 29.7% 
Liquour: 35.3% 
Whiskey. Gin. Vodka: 35.0% 
  
Women 
≥15 years: 51.2% 
<15 years: 1.1% 
15-24 years: 23.3% 
25-34 years: 52.9% 
35-44 years: 67.4% 
45-54 years: 60.8% 
55-64 years: 57.2% 
65-74 years: 52.8% 
      ≥75 years: 46.0% 
Wine: 92.6% 
Beer: 28.3% 
Brandy: 2.6% 
Liquour: 26.3% 
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Whiskey. Gin. Vodka: 8.7% 
 
        Fruits Prevalence of 
consumption the 
day before the 
survey 
  
  
Both sexes 
All ages: 83.7% 
≥15 years: 83.0% 
0-4 years: 82.4% 
5-14 years: 88.5% 
15-24 years: 85.3% 
25-64 years: 83.3% 
≥65 years: 79.7% 
 
        Vegetables Prevalence of 
consumption the 
day before the 
survey 
  
Both sexes 
All ages: 84.1% 
≥15 years: 84.9% 
0-4 years: 75.3% 
5-14 years: 80.9% 
15-24 years: 80.8% 
25-64 years: 85.4% 
≥65 years: 87.2% 
 
        Overweight 
(25 ≤ BMI < 30) 
Prevalence Men 
≥18 years: 40.6% 
18-24 years: 22.2% 
25-34 years: 36.8% 
35-44 years: 45.6% 
45-54 years: 47.0% 
55-64 years: 48.0% 
65-74 years: 47.7% 
≥75 years: 42.2% 
  
Women 
≥18 years: 30.7% 
18-24 years: 11.3% 
25-34 years: 23.5% 
35-44 years: 34.5% 
45-54 years: 38.2% 
55-64 years: 42.0% 
65-74 years: 37.7% 
≥75 years: 31.0% 
 
        Obesity 
(BMI ≥ 30) 
Prevalence Men 
≥18 years: 9.9% 
18-24 years: 1.8% 
25-34 years: 6.6% 
35-44 years: 10.3% 
45-54 years: 15.3% 
55-64 years: 15.3% 
65-74 years: 14.3% 
≥75 years: 9.8% 
  
      Women 
≥18 years: 12.1% 
18-24 years: 2.3% 
25-34 years: 6.2% 
35-44 years: 11.3% 
45-54 years: 19.2% 
55-64 years: 18.7% 
65-74 years: 17.6% 
≥75 years: 13.3% 
 
Correia, 2001 2000 40  men 33-73 Tobacco Prevalence of 
current 
consumption 
 
Men, 33-73 years: 30% 
Bastos, 
2013a 
1999-2003 2067 18-92 H. pylori Prevalence of 
infection (ELISA) 
Both sexes 
18-92 years: 84.2% 
18-40 years: 75.3% 
41-60 years: 89.0% 
61-92 years: 89.5% 
Men, 18-92 years: 85.0% 
Women, 18-92 years: 83.7% 
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Lopes, 2006 1999-2003 921 men, 
1477 
women 
18-92 Vegetables (not 
including soup) 
Prevalence of daily 
consumption 
Men 
≥ 18 years: 81.5% 
18-39 years: 82.1% 
40-49 years: 85.0% 
50-64 years: 80.4% 
≥ 65 years: 79.7% 
  
Women 
≥ 18 years: 84.8% 
18-39 years:83.7% 
40-49 years: 90.0% 
50-64 years: 86.3% 
≥ 65 years: 78.5% 
 
        Fruits Prevalence of daily 
consumption 
Men 
≥ 18 years: 87.4% 
18-39 years: 83.8% 
40-49 years: 86.5% 
50-64 years: 89.5% 
≥ 65 years: 88.2% 
  
Women 
≥ 18 years: 91.0% 
18-39 years: 85.3% 
40-49 years: 91.8% 
50-64 years: 93.4% 
≥ 65 years: 91.7% 
 
        Alcohol Prevalence of daily 
consumption 
  
Men 
≥ 18 years: 68.8% 
18-39 years: 40.2% 
40-49 years: 75.5% 
50-64 years: 78.4% 
≥ 65 years: 72.8% 
 
      Women 
≥ 18 years: 25.3% 
18-39 years: 9.7% 
40-49 years: 27.6% 
50-64 years: 32.0% 
≥ 65 years: 27.1% 
 
Santos, 2003 1999-2003 563 men, 
873 women 
18-92 Overweight 
(25 ≤ BMI < 30) 
 
Prevalence Men: 49.9% 
Women: 36.5% 
 
    
 
  Obesity 
(BMI ≥ 30) 
Prevalence Men: 13.9% 
Women: 26.1% 
 
Santos, 2004 1999-2003 629 men, 
1015 
women 
18-92 Tobacco Prevalence of 
current 
consumption 
Men 
18-24 years: 44.0% 
25-34 years: 61.5% 
35-44 years: 49.7% 
45-54 years: 38.0% 
55-64 years: 23.8% 
64-74 years: 17.1% 
75-93 years: 11.1% 
  
Women 
18-24 years: 40.7% 
25-34 years: 36.2% 
35-44 years: 31.4% 
45-54 years: 15.7% 
55-64 years: 5.8% 
64-74 years: 0.8% 
75-93 years: 1.3% 
 
Santos, 2007 1999-2003 832 men, 
1332 
women 
18-92 Alcohol Prevalence of 
consumption 
Men 
Current/ocasional drinker: 
88.8% 
Former drinker: 6.4% 
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Never drinker: 4.8% 
  
Women 
Current/ocasional drinker: 
65.8% 
Former drinker: 8.3% 
Never drinker: 25.9% 
 
Clemente, 
2004  
2003 154 men, 
226 women 
18-30 Tobacco Prevalence of daily 
consumption 
Men: 10.4% 
Women: 16.4% 
 
 
Bastos, 
2013b 
2003-2004 2204 13 H. pylori Prevalence of 
infection (ELISA) 
Both sexes: 66.2% 
Boys: 68.4% 
Girls: 63.6% 
 
Fraga, 2011 2003-2004 946 boys, 
1029 girls 
13 Alcohol Experimenter (ever 
experimented with 
alcohol), drinker 
(consumption at 
least once per 
month) 
Boys 
Drinker: 6.6% 
Experimenter: 44.9% 
 
Girls 
Drinker: 4.7% 
Experimenter: 50.0% 
 
Ramos, 2004 2003-2004 1135 13 Fruits Daily mean 
consumption 
Boys: 273g/day 
Girls: 303g/day 
 
        Vegetables Daily mean 
consumption 
  
Boys: 147g/day 
Girls: 153g/day 
Ramos, 2007 2003-2004 1045 boys, 
1116 girls 
3 Overweight Prevalence, 
calculated using the 
International Obesity 
Taskforce 
Recommendations 
 
Boys: 20.8%  
Girls: 18.8% 
 
    
Obesity Prevalence, 
calculated using the 
International Obesity 
Taskforce 
Recommendations 
 
Boys: 6.6% 
Girls: 5.7% 
 
INE, 2008 2005-2006 3000 
households 
All ages Fruits Household expenses,  
in euros 
213€ (1.3% of the 
expenses) 
        Vegetables Household expenses,  
in euros 
 
241€ (1.4% of the 
expenses) 
INSA, 2007 2005-2006 6084 All ages Tobacco Prevalence of 
current consumption 
Men 
≥15 years: 31.4% 
15-24 years: 33.1% 
25-34 years: 37.7% 
35-44 years: 47.3% 
45-54 years: 32.6% 
55-64 years: 16.6% 
64-74 years: 13.6% 
≥75 years: 8.8% 
<20 cig/day: 75.4% 
≥21 cig/day: 22.7% 
  
Women 
15-74 years: 9.8% 
15-24 years: 11.4% 
25-34 years: 12.8% 
35-44 years: 17.4% 
45-54 years: 7.1% 
55-64 years: 2.9% 
64-74 years: 1.5% 
<20 cig/day: 92.8% 
≥21 cig/day: 5.0% 
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        Alcohol Prevalence of 
consumption the 
year before the 
survey 
  
  
  
  
  
Men 
≥15 years: 81.9% 
<15 years: 4.0% 
15-24 years: 54.0% 
25-34 years: 85.4% 
35-44 years: 86.0% 
45-54 years: 91.4% 
55-64 years: 90.9% 
65-74 years: 91.0% 
≥75 years: 77.9% 
Wine: 91.1% 
Beer: 78.9% 
Brandy: 32.2% 
Liquour: 46.8% 
Whiskey. Gin. Vodka: 38.7% 
  
Women 
≥15 years: 60.9% 
<15 years: 1.3% 
15-24 years: 36.8% 
25-34 years: 56.4% 
35-44 years: 70.6% 
45-54 years: 72.3% 
55-64 years: 69.8% 
65-74 years: 61.0% 
≥75 years: 58.0% 
Wine: 89.8% 
Beer: 35.3% 
Brandy: 4.8% 
Liquour: 38.0% 
Whiskey. Gin. Vodka: 10.9% 
 
        Overweight 
(25 ≤ BMI < 30) 
Prevalence Men 
≥18 years: 40.0% 
18-24 years: 18.0% 
25-34 years: 39.2% 
35-44 years: 41.0% 
45-54 years: 48.7% 
55-64 years: 47.8% 
65-74 years: 42.9% 
≥75 years: 42.3% 
  
Women 
≥18 years: 32.8% 
18-24 years: 15.1% 
25-34 years: 21.6% 
35-44 years: 35.5% 
45-54 years: 36.7% 
55-64 years: 43.9% 
65-74 years: 43.6% 
≥75 years: 34.9% 
 
        Obesity 
(BMI ≥ 30) 
Prevalence Men 
≥18 years: 14.6% 
18-24 years: 5.0% 
25-34 years: 7.1% 
35-44 years: 14.1% 
45-54 years: 21.2% 
55-64 years: 21.2% 
65-74 years: 23.5% 
≥75 years: 15.7% 
  
Women 
≥18 years: 15.2% 
18-24 years: 5.0% 
25-34 years: 9.5% 
35-44 years: 11.5% 
45-54 years: 22.6% 
55-64 years: 24.7% 
65-74 years: 20.0% 
≥75 years: 14.4% 
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Lobão, 2010 2007 165 men, 
337 women 
18-84 Tobacco Prevalence of 
current consumption 
 
Men: 25% 
Women: 19% 
 
Saleiro, 2008 2007 173 men, 
165 women 
17-41 Tobacco Prevalence of 
current consumption 
 
Men: 31.8% 
Women: 10.9% 
 
Vasques, 
2012 
2008 907 boys, 
879 girls 
6-13 Overweight Prevalence, 
calculated using the 
International Obesity 
Taskforce 
Recommendations 
 
Boys: 23.2% 
Girls: 22.1% 
         Obesity Prevalence, 
calculated using the 
International Obesity 
Taskforce 
Recommendations 
 
Boys: 8.7% 
Girls: 10.0% 
Lopes, 2014 2009-2010 2942 boys, 
2869 girls 
4-5 Vegetables Prevalence of daily 
consumption 
Both sexes: 97.3% 
 
 
          Daily mean 
consumption 
  
Boys: 101.8 g/day 
Girls: 99.9 g/day 
        Fruits Prevalence of daily 
consumption 
Both sexes: 86.2% 
 
 
          Daily mean 
consumption 
Boys: 168.7 g/day 
Girls: 163.8 g/day 
 
Lunet, 2014 2009-2011 1047 4-5 H. pylori Prevalence of 
infection (ELISA) 
Both sexes: 30.6% 
Boys: 29.9% 
Girls: 31.4% 
 
INE, 2012 2010-2011 3570 
households 
All ages Fruits Household expenses,  
in euros 
219€ (1.1% of the 
expenses) 
        Vegetables Household expenses,  
in euros 
 
244€ (1.2% of the 
expenses) 
Dias, 2011 2011 925 men, 
1489 
women 
18-92 Alcohol Prevalence of 
current consumption 
Men: 85.5% 
Women: 53.3% 
 
 
BMI: Body mass index; H. pylori: Helicobacter pylori; ELISA: Enzyme-linked immunosorbent assay; UBT: Urea breath 
test. 
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MODIFIABLE FACTORS AND ESOPHAGEAL CANCER: A SYSTEMATIC 
REVIEW OF PUBLISHED META-ANALYSES 
 
Clara Castro1,2, Bárbara Peleteiro2,3, Nuno Lunet2,3 
1 North Region Cancer Registry (RORENO) – Portuguese Oncology Institute of Porto, Porto, 
Portugal 
2 EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal 
3 Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of 
Porto Medical School, Porto, Portugal 
 
 
ABSTRACT 
Background: There are marked differences in the etiology of the major histological types of 
esophageal cancer (EC) – squamous cell carcinomas (ESCC) and adenocarcinomas (EAC). This 
study aimed to summarize the current scientific knowledge on modifiable risk factors for EC, by 
histological type. 
Methods: A systematic review of meta-analyses referenced in PubMed and ISI Web of 
Knowledge until September 2015 was performed.  
Results: We identified 95 meta-analyses on risk factors for ESCC (n=47), EAC (n=46) or EC (n=51). 
ESCC risk significantly increased with alcohol and maté drinking, smoking and red and processed 
meat consumption, while it was negatively associated with body mass index and consumption 
of fruit, vegetable, white meat, folate and some carotenoids. Cessation of drinking and smoking 
significantly reduced ESCC risk. For EAC, an increased risk was reported for smoking, body mass 
index, gastroesophageal reflux and red and processed meat consumption, while risk decreased 
with Helicobacter pylori infection, low/moderate alcohol drinking, physical activity and 
consumption of fruit, vegetables, folate, fiber, beta-carotene and vitamin C.  
Conclusions: Differences in results between meta-analyses and mechanisms underlying some of 
the associations found are discussed. This work reinforces the importance of a separate 
assessment of EC subtypes to allow for a proper evaluation of incidence trends and planning of 
prevention/control interventions. 
 
KEYWORDS 
Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Review; Risk factors.  
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INTRODUCTION 
There are marked differences between the tumors of the major histological types of esophageal 
cancer (EC) regarding incidence and mortality trends, which reflect the specificities of each 
subtype regarding its determinants[1]. 
Esophageal squamous cell carcinoma (ESCC) comprises most cases of esophageal cancer[2], 
although its incidence has been steadily decreasing or stabilizing in Western countries[3]. The 
main risk factors of ESCC occurrence are tobacco smoking and alcohol consumption and many 
studies have shown both the independent and synergistic effects of these determinants[4]. 
Esophageal adenocarcinoma (EAC) incidence rates have been steadily increasing in several 
Western countries[3], although there are differences, either between countries[1] and between 
regions within the same country[5]. The upward trends are in part due to the increased 
prevalence of recognized risk factors such as gastroesophageal reflux disease (GERD) and 
obesity[6], but they may also be explained by variation in other modifiable exposures, such as 
smoking, diet and Helicobacter pylori (HP) infection[6-9]. 
A large body of research has been devoted to the study of the determinants of esophageal 
cancer, as summarized in several meta-analyses. This study aims to summarize the state of the 
art on the etiology of EC, by systematically reviewing published meta-analyses on the main 
modifiable factors associated with the occurrence of esophageal cancer, by histological type. 
 
METHODS 
PubMed and ISI Web of Knowledge were searched up to September 2015 to identify published 
meta-analyses addressing the association between the main modifiable exposures and 
esophageal cancer. The titles and abstracts of the retrieved articles were read and full texts were 
obtained for the studies considered potentially relevant. In addition, references cited in the 
identified articles were manually searched. 
Studies were included if a meta-analysis based on published results or an individual participant 
data meta-analysis was performed to quantify the association between modifiable exposures 
and EC, ESCC or EAC. Only full-length papers published in English, Portuguese, Spanish, French, 
Italian or Polish were included. Studies focusing on the impact of the cessation of modifiable 
exposures on the risk of EC, EAC or ESCC were also kept in our review. Studies were excluded if: 
(1) EC, ESCC or EAC was not reported as an outcome of interest; (2) determinants other than 
alcohol drinking, smoking and smokeless tobacco, HP infection, GERD, Barrett’s Esophagus, 
obesity/BMI, physical activity or diet were evaluated; (3) no summary estimate was provided in 
the form of an odds ratio (OR), relative risk (RR) or hazard ratio (HR), along with the 
correspondent 95% confidence interval (CI); (4) results provided constituted duplicate 
information from previous studies (i.e., reviews mentioning as summary estimate a result from 
a meta-analysis already included in our review). 
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Since EC is a relatively rare and a highly lethal disease, we ignored the distinction between RR, 
OR and HR, reporting RR henceforth as the effect estimate. For each study, the following 
information was extracted: first author’s name, publication year, number of studies included in 
the meta-analysis and corresponding study design when available, EC histological type 
evaluated, risk factor assessed, categories of exposure compared, the RR and corresponding 
95% CI. Stratified results by sex, study type and geographical area and dose-response RRs were 
collected, whenever available. If both fixed and random effects estimates were provided, the 
latter were used as they allow for some heterogeneity between studies. 
All studies were assessed independently by two researchers (CC and BP) to determine their 
eligibility and for data extraction; disagreements were discussed and resolved by consensus or 
involving a third researcher (NL).  
Each meta-analysis obtained from a systematic review was attributed a quality score, ranging 
from 0 to 11, based on the AMSTAR tool[10]. Results obtained were summarized using a harvest 
plot, for the most commonly evaluated determinants. Forest plots describing the overall and 
sex-specific RRs on the main determinants of EAC and ESCC were obtained using Stata Statistical 
Software, version 11.0[11]. 
 
RESULTS 
We identified 95 publications reporting results from meta-analyses on the association between 
the aforementioned risk factors and the occurrence of ESCC (n=47), EAC (n=46) or EC (n=51). 
The systematic review flow-chart is presented as Supplementary Figure 1. Information extracted 
for each study is accessible in Supplementary Table 1, and quality assessment is presented in 
Figure 1 and Supplementary Table 2. The minimum and maximum quality scores found were of 
3 and 10, respectively, and 47 meta-analyses had a score of 7 or higher. The main findings for 
each determinant of EC are presented below. 
 
Alcohol drinking 
Twenty five studies evaluated the association between alcohol drinking and EC, 11 of which did 
not include histology-specific RRs[12-22].  
Eight studies reported a significant dose-response effect of alcohol drinking on EC, both in the 
overall[12, 13, 15, 16, 18, 23] and subgroup analyses by sex[12], geographical area (Mediterranean and 
Non-Mediterranean)[14],  study  design  (case-control  and  cohort  studies)[22]  and  type  of  drink 
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Figure 1: Harvest plot of the overall association between the main determinants of esophageal cancer and its occurrence, by 
subtype, when comparing the highest with the lowest levels of exposure or dose-response effects. Each bar corresponds to a meta-
analysis (based on systematic reviews in black, otherwise in grey) and depicts its quality score; labels correspond to the number of 
studies included in the estimate provided in each meta-analysis; a diagonal pattern indicates that the estimate was obtained from 
case-control studies only. Meta-analyses are ordered according to year of publication (x-axis). 
 
(wine[13] and beer[22]). Overall, an increment of 100g/week of alcohol consumption was found to 
increase EC risk by 15% (RR=1.15, 95%CI: 1.08, 1.22)[23]. 
The association between ESCC and alcohol consumption was addressed in 11 studies (Figure 
2A)[23-33]. Sex-specific estimates showed a non-significantly higher ESCC risk among men than 
women: RRs were of 3.7 and 2.1, respectively, when comparing ever with never drinkers[26] and 
of 1.46 and 1.28 when comparing light drinkers with never drinkers[24]. Age at starting drinking 
and the number of drinking years did not relevantly change ESCC risk[26]. An increment of 100 
g/week of alcohol consumption was found increasing ESCC risk by 20%[23]. A dose-response 
effect was also reported in meta-analyses evaluating alcohol consumption as the number of 
drinks per day[29, 31], drink-years[31] and grams of pure ethanol consumed per day or per week[24-
26, 30, 33]. Among men, RRs ranged between 1.39 (95%CI: 1.11, 1.74) for 1-12.5 g/day and 4.69 
(95%CI: 3.49, 6.31) for over 50 g/day, while among women corresponding values were of 1.14 
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(95%CI: 0.87, 1.49) and 8.32 (95%CI: 2.95, 23.45), when compared with non-drinkers[25]. No 
significant differences were found in ESCC risk between case-control and cohort studies[24, 25], 
nor between different geographical areas (Asia/Non-Asia[30], Europe/Asia[32] and 
Europe/Asia/North America[24, 25]). 
Six meta-analyses reported on alcohol drinking and EAC (Figure 2B)[23, 28, 29, 31, 34, 35]. Two 
compared ever with never drinkers: while Drahos et al.[34] reported a significantly reduced EAC 
risk among ever drinkers (RR=0.78, 95%CI: 0.64, 0.96), Fahey et al. did not find a significant 
association (RR=1.08, 95%CI: 0.85, 1.37)[28]. Another study reported a borderline non-significant 
association when comparing drinkers with non-drinkers[35]. Although point estimates globally 
increased with alcohol consumption, no significant associations were found in most meta-
analyses, even at high levels of consumption[23, 28, 31, 35]. An exception was the subgroup analysis 
reported by Freedman et al.[29] regarding the type of drink, in which drinking up to one glass of 
wine per day was found reducing the risk of EAC in comparison with non-drinkers. For individuals 
without GERD, EAC risk was found approximately 50% lower among drinkers than among non-
drinkers, regardless of the number of drinks consumed per day[29]; this reduced risk was also 
observed in a more recent meta-analysis, in the overall analysis and in the age group ≥ 70 years 
old[34]. 
 
Tobacco smoking 
Fourteen studies evaluated the association between tobacco smoking and EC, EAC or ESCC[17, 23, 
26-28, 31, 32, 34, 36-41]. Using never smokers as the reference category, results obtained from the five 
studies not providing histology-specific RRs yielded no significant differences between sexes, 
study designs (case-control and cohort studies), ethnicities (African-Americans, Asians and 
Caucasians, though Asians had a lower point estimate), geographical areas (Western and Non-
Western countries), smoking habits (former, current and ever smokers) or adjustment (or not) 
for alcohol consumption[17, 36, 37, 39, 40]. A substantially higher risk of EC was found among drinkers 
(RR=6.01, 95%CI: 3.82, 9.44) than among non-drinkers (RR=2.45, 95%CI: 2.06, 2.91), when 
comparing current with never smokers[36]. Overall, an increment of 100 g/week of tobacco 
consumption was found to increase the risk of EC by 32% (RR=1.32, 95%CI: 1.15, 1.52)[23]. Six 
meta-analyses focused on tobacco smoking and ESCC (Figure 3A)[23, 26-28, 31, 32]. Current smokers 
had a significantly higher risk of ESCC than never smokers (RR=5.1 among men, RR=3.1 among 
women)[26] and presented twice the risk of former smokers (RR=3.13, 95%CI: 2.53, 3.86 vs. 
RR=1.68, 95%CI: 1.44, 1.96)[32]. An increment of 100 g/week of tobacco consumption was found 
increasing ESCC overall risk by 25%[23]. Dose-response effects were reported with the number of 
cigarettes smoked per day (cig/day)[26], the number of smoking years[26] and the number of pack-
years[28, 31], using non-smokers as reference. People who had started smoking after they were 21 
years old had a significantly lower risk of ESCC than those aged 13 or younger at smoking onset 
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Figure 2: Forest plots of overall and sex-specific associations between alcohol drinking and the occurrence of: (A) esophageal squamous cell carcinoma (ESCC); (B) esophageal adenocarcinoma (EAC). RR: relative risk, CI: confidence 
interval. 
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Figure 3: Forest plots of overall 
and sex-specific associations 
between tobacco smoking and 
the occurrence of: (A) 
esophageal squamous cell 
carcinoma (ESCC); (B) 
esophageal adenocarcinoma 
(EAC). RR: relative risk, CI: 
confidence interval. 
 
 
(RR=0.6 among men and RR=0.2 among women)[26]. Prabhu et al.[32] found a lower ESCC risk in 
Asia (RR=2.31, 95%CI: 1.78, 2.99) than in Europe (RR=4.21, 95%CI: 3.13, 5.66) when comparing 
current with never smokers. 
Six studies reported the association between tobacco smoking and EAC (Figure 3B)[23, 28, 31, 34, 38, 
41]. The only meta-analysis providing sex-specific estimates showed a non-significantly higher 
EAC risk among men (RR=2.10 for men, RR=1.74 for women)[38], with the strength of association 
being much lower than that of ESCC. As for ESCC, an increasing EAC risk was found with an 
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increment of 100 g/week of tobacco consumption (RR=1.27, 95%CI: 1.11, 1.46)[23] and with the 
number of pack-years[31, 34, 38]. When comparing ever with never smokers, the association 
between smoking and EAC was found significant in two meta-analyses(RR≈1.9)[38, 41], but not in 
a third one (RR=0.96, 95%CI: 0.82, 1.12, n=4)[28]. Drahos et al.[34] performed an age-specific 
analysis and found a significant association of both current and former smoking with the risk of 
EAC, for all age groups; the highest estimates were observed for ages 50-59 years (RR=3.75 for 
current and RR=2.95 for former smokers) and the lowest for ages 60-69 years (RRs of 1.81 and 
1.86, respectively). 
 
Alcohol drinking/tobacco smoking cessation 
Time since cessation of alcohol drinking (Supplementary Figure 2A) or tobacco smoking 
(Supplementary Figure 2B) was assessed in four meta-analyses[26, 27, 42, 43]. For EC as a whole, 
using current drinkers as the reference category, the RRs obtained for never drinkers and the 
group of 15 or more years since drinking cessation were similar (RR=0.37) and did not relevantly 
change after adjustment for smoking[43]. In 2012, a comparison between the longest cessation 
group and current drinkers yielded a RR=0.46 (95%CI: 0.34, 0.63)[42]. 
Ten or more years since cessation did not suffice to reduce ESCC risk to the values observed 
among never drinking men nor among never smoking men; among women, five and ten years 
since cessation were enough to reach similar values to the ones obtained for never drinkers and 
never smokers, respectively[26]. Male drinkers who had quitted between the ages of 48 and 57 
had a significantly higher ESCC risk than those quitting before they were 48 years old; otherwise, 
age at quitting drinking or smoking did not significantly change ESCC risk[26]. The risk of ESCC 
among men was shown to decrease by 4% per year since cessation of alcohol drinking (RR=0.96, 
95%CI: 0.94, 0.98) and by 2% per year since cessation of tobacco smoking (RR=0.98, 95%CI: 0.97, 
0.99)[27]. No meta-analyses were found on the association between alcohol drinking cessation 
or tobacco smoking cessation and EAC. 
 
Waterpipe smoking and smokeless tobacco 
Akl et al.[44] reported a higher risk of EC among current waterpipe smokers, in comparison with 
never smokers, although this association was not statistically significant (RR=1.85, 95%CI: 0.95, 
3.58) and it was based on a single observational study. Akhtar et al.[45] performed the only meta-
analysis focusing on areca nut (also commonly referred to as betel nut) chewing, and reported 
an increased risk of ESCC for chewers in comparison with non-chewers (RR=3.05, 95%CI: 2.41, 
3.87); the risk estimate provided did not relevantly change when considering only men nor when 
adjusting for education, tobacco chewing, alcohol drinking or fruit and vegetable intake. 
Among never tobacco smokers, the use of snus (a moist powder tobacco product originating 
from a variant of dry snuff, and consumed by placing it under the upper lip for extended periods 
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of time) significantly increased the risk of ESCC (RR=3.5, 95%CI: 1.6, 7.6) and reduced, though 
not significantly, the risk of EAC (RR=0.2, 95%CI: 0.0, 1.9)[46].  
The effects of smokeless tobacco, including any form of chewing tobacco, oral snuff, snus or 
tobacco pastes or powders, have been assessed by three meta-analyses[47-49]. In 2008, Boffeta 
et al.[47] reported an increased risk of EC among ever users in comparison with never users 
(RR=1.6, 95%CI: 1.1, 2.3), with significant results in Nordic countries (four studies), but not in the 
United States of America (USA) (one study). In 2009, Lee et al.[48] reported summary point 
estimate lower than the one previously found (RR=1.25; 95%CI: 1.03, 1.51), which was significant 
in the USA (six studies), but not in Nordic countries (using the same four studies, but with a 
different combination of results). When adjusting for tobacco smoking, there was no significant 
association between smokeless tobacco and the risk of EC (RR=1.13, 95%CI: 0.95, 1.36), while 
there was a higher EC risk among never smokers (RR=1.91, 95%CI: 1.15, 3.17)[48]. In 2015, Siddiqi 
et al.[49] reported a significantly higher risk of EC among ever smokeless tobacco users, in 
comparison with never users (RR=2.17, 95%CI: 1.70, 2.78), which remained significant when 
restricting the analysis to studies performed in India (n=7), Pakistan (n=2) and Sweden (n=5), but 
not in Norway (n=1) and North America (n=1). 
 
H. pylori infection 
The effect of HP infection was evaluated by five meta-analyses that reported results for both 
ESCC and EAC (Figure 4)[50-54]. All reported similar results, showing no association between HP 
and ESCC, while for EAC a protective effect of HP infection was found (RR≈0.5). When comparing 
cytotoxin-associated gene A (CagA) positive strains with CagA negative strains, results were 
similar[51, 53]. However, in 2013, protective effects of both HP infection (RR=0.66, 95%CI: 0.43, 
0.89) and CagA positive strains (RR=0.77, 95%CI: 0.65, 0.92) were found regarding ESCC risk 
when the analyses were restricted to studies from Iran and China[52]. 
 
GERD symptoms 
The association between GERD symptoms and EAC has been assessed by three meta-analyses, 
which reported a gradually increased risk of EAC with the increasing frequency and duration of 
GERD symptoms[34, 55, 56]. Patients with weekly symptoms presented an EAC risk of 4.92 (95%CI: 
3.90, 6.22) when compared to individuals with less than weekly frequency or no symptoms, 
which rose to 7.40 (95%CI: 4.94, 11.10) when patients had daily symptoms[55]. Less than 10 to 
15 years of symptoms duration yielded an EAC risk of 3.05 (95%CI: 1.53, 6.08), while more than 
20 years in duration presented a risk of 5.41 (95%CI: 2.45, 11.9)[55]. RRs were generally lower for 
regurgitation   (e.g.,   RR=4.94  for  daily   regurgitation  vs.   RR=7.42  for  daily  heartburn,  when  
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Figure 4: Forest plot of overall 
association between H. pylori and 
the occurrence of esophageal 
cancer, by histological subtype. 
RR: relative risk, CI: confidence 
interval, ESCC: esophageal 
squamous cell carcinoma, EAC: 
esophageal adenocarcinoma. 
 
 
compared to individuals with no symptoms)[56]. When comparing more than daily with no 
symptoms, individuals aged 50-59 presented the lowest estimates (RR=4.65 for heartburn and 
RR=3.25 for regurgitation), while individuals aged less than 50 or over 70 presented the highest 
values (RR=6.84 and 11.41 for heartburn, and RR=7.00 and RR=6.58 for regurgitation, 
respectively)[34]. 
 
Barrett’s Esophagus 
Only one meta-analysis focused this risk factor, showing a non-significantly decreased EAC risk 
among individuals with short segment Barrett’s Esophagus when compared to conventional 
Barrett’s Esophagus (RR=0.55, 95%CI: 0.19, 1.50)[57]. 
 
BMI 
Twelve publications assessed BMI (Supplementary Figure 3), one of which did not provide 
histology-specific RRs[58]. ESCC was focused by four meta-analyses[22, 28, 59, 60]. No significant 
change was found in ESCC risk with an increment of 1 kg/m2[22], but a significant reduction was 
found with an increment of 5 kg/m2 (RR=0.71 for men and RR=0.57 for women)[59]. This 
protective effect remained when performing analysis by study design, with a significantly lower 
RR being found in case-control studies (RR per 5 kg/m2=0.49, 95%CI: 0.44, 0.55) than in cohort 
studies (RR=0.69, 95%CI: 0.63, 0.75)[60]. In 2015, a significantly reduced ESCC risk was found 
among individuals with a BMI over 25 (RR=0.8, 95%CI: 0.67, 0.95), but not among obese 
individuals (RR=1.05, 95%CI: 0.76, 1.46), when compared to a normal weight[28]. 
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EAC was focused by 11 studies, eight of which reported a significant dose-response effect of BMI 
[22, 34, 59-64]. In 2013, EAC risk was found increasing by 13% per 5 kg/m2 (RR=1.13, 95%CI: 1.11, 
1.16)[64], and a RR of 2.51 (95%CI: 1.56, 4.04) was reported when comparing the highest with the 
lowest category of central adiposity[65]. However, non-significant associations were found when 
comparing obese with normal weight men (RR=1.23, 95%CI: 0.58, 2.60)[66], or when restricting 
analyses to individuals aged less than 50 (RR=1.64, 95%CI: 0.99, 2.73) or older than 70 years old 
(RR=1.19, 95%CI: 0.93, 1.52), in the comparison between overweight and normal weight 
individuals[34]. 
 
Physical activity 
Five meta-analyses were published, between 2014 and 2015, focusing the association between 
physical activity or sedentarism and the occurrence of EC[28, 67-70], one of which did not provide 
histology-specific estimates[69]. The remaining four meta-analyses compared the highest with 
the lowest levels of exercise, finding no significant association with ESCC[28, 67, 68, 70]. Two meta-
analyses found a significant protective effect of physical activity on EAC risk (RR=0.79, n=7[67] 
and RR=0.68, n=4[70]), while the other two found no significant association[28, 68]. 
Further stratified results were only available for EC as a whole. A significantly reduced risk of EC 
was reported for studies from North America (RR=0.77, 95%CI: 0.64, 0.92), Australia (RR=0.72, 
95%CI: 0.57, 0.91) and Middle East (RR=0.48, 95%CI: 0.29, 0.81)[67], but not from Europe or 
Asia[67, 68, 70]. A reduced risk of EC was also reported among men and women, and in both case-
control and cohort studies[67, 68, 70]. 
 
Diet 
No significant changes in ESCC risk were found regarding dietary glycemic index[71, 72]. In 2009, 
Mulholland et al. [71] reported a significantly increased ESCC risk per 100 units/day of glycemic 
load (RR=1.2), based in a single case-control study; in 2015, a meta-analysis based on four 
studies showed a lack of association when comparing the highest with the lowest categories of 
glycemic load[72].  In 2012, Yu et al.[73] found no significant association between energy intake 
and EC. In 2014, when comparing the highest with the lowest levels of intake, ESCC risk was 
significantly reduced among individuals presenting a healthy dietary pattern (described as a 
higher loading of fruits, fresh vegetables, dietary fiber and antioxidants and a lower loading of 
fat dairy, processed food and meat) (RR=0.36) and increased for an alcohol dietary pattern 
(RR=2.34), while it did not significantly change for a western dietary pattern (higher loading of 
fat, animal food and processed food, and a lower loading of fruits, vegetables, and dietary 
fibres)[74]. No similar meta-analyses were found regarding EAC. 
Four meta-analysis on fruits and/or vegetables did not report histology-specific estimates[22, 75-
77]. ESCC risk was reduced by 40% to 60% when the highest intake of fruits or vegetables was 
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compared to the lowest intake[78, 79], with no significant associations being found among 
women[78] (Supplementary Figure 4). Regarding fruit consumption, ESCC risk was significantly 
lower in Europe and in South America (RR≈0.4) than in Asia (RR=0.67), while for vegetable 
consumption it was significantly lower in Europe (RR=0.3) than in Asia, South America and the 
USA (RR≈0.65)[79].  An increment of 100g/day of fruit intake was found decreasing ESCC risk by 
nearly 40%, while an increment of 100g/day in vegetable consumption reduced it by 16%[79]; for 
EAC, corresponding values were of 13% and 9%, respectively[80]. Increasing intakes of 50g/day 
of citrus fruits, raw vegetables and non-starchy vegetables were found decreasing EC risk by 
30%, 31% and 13%, respectively[22], while the consumption of pickled vegetables was found 
doubling ESCC risk (RR=2.08, 95%CI: 1.66, 2.60), when compared to no or low consumption[81]. 
When comparing the highest with the lowest category of intake, no significant associations were 
found for ESCC with the consumption of meat (overall[82, 83] and among women[78]), barbecue[78], 
cereals[78], fat (among women)[78], fiber[84], salt (among women)[78], acrylamide[85, 86], zink[87], 
beta-carotene [88], green tea[89], coffee[78, 89, 90], coffee with milk[78] and soft drinks[91]. Using the 
same categories of exposure, a significantly increased ESCC risk was found regarding the 
consumption of meat (RR=1.46, 95%CI: 1.11, 1.92 among men)[78], red meat (RRs between 1.55 
and 1.86)[82, 83, 92, 93], fat (RR=1.57 among men)[78], salt (RR=2.11 among men)[78], while a 
significantly decreasing ESCC risk was reported regarding the consumption of white meat 
(RR=0.63)[83], folate (RR≈0.65)[94, 95], alpha-carotene (RR=0.82)[88], beta-cryptoxanthin 
(RR=0.83)[88], lycopene (RR=0.74)[88] and tea (RR=0.53 among men)[78]. In 2014, a meta-analysis 
on poultry consumption found a significantly reduced ESCC risk (RR=0.73)[83] when comparing 
the highest with the lowest total meat consumption, which had not been reported in a previous 
study[82]. For red meat, a dose-response effect was found per increasing 100 g/day (RR=1.41, 
95%CI: 1.16, 1.70)[93]. Three meta-analyses evaluated the association between fish and ESCC: 
while one of them found a significant protective effect in the overall analysis, based on 17 
studies, when comparing the highest with the lowest categories of intake (RR=0.81, 95%CI: 0.66, 
0.99)[96], the other two found no significant association[82, 83]. The association between processed 
meat and ESCC was assessed by four meta-analyses published between 2013 and 2014: three of 
them[82, 83, 92] yielded an increasing though not significant association in the overall analysis, while 
the fourth one[93] presented a RR of 1.55 (95%CI:1.22, 1.97) when comparing the highest with 
the lowest categories of intake and found a significant dose-response effect per increasing 50 
g/day of processed meat intake on ESCC risk (RR=1.81, 95%CI: 1.32, 2.48)[93]. A significant dose-
response effect was found between the consumption of maté and the occurrence of ESCC[78, 97]; 
the association between maté drinking and ESCC was found stronger among women than men, 
and no significant differences were found between people who had quitted drinking maté for 
10 or more years and never drinkers[78]. 
For EAC, no significant associations were found with the consumption of poultry[82, 83], white 
meat[83], fish[82, 83, 96], acrylamide[85, 86], zink[87], vitamin E[98], coffee[89, 90] and soft drinks[91], while 
a decreasing risk was found regarding folate (RR≈0.5)[94, 95], fiber (RR=0.66)[84], beta-carotene 
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(RR=0.46)[88, 98] and vitamin C intake (RR=0.49)[98] and an increasing risk was reported with the 
consumption of total meat (RR=1.96)[83], red meat (RR between 1.2 and 1.4)[82, 83, 92, 99] and 
processed meat (RR≈1.4)[82, 83, 92, 99]. 
No significant associations for EC were found with barbecued meat[82], eggs[22], milk and dairy 
products[22], acrylamide[85] and black tea[89] consumption, while a protective effect was found 
regarding white meat (RR=0.71)[82], fish (RR=0.91)[100], folate (RR=0.6)[101] and lutein and 
zeaxanthin intake (RR=0.71)[88]. While a meta-analysis found a significant protective effect of 
coffee for EC (RR=0.55)[102], a more recent study yielded no significant association, except among 
Asian results (RR=0.67)[89]. A decreasing EC risk was also found regarding green tea consumption 
among women (RR between 0.32 and 0.46[89, 103, 104]), but not among men or in the overall 
analysis[17, 89, 103, 104].  
EC risk increased with the consumption of hot/very hot beverages (RR=1.77) and foods 
(RR=2.09)[105]. This association was also found significant for ESCC (RR=1.6, 95%CI: 1.29, 2.00), 
but not for EAC (RR=0.79, 95%CI: 0.53, 1.16)[105]. Restricting the analyses to the type of drink, a 
significantly increasing risk of ESCC was found when comparing very hot to cold/warm maté 
(RR=1.77 for men and RR=2.47 for women), tea (RR=8.73 for men and RR=2.20 for women) and 
coffee with milk among men (RR=2.22), while no significant associations were found for coffee 
(both sexes) and coffee with milk (for women)[78]. 
 
Interactions between risk factors 
Seven studies evaluated the interaction between some of the aforementioned risk factors for 
EC, EAC or ESCC[4, 17, 26, 36, 45, 62, 78]. For ESCC, significant interactions were found between areca 
nut chewing and tobacco smoking (RR=6.79, 95%CI: 4.71, 9.79)[45], tobacco smoking and alcohol 
drinking (RR=3.28, 95%CI: 2.11, 5.08)[4] and between the consumption of maté at very hot 
temperatures and drinking more than 1.5 liters of maté per day (RR=4.14, 95%CI: 2.24, 7.67)[78]. 
For EAC, a significant interaction was found between overweight/obesity (BMI≥27.5 kg/m2) and 
the presence of GERD symptoms (RR=3.18, 95%CI: 2.45, 4.13)[62], but no modifying effects were 
found between overweight/obesity and cigarette smoking or alcohol drinking. 
Ishikawa et al.[17] evaluated the potential effect modifications of smoking (current), alcohol 
(daily) and green tea (≥3 cups/day) consumption on EC risk, by analyzing combined categories 
of these variables and using people with none of the exposures as reference. The interactions 
between smoking and alcohol drinking, smoking and green tea consumption, alcohol and green 
tea consumption and all three variables yielded RRs of 9.23 (95%CI: 2.10, 40.60), 4.99 (95%CI: 
1.11, 22.43), 2.97 (95%CI: 0.53, 16.58) and 11.10 (95%CI: 2.63, 46.51), respectively. Ansary-
Moghaddam et al.[36] also evaluated the interaction between smoking and alcohol, using 15 
studies, and obtained a RR of 10.0 (95%CI: 4.08, 24.50) for EC. 
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DISCUSSION 
The association between the most well-known risk factors for esophageal cancer and its 
occurrence have been extensively described in the literature and an increasing number of meta-
analyses have been published focusing those determinants. The risk of ESCC increased with 
alcohol and maté drinking, tobacco smoking and with red and processed meat consumption, 
while it was negatively associated with body mass index and the consumption of fruit, vegetable, 
white meat, folate and some carotenoids. For EAC, a significantly increased risk was reported 
for tobacco smoking, body mass index, increasing frequency and duration of gastroesophageal 
reflux symptoms and red and processed meat consumption, while it was reduced by 
Helicobacter pylori infection, low/moderate alcohol drinking, physical activity and the 
consumption of fruit, vegetables, folate, fiber, beta-carotene and vitamin C. 
To the best of our knowledge, this is the first systematic review of meta-analyses on esophageal 
cancer environmental risk factors. Although methodological limitations are inherent to the 
primary studies included in the meta-analyses, this review depicts the state of the art on the 
modifiable risk factors for EC, showing marked differences between its subtypes regarding the 
strength of association with each determinant. 
When a meta-analysis was published regarding a risk factor, a new meta-analysis on the same 
determinant usually yielded further stratified results, or it was based on a different set of 
observational studies (e.g., from a different geographical area). In most situations, risk estimates 
did not differ significantly between meta-analyses focusing on the same risk factors, but there 
were some exceptions which should be discussed. 
Most meta-analyses found no significant association between alcohol drinking and EAC, even at 
high levels of consumption. However, two meta-analyses, originated from pooled analysis of 
studies included in the International Barrett’s and Esophageal Adenocarcinoma Consortium 
(BEACON), suggested a protective effect of low/moderate alcohol consumption on EAC risk[29, 
34]. In 2011, based on nine case-control and two cohort studies, Freedman et al.[29] suggested 
that modest alcohol drinking, particularly less than one drink per day, might be associated with 
reduced EA risk. Although the inverse associations found could be due to chance (the 
stratification of results led to a small number of cases in each strata) or recall bias (since most 
of the included studies were of case-control design), the authors argued that these results could 
also depict a true association, as alcohol consumption may have favorable effects on insulin 
resistance or levels of serum lipids and lipoproteins[106], which may be important for EAC risk. In 
2015, two meta-analyses compared ever with never drinkers: while Drahos et al.[34] found a 
significant protective effect of alcohol consumption on EAC risk, at all ages and in people aged 
70 or older, Fahey et al.[28] found no significant association. Although results obtained by Fahey 
et al. were based on a systematic review, only two case-control studies (from Sweden and the 
USA) were used to obtain the summary estimates, while Drahos et al. used individual data from 
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8 BEACON case-control studies (from Australia, Ireland, Sweden and the USA). Therefore, results 
provided by the latter are more reliable, since a larger number of studies was included in the 
analysis, and the usage of individual data allows for the adjustment of each study’s results to 
the same variables, ensuring the comparability of results. 
Tobacco consumption was found significantly increasing EAC risk in all meta-analyses, with the 
exception of Fahey et al.[28], who compared ever with never smokers, based on 4 studies, and 
found no significant association. As before, this lack of association is probably due to the smaller 
number of studies included in the meta-analysis, in comparison with the other studies 
performing similar evaluations[34, 38, 41].  
For smokeless tobacco, the conflicting results found between Boffetta et al.[47] and Lee and 
Hamling[48] were discussed in a commentary[107] which concluded that the latter results were 
more reliable, as authors included a larger number of studies, used smoking-adjusted estimates 
whenever possible and, for studies where the RR was not provided but could be derived from 
data, they calculated an estimate of the effect measure, instead of excluding those papers. 
Those results were also more reliable than the ones provided in a more recent meta-analysis, 
which presented a higher RR but found a high degree of heterogeneity (I2=76%) between the 
studies included in the analysis[49].  
Two meta-analyses[67, 70] found an inverse association between physical activity and EAC risk, 
while two other[28, 68] found no significant association. As before, the meta-analyses which did 
not provide a significant result were the ones including the smaller number of studies in the 
analyses (only two observational studies included in each). Proposed mechanisms for the 
protective effect of physical activity on cancer are that it may prevent carcinogenesis by reducing 
insulin resistance and lowering fasting insulin levels, increasing the concentration of anti-
inflammatory adipocytoxines [108], decreasing oxidative stress and enhancing DNA repair[109]. 
In all meta-analyses found in our study, HP infection was consistently described as having a 
protective effect of EAC risk, while no significant association was found with ESCC. The 
mechanisms underlying the inverse association between HP infection and EAC are not clear, but 
it has been suggested that hypoacidity in association with gastric atrophy may have a role[110]. 
GERD is one of the most commonly mentioned risk factors for EAC in epidemiological studies, 
but few meta-analyses have focused this determinant. A strong association between GERD 
symptoms and EAC has been described, with estimated ORs ranging from 5 to over 40[8, 111], a 
variability that reflects the increase in risk with the duration, frequency and severity of 
symptoms. The high heterogeneity between studies, which has also been reported in the meta-
analyses included in our study, may explain why most reviews on GERD symptoms do not 
provide summary estimates.  
Overweight and obesity were consistently reported as risk factors for EAC, but a protective effect 
of BMI was found regarding ESCC. Overweight and obesity have been proposed to increase 
reflux, causing chronic inflammation and Barrett’s Esophagus, which predisposes to EAC[112]. 
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However, studies have shown that only a small proportion (≈5%) of EAC cases are previously 
diagnosed with Barrett’s Esophagus, and that patients with this condition rarely develop EAC[113]. 
Furthermore, both independent and synergistic effects of BMI and GERD have been reported[62], 
which means that other mechanisms are also in place. The systemic inflammatory state led by 
the altered metabolism of obese patients, and the associated impact of adipocytokines and pro-
coagulant factors released by adipocytes in central fat, has been a proposed explanation for 
obesity's association with EAC[114]. Some authors have argued that the observed inverse 
association between BMI and ESCC is real, though not necessarily causal[59, 60]. Since a high 
consumption of fruit and vegetables and the adoption of healthy dietary patterns have also been 
reported to be inversely associated with ESCC, it has been proposed that a low calorie diet which 
lowers BMI is likely to be restricted in micronutrients, and these deficiencies could lead to 
increased risk of ESCC[60]. Another possible explanation is a negative confounding of the BMI and 
cancer association by smoking intensity[115], which has been supported by studies presenting an 
inverse association between BMI and ESCC risk among smokers, but not among non-
smokers[116]. 
Although our quality assessment of included studies has shown that most meta-analyses 
published regarding EC risk factors are of good quality, the key limitation on the interpretability 
of our findings is the heterogeneity between (and within each of) the meta-analyses selected 
for inclusion in our review. Among the 95 selected studies, 81 were performed following a 
systematic review of literature, 12 were obtained through pooled analysis and 2 did not clearly 
state the inclusion criteria. Among the studies conducting systematic reviews, some focused on 
a specific geographical area (e.g., Japan[20, 40]) or included only studies of a given design (e.g., 
cohort studies[100, 102]); 6 of the pooled analyses used data from BEACON, 3 used data from 
studies conducted in South America, 2 in Asia and 1 in Italy. Thus, cultural aspects, customs and 
lifestyles of each geographical area are likely explanations for the differences found between 
summary estimates provided for some determinants, namely regarding diet. Out of the 51 meta-
analysis found for EC, 32 did not provide histology-specific estimates, even though 12 of those 
studies specifically focused EC as an outcome of interest, while the others targeted digestive 
cancers, neoplasms in general and other public health outcomes such as cardiovascular diseases, 
presenting EC as an accessory result. Furthermore, moderate to high degrees of heterogeneity 
were observed in several of the studies included in our review, even when performing stratified 
analyses by sex, geographical area or study design. In fact, many authors have mentioned the 
difficulties in performing stratified meta-analyses using available data from observational 
studies, since there is no standardization in data collection and data reporting[28, 115]. 
Our study has shown that a significant reduction in ESCC risk could be obtained from alcohol 
drinking and tobacco smoking cessation, with RRs reaching similar values to the ones observed 
in individuals who never drank or smoked, within some years after cessation. This depicts the 
importance of planning interventions aimed to reduce the consumption of both alcohol and 
tobacco. Future studies focusing on EAC to provide such estimates would also be useful, 
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especially given the marked increase in EAC incidence trends observed in Western countries in 
the last decades[1, 117].  
Our inclusion criteria led to the exclusion of many studies focusing on medications (e.g., 
nonsteroidal anti-inflammatory drugs), treatments and genetic factors. Future reviews on these 
factors could yield relevant information on the etiology of EC, namely through the evaluation of 
confounding/synergistic effects with the determinants we have included in our work. There are 
some comorbidities which have also been assessed through meta-analyses and may be worth 
analyzing in future studies. Examples include an increased risk of ESCC found in people with 
gastric atrophy (RR=1.94, 95%CI: 1.48, 2.55)[118] and in Human Papiloma Virus seropositive 
individuals (for HPV16 E6, HPV6 L1, HPV6 E6§ and HPV11 L1 subtypes)[119], and an increased risk 
of EAC in the presence of diabetes mellitus (RR=2.12, 95%CI: 1.01, 4.46)[120].  
In conclusion, this comprehensive systematic review summarizes the state of the art on the 
etiology of EC, showing evident differences between ESCC and EAC regarding some risk factors. 
This reinforces the importance of a separate assessment of EC subtypes to allow for a proper 
discussion of incidence trends and a suitable planning of interventions towards the reduction of 
cancer burden in the population. 
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Supplementary Table 1: Description of the Meta-analyses Included in the Systematic Review. 
First author, 
year (ref) 
Outcome 
(measures) 
Databases 
searched 
(time period) 
Search expression / terms 
Search restrictions 
Number and type 
of studies included, 
when available 
Quality score 
assessment 
Summary estimate (95% CI) 
Heterogeneity (I2 and sources) 
Publication bias 
ALCOHOL       
Holman, 1996[16] EC 
(mortality) 
MEDLINE 
(1980-1994) 
 
Citation tracking 
Not stated 
 
Restricted to studies published in English and study 
populations primarily of European origin 
7 No Responsible (0-2.9 drinks/day) vs. Abstinence 
RR=1.80 (1.63-1.99), n=7 
 
Hazardous (3-4.9 drinks/day) vs. Abstinence 
RR=2.37 (2.03-2.76), n=7 
 
Harmful (≥5 drinks/day) vs. Abstinence 
RR=4.26 (3.70-4.90), n=7 
Castellsagué, 
1999[26] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ever vs. never drinkers 
Men – OR=3.7 (2.7-4.9) 
Women – OR=2.1 (1.3-3.3) 
 
Current vs. never drinkers 
Men – OR=4.4 (3.1-6.2) 
Women – OR=2.2 (1.3-3.9) 
 
Ex- vs. never drinkers 
Men – OR=3.4 (2.3-5.0) 
Women – OR=1.9 (0.9-3.8) 
 
Average amount of pure ethanol/day (ml) 
Men 
1-24 – OR=1.8 (1.2-2.6) 
25-49 – OR=3.0 (2.1-4.4) 
50-149 – OR=4.1 (3.0-5.8) 
150-249 – OR=6.9 (4.5-10.6) 
≥ 250 – OR=11.5 (7.4-17.6) 
Women 
1-24 – OR=2.1 (1.1-3.9) 
25-49 – OR=2.3 (1.1-5.0) 
≥ 50 – OR=2.0 (1.0-4.2) 
 
Years of alcohol drinking 
Men 
1-29 – OR=2.9 (2.0-4.2) 
30-39 – OR=4.6 (3.2-6.5) 
40-49 – OR=3.6 (2.6-5.1)  
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≥ 50 – OR=4.0 (2.7-5.9) 
Women 
1-29 – OR=2.9 (1.4-5.9) 
30-39 – OR=2.0 (0.8-5.0) 
40-49 – OR=1.6 (0.6-4.1) 
≥ 50 – OR=2.1 (1.0-4.3) 
 
Age at starting drinking 
Men 
17-19 – OR=1.1 (0.8-1.5) 
20-24 – OR=0.9 (0.7-1.3) 
≥ 25 – OR=0.9 (0.7-1.3) 
Women 
17-24 – OR=1.1 (0.4-3.0) 
≥ 25 – OR=1.1 (0.4-3.4) 
 
Age at quitting drinking 
Men 
48-57 – OR=2.2 (1.1-4.6) 
58-65 – OR=2.2 (1.0-5.0) 
≥ 66 – OR=1.0 (0.4-2.6) 
Women 
≥ 58 – OR=1.8 (0.2-14.4) 
 
Years since quitting drinking 
Men 
1-4 – OR=0.9 (0.7-1.3) 
5-9 – OR=0.8 (0.5-1.4) 
≥ 10 – OR=0.6 (0.4-0.9) 
Women 
1-4 – OR=1.3 (0.4-4.4) 
≥ 5 – OR=0.6 (0.2-1.8) 
 
Type of drink 
Men 
Ever beer – OR=2.6 (1.8-3.8) 
Ever wine – OR=3.5 (2.6-4.8) 
Ever spirits – OR=4.5 (3.3-6.1) 
Women 
Ever beer – OR=5.5 (1.6-19.5) 
Ever wine – OR=1.6 (1.0-2.7) 
Ever spirits – OR=8.0 (2.7-23.9) 
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Corrao, 1999[14] EC 
(risk) 
MEDLINE 
(1966-1998) 
 
Citation tracking 
Not stated 14 
 
1 cohort 
13 case-control 
Questions 
related to the 
study design, 
alcohol 
consumption 
data collection 
methods and 
data analysis 
were used to 
obtain quality 
score. 
Dose-response analysis 
 
ACCORDING TO GEOGRAPHIC AREA 
 
Mediterranean 
25 g/day – RR=1.6 (1.5-1.7) 
50 g/day – RR=2.5 (2.2-2.8) 
100 g/day – RR=6.0 (4.6-7.8) 
 
Other areas 
25 g/day – RR=1.5 (1.3-1.7) 
50 g/day – RR=2.2 (1.7-2.8) 
100 g/day – RR=4.5 (2.6-7.8) 
Bosetti, 2000[13] EC 
(risk) 
Pooled analysis 
of two case-
control studies 
conducted in the 
greater Milan 
area and in the 
province of 
Pordenone, in 
northern Italy, 
between 1984 
and 1998 
NA 2 case-control NA Total alcohol, according to the number of drinks/day 
3-4 vs. 1-2 – OR=1.98 (1.46-2.67) 
5-7 vs. 1-2 – OR=4.22 (3.10-5.75) 
8-11 vs. 1-2 – OR=7.60 (5.51-10.48) 
≥ 12 vs. 1-2 – OR=12.35 (8.37-18.21) 
 
Wine only, according to the number of drinks/day 
3-4 vs. 1-2 – OR=1.70 (1.14-2.54) 
5-7 vs. 1-2 – OR=4.21 (2.69-6.58) 
8-11 vs. 1-2 – OR=8.76 (5.37-14.27) 
≥ 12 vs. 1-2 – OR=17.90 (6.56-48.85) 
 
Wine and other, according to the number of 
drinks/day 
3-4 vs. 1-2 – OR=1.83 (1.20-2.79) 
5-7 vs. 1-2 – OR=3.50 (2.34-5.25) 
8-11 vs. 1-2 – OR=6.01 (3.97-9.11) 
≥ 12 vs. 1-2 – OR=10.00 (6.30-15.87) 
 
Beer, according to the number of drinks/day 
1-2 vs. 0 – OR=0.96 (0.75-1.23) 
≥ 3 vs. 0 – OR=1.35 (0.91-1.99) 
 
Spirits, according to the number of drinks/day 
1-2 vs. 0 – OR=0.99 (0.79-1.23) 
≥ 3 vs. 0 – OR=1.51 (0.95-2.38) 
Castellsagué, 
2000b[27] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
NA 5 case-control NA Ex- vs. current drinkers 
Men – OR=0.7 (0.5-0.9) 
 
Never vs. current drinkers 
Papers | 117 
conducted in 
high-risk areas in 
South America 
Men – OR=0.3 (0.1-0.7) 
 
Years since quitting drinking 
Men 
1-2 – OR=0.8 (0.6-1.3) 
3-5 – OR=0.7 (0.4-1.2) 
6-9 – OR=0.7 (0.3-1.2) 
10-18 – OR=0.6 (0.3-1.1) 
≥ 19 – OR=0.4 (0.2-0.8) 
 
Trend per cessation year 
Men – OR=0.96 (0.94-0.98) 
Bagnardi, 2001[12] EC 
(risk) 
MEDLINE, 
Current 
Contents, 
EMBASE, CAB 
Abstracts and 
Core Biomedical 
Collection 
(1966-2000) 
 
Citation tracking 
Not stated 28 
 
1 cohort 
27 case-control 
No Dose-response analysis 
All studies 
25 g/day – RR=1.51 (1.48-1.55) 
50 g/day – RR=2.21 (2.11-2.31) 
100 g/day – RR=4.23 (3.91-4.59) 
 
Studies presenting unadjusted estimates for smoking 
25 g/day – RR=1.50 (1.47-1.55) 
50 g/day – RR=2.19 (2.08-2.31) 
100 g/day – RR=4.18 (3.79-4.60) 
 
Studies presenting adjusted estimates for smoking 
25 g/day – RR=1.52 (1.46-1.57) 
50 g/day – RR=2.23 (2.09-2.38) 
100 g/day – RR=4.31 (3.84-4.85) 
 
 
ACCORDING TO SEX 
 
Men 
25 g/day – RR=1.43 (1.38-1.48) 
50 g/day – RR=1.98 (1.87-2.11) 
100 g/day – RR=3.49 (3.14-3.89) 
 
Women 
25 g/day – RR=1.52 (1.42-1.63) 
50 g/day – RR=2.24 (1.95-2.58) 
100 g/day – RR=4.45 (3.37-5.87) 
Zeka, 2003[23] EC, ESCC, EAC 
(risk) 
MEDLINE 
(1966-2001) 
Not stated 8 case-control No Trend estimation (per 100g/week of consumption) 
 
Esophageal cancer 
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β=0.14 (SE: 0.03), n=8, I2=77% 
 
Esophageal adenocarcinoma 
β=0.05 (SE: 0.03), n=2, I2=0% 
 
Esophageal squamous cell carcinoma 
β=0.18 (SE: 0.01), n=2, I2=0% 
 
Mixed esophageal carcinoma 
β=0.19 (SE: 0.09), n=2, I2=92% 
Corrao, 2004[15] EC 
(risk) 
MEDLINE, 
EMBASE 
(1966-1998) 
 
Citation tracking 
The search process involved combining the keywords 
‘‘alcohol consumption’’, ‘‘relative risk’’, and the specific 
‘‘conditions’’. These keywords were exploded in the 
search, thus to include all the articles investigating the 
same issue, but reporting the same term in different forms 
(i.e., ‘‘alcohol consumption’’ or ‘‘alcohol intake’’, ‘‘relative 
risk’’ or ‘‘risk ratio’’ or ‘‘odds ratio’’, ‘‘cancer’’ or 
‘‘malignant neoplasm’’ or ‘‘neoplasia’’, ‘‘cerebrovascular 
disease’’ or ‘‘stroke’’) 
 
No language restrictions. 
14 
 
1 cohort 
13 case-control 
Questions 
related to the 
study design, 
alcohol 
consumption 
data collection 
methods and 
data analysis 
were used to 
obtain quality 
score. 
Dose-response analysis 
All studies 
25 g/day – RR=1.39 (1.36-1.42) 
50 g/day – RR=1.93 (1.85-2.00) 
100 g/day – RR=3.59 (3.34-3.87) 
Ishikawa, 2006[17] EC 
(incidence) 
Pooled analysis 
of prospective 
cohort studies 
conducted in 
Miyagi 
Prefecture, 
Japan 
NA 2 cohort NA Former vs. never/occasionally drinkers 
HR=1.55 (0.58-4.14) 
 
Daily vs. never/occasionally drinkers 
HR=2.73 (1.55-4.81) 
Rehm, 2007[43] EC 
(risk) 
MEDLINE 
(1966-2006), 
EMBASE 
(1980-2006), 
WEB OF SCIENCE 
(1980-2006), 
PSYCHINFO 
(1980-2006) 
 
Citation tracking 
The following key search terms were used: (["mouth 
cancer" OR "oral cavity cancer" OR "oropharynx cancer" 
OR "oropharyngeal cancer OR "pharyngeal cancer" OR 
"head and neck cancer" OR "esophageal cancer"] AND 
"alcohol") AND ("risk" OR "association") AND ("cessation" 
OR "stopping drinking" OR "quitting drinking" OR 
"abstinence") 
 
Restricted to studies published in English 
5 case-control No Years since cessation vs. current drinkers 
 
All studies 
>0-2 – OR=2.50 (2.23-2.80) 
2-5 – OR=1.10 (1.03-1.17) 
5-10 – OR=0.85 (0.78-0.92) 
10-15 – OR=0.85 (0.79-0.92) 
>15 – OR=0.37 (0.33-0.41) 
Never drinkers – OR=0.37 (0.35-0.39) 
 
Studies presenting adjusted estimates for smoking 
>0-2 – OR=2.50 (2.23-2.80) 
2-5 – OR=1.10 (1.03-1.18) 
5-10 – OR=0.85 (0.79-0.92) 
10-15 – OR=0.85 (0.79-0.92) 
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>15 – OR=0.35 (0.31-0.39) 
Never drinkers – OR=0.37 (0.35-0.39) 
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
21 
 
1 cohort 
20 case-control 
No Total alcoholic drinks 
Per 1 drink/week increment 
Cohort – RR=1.26 (1.10-1.44), n=1 
Case-control – RR=1.04 (1.03-1.05), n=20, I2=90.6% 
 
Beers 
Per 1 drink/week increment 
RR=1.05 (1.03-1.07), n=5, I2=90.5% 
Rota, 2010[33] ESCC 
(risk, 
incidence, 
mortality) 
MEDLINE 
(inception-2008) 
 
Citation tracking 
Not stated 15 
 
1 cohort 
14 case-control 
No Ethanol in grams/day (reference category: 0) 
25 – OR=2.81 (1.79-4.40) 
50 – OR=5.11 (2.63-9.94) 
100 – OR=11.00 (4.61-26.24) 
Freedman, 2011[29] ESCC, EAC 
(risk) 
International 
BEACON 
Consortium 
NA 12 
 
2 nested case-
control 
9 case-control 
NA EAC 
 
Drinks/day (reference category: 0) 
All types 
>0-0.5 – OR=0.86 (0.65-1.13), I2=41% 
0.5-<1 – OR=0.63 (0.41-0.99), I2=63% 
1-<3 – OR=0.81 (0.60-1.09), I2=44% 
3-<5 – OR=0.86 (0.59-1.24), I2=47% 
5-<7 – OR=0.93 (0.66-1.31), I2=0% 
≥7 – OR=0.97 (0.68-1.36), I2=16% 
 
Beer 
>0-0.5 – OR=0.75 (0.53-1.07), I2=51% 
0.5-<1 – OR=0.71 (0.44-1.15), I2=43% 
1-<3 – OR=0.72 (0.51-1.04), I2=8% 
3-<5 – OR=0.60 (0.36-1.01), I2=16% 
≥5 – OR=0.63 (0.40-0.99), I2=0% 
 
Liquor 
>0-0.5 – OR=0.71 (0.49-1.02), I2=56% 
0.5-<1 – OR=0.95 (0.66-1.35), I2=4% 
1-<3 – OR=1.09 (0.60-1.97), I2=59% 
3-<5 – OR=1.27 (0.75-2.13), I2=0% 
≥5 – OR=1.52 (0.82-2.80), I2=0% 
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Wine 
>0-0.5 – OR=0.67 (0.45-0.99), I2=57% 
0.5-<1 – OR=0.59 (0.39-0.88), I2=11% 
1-<3 – OR=0.71 (0.49-1.03), I2=5% 
≥3 – OR=1.49 (0.80-2.78), I2=0% 
 
Drinks/day (reference category: 0) 
All types 
>0-0.5 – OR=0.86 (0.65-1.13), I2=41% 
0.5-<1 – OR=0.63 (0.41-0.99), I2=63% 
1-<3 – OR=0.81 (0.60-1.09), I2=44% 
3-<5 – OR=0.86 (0.59-1.24), I2=0% 
 
ACCORDING TO SEX 
Women 
>0-0.5 – OR=1.20 (0.59-2.44), I2=28% 
0.5-<1 – OR=0.85 (0.35-2.09), I2=0% 
1-<3 – OR=1.29 (0.63-2.67), I2=0% 
3-<5 – OR=4.25 (1.60-11.30), I2=0% 
 
Men 
>0-0.5 – OR=0.77 (0.55-1.08), I2=48% 
0.5-<1 – OR=0.58 (0.35-0.95), I2=65% 
1-<3 – OR=0.74 (0.50-1.07), I2=57% 
3-<5 – OR=0.74 (0.48-1.15), I2=54% 
≥5 – OR=0.85 (0.65-1.11), I2=0% 
 
ACCORDING TO GERD 
No reflux 
>0-0.5 – OR=0.69 (0.43-1.10), I2=20% 
0.5-<1 – OR=0.48 (0.30-0.77), I2=0% 
1-<3 – OR=0.55 (0.33-0.92), I2=37% 
3-<5 – OR=0.49 (0.31-0.80), I2=0% 
≥5 – OR=0.55 (0.34-0.89), I2=0% 
 
Reflux 
>0-0.5 – OR=0.87 (0.52-1.47), I2=28% 
0.5-<1 – OR=0.44 (0.24-0.81), I2=30% 
1-<3 – OR=0.80 (0.53-1.22), I2=0% 
3-<5 – OR=0.66 (0.39-1.10), I2=0% 
≥5 – OR=1.21 (0.74-1.99), I2=0% 
 
ACCORDING TO SMOKING 
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Never smokers 
>0-0.5 – OR=0.96 (0.68-1.35), I2=0% 
0.5-<1 – OR=0.67 (0.41-1.08), I2=0% 
1-<3 – OR=0.82 (0.54-1.24), I2=0% 
3-<5 – OR=0.71 (0.38-1.34), I2=0% 
≥5 – OR=1.38 (0.71-2.69), I2=0% 
 
Former smokers 
>0-0.5 – OR=0.66 (0.38-1.15), I2=58% 
0.5-<1 – OR=0.62 (0.29-1.31), I2=73% 
1-<3 – OR=0.73 (0.41-1.29), I2=65% 
3-<5 – OR=0.84 (0.47-1.50), I2=52% 
≥5 – OR=0.85 (0.57-1.27), I2=1% 
 
Current smokers 
>0-0.5 – OR=1.01 (0.58-1.75), I2=0% 
0.5-<1 – OR=0.67 (0.33-1.38), I2=0% 
1-<3 – OR=0.78 (0.43-1.44), I2=0% 
3-<5 – OR=0.85 (0.44-1.63), I2=0% 
≥5 – OR=1.09 (0.61-1.97), I2=0% 
 
ACCORDING TO BMI 
18.5-<25 Kg/m2 
>0-0.5 – OR=0.90 (0.61-1.32), I2=0% 
0.5-<1 – OR=0.63 (0.30-1.34), I2=51% 
1-<3 – OR=1.00 (0.63-1.59), I2=25% 
3-<5 – OR=0.99 (0.59-1.64), I2=6% 
≥5 – OR=1.19 (0.74-1.92), I2=0% 
 
25-<30 Kg/m2 
>0-0.5 – OR=0.75 (0.50-1.13), I2=31% 
0.5-<1 – OR=0.58 (0.35-0.97), I2=40% 
1-<3 – OR=0.68 (0.43-1.07), I2=42% 
3-<5 – OR=0.79 (0.48-1.31), I2=35% 
≥5 – OR=0.69 (0.46-1.03), I2=0% 
 
30-<35 Kg/m2 
>0-0.5 – OR=1.09 (0.63-1.90), I2=0% 
0.5-<1 – OR=1.00 (0.30-3.28), I2=45% 
1-<3 – OR=0.65 (0.33-1.25), I2=0% 
3-<5 – OR=0.63 (0.12-3.26), I2=66% 
≥5 – OR=0.54 (0.24-1.22), I2=0% 
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≥35 Kg/m2 
>0-0.5 – OR=2.43 (0.74-7.96), I2=0% 
0.5-<1 – OR=1.23 (0.22-6.89), I2=0% 
1-<3 – OR=1.79 (0.35-9.24), I2=0% 
3-<5 – OR=0.99 (0.14-6.88), I2=0% 
≥5 – OR=3.61 (0.76-17.04), I2=0% 
 
Duration in years (reference category: 0) 
>0-<10 – OR=0.94 (0.56-1.57), I2=0% 
10-<20 – OR=1.15 (0.77-1.74), I2=1% 
20-<30 – OR=0.83 (0.55-1.24), I2=24% 
30-<40 – OR=0.76 (0.53-1.07), I2=17% 
40-<50 – OR=0.74 (0.49-1.10), I2=37% 
≥50 – OR=0.71 (0.48-1.05), I2=22% 
 
Drinks-years (reference category: 0) 
>0-<25 – OR=0.75 (0.56-0.99), I2=0% 
25-<50 – OR=0.66 (0.44-0.99), I2=26% 
50-<100 – OR=0.75 (0.54-1.02), I2=0% 
100-<200 – OR=0.67 (0.48-0.94), I2=0% 
200-<300 – OR=1.04 (0.69-1.57), I2=0% 
≥300 – OR=0.97 (0.50-1.88), I2=45% 
 
 
ESCC 
 
Drinks/day (reference category: 0) 
All types 
>0-0.5 – OR=0.80 (0.56-1.14), I2=18% 
0.5-<1 – OR=1.23 (0.55-2.74), I2=67% 
1-<3 – OR=2.56 (1.10-5.96), I2=79% 
3-<5 – OR=4.56 (2.32-8.96), I2=67% 
5-<7 – OR=7.17 (2.98-17.25), I2=69% 
≥7 – OR=9.62 (4.26-21.71), I2=71% 
Islami, 2011[30] ESCC 
(risk) 
Previous meta-
analysis plus 
MEDLINE 
(1999-2010) 
 
Citation tracking 
‘‘Esophageal Neoplasms’’ [MeSH Terms] and [cohort OR 
prospective OR (case-control) OR (case control)] 
53 
 
13 cohort 
40 case-control 
No Light intake (< 12.5 g/day) 
All studies – RR=1.31 (1.10-1.57), n=26, I2=56.2% 
Cohort – RR=1.35 (0.92-1.98), n=8, I2=81.1% 
More precise estimates – RR=1.32 (0.90-1.60), n=19, 
I2=73.2% 
Population-based controls – RR=1.16 (0.87-1.55), 
n=13, I2=77.3% 
Only ESCC – RR=1.25 (1.01-1.56), n=16, I2=61.0% 
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Adjusted results – RR=1.38 (1.14-1.67), n=19, 
I2=51.5% 
 
ACCORDING TO GEOGRAPHIC AREA 
All studies 
Asia – RR=1.63 (1.20-2.22), n=9, I2=73.1% 
Other regions – RR=1.17 (0.99-1.39), n=17, I2=32.8% 
Adjusted results (at least for age, alcohol and 
tobacco) 
Asia – RR=1.52 (1.06-2.19), n=8, I2=67.4% 
Other regions – RR=1.28 (1.04-1.59), n=11, I2=32.1% 
Prospective studies 
Asia – RR=1.89 (1.49-2.41), n=5, I2=17.8% 
Other regions – RR=1.03 (0.76-1.39), n=3, I2=29.2% 
 
 
Moderate intake (12.5-50 g/day) 
All studies – RR=2.27 (1.89-2.72), n=47, I2=85.3% 
Cohort – RR=2.15 (1.55-2.98), n=12, I2=86.7% 
More precise estimates – RR=2.23 (1.84-2.71), n=38, 
I2=87.1% 
Population-based controls – RR=1.92 (1.49-2.47), 
n=23, I2=85.0% 
Only ESCC – RR=2.32 (1.80-2.99), n=27, I2=85.8% 
Adjusted results – RR=2.62 (2.07-3.31), n=28, 
I2=82.8% 
 
ACCORDING TO GEOGRAPHIC AREA 
All studies 
Asia – RR=2.17 (1.58-2.96), n=21, I2=90.9% 
Other regions – RR=2.34 (1.90-2.88), n=26, I2=74.1% 
Adjusted results (at least for age, alcohol and 
tobacco) 
Asia – RR=2.52 (1.69-3.74), n=14, I2=88.4% 
Other regions – RR=2.69 (2.05-3.53), n=14, I2=71.3% 
Prospective studies 
Asia – RR=1.96 (1.20-3.22), n=8, I2=88.8% 
Other regions – RR=2.46 (1.55-3.90), n=4, I2=82.7% 
 
 
High intake (> 50 g/day) 
All studies – RR=4.89 (3.84-6.23), n=39, I2=87.1% 
Cohort – RR=3.35 (2.06-5.46), n=9, I2=91.4% 
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More precise estimates – RR=3.35 (2.35-4.78), n=16, 
I2=94.5% 
Population-based controls – RR=3.77 (2.60-5.47), 
n=18, I2=91.0% 
Only ESCC – RR=5.38 (3.80-7.61), n=20, I2=88.4% 
Adjusted results – RR=5.54 (3.92-7.82), n=21, 
I2=89.9% 
 
ACCORDING TO GEOGRAPHIC AREA 
All studies 
Asia – RR=4.02 (2.76-5.83), n=18, I2=91.6% 
Other regions – RR=5.73 (4.41-7.44), n=21, I2=79.9% 
Adjusted results (at least for age, alcohol and 
tobacco) 
Asia – RR=4.31 (2.46-7.55), n=10, I2=91.8% 
Other regions – RR=6.94 (4.71-10.22), n=11, 
I2=83.3% 
Prospective studies 
Asia – RR=3.65 (2.03-6.55), n=7, I2=92.3% 
Other regions – RR=2.64 (0.75-9.37), n=2, I2=93.3% 
Li, 2011[19] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
EMBASE, 
CNKI, VIP 
(inception-2010) 
 
Citation tracking 
mixture of free text and index terms 
 
Restricted to studies conducted on Chinese populations 
and published in English or Chinese. 
36 
 
2 cohort 
34 case-control 
Newcastle-
Ottawa scale  
Drinkers vs. non drinkers 
All studies – RR=1.78 (1.38-2.30), n=36, I2=90% 
 
ACCORDING TO SEX 
Men – RR=1.82 (1.49-2.22) 
Women – RR=0.91 (0.47-1.77) 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.08 (0.94-1.23), n=2, I2=96% 
Case-control – RR=1.79 (1.47-2.17), n=34, I2=87% 
Oze, 2011[20] EC 
(risk) 
MEDLINE 
(1950-2010), 
Ichushi 
(1983-2010) 
 
Citation tracking 
using the following as keywords: alcohol, esophagus, 
esophageal cancer, cohort, follow-up, case–control, Japan 
and Japanese 
 
Restricted to studies conducted on Japanese populations 
and published in English or Japanese. 
13 
 
4 cohort 
9 case-control 
No Ever vs. never drinkers 
All studies – RR=3.30 (2.30-4.74), n=12, I2=80%, 
Egger test: p=0.713 
Only adjusted estimates for smoking – RR=3.36 
(1.66-6.78), n=4, I2=83% 
Jarl, 2012[42] EC 
(risk) 
MEDLINE 
(inception-
2011), 
Google Scholar 
(first 30 hits) 
 
Citation tracking 
[‘alcohol’ AND (‘oesophageal cancer’ OR ‘esophageal 
cancer’) AND ‘risk’ AND (‘cessation’ OR ‘quit drinking’ OR 
‘quitting drinking’ OR ‘stop drinking’ OR ‘stopping drinking’ 
OR ‘abstainers’ OR ‘abstinence’)] 
 
Restricted to studies published in English 
17 
 
2 cohort 
15 case-control 
No Alcohol cessation (high vs. current) 
OR=0.46 (0.34-0.63), n=9, I2=26.6% 
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Lubin, 2012[31] ESCC, EAC 
(risk) 
International 
BEACON 
Consortium 
NA 12 
 
2 nested case-
control 
10 case-control 
NA Drink-years (reference category: 0) 
 
Esophageal adenocarcinoma 
1-49 – OR=0.74 (0.6-0.9) 
50-99 – OR=0.77 (0.5-1.1) 
100-149 – OR=0.60 (0.4-0.9) 
150-199 – OR=0.62 (0.4-1.1) 
≥200 – OR=0.67 (0.4-1.2) 
 
Esophageal squamous cell carcinoma 
1-49 – OR=1.31 (0.9-1.9) 
50-99 – OR=2.18 (1.3-3.8) 
100-149 – OR=2.96 (1.6-5.3) 
150-199 – OR=3.52 (1.8-6.9) 
≥200 – OR=3.82 (1.9-7.8) 
 
 
Drinks/day (reference category: 0.1-1.0) 
 
Esophageal adenocarcinoma 
1.0-2.9 – OR=1.09 (0.8-1.4) 
3.0-4.9 – OR=1.27 (0.8-1.9) 
5.0 -9.9– OR=1.56 (0.9-2.7) 
≥10 – OR=1.87 (0.9-3.7) 
 
Esophageal squamous cell carcinoma 
1.0-2.9 – OR=1.32 (0.9-1.9) 
3.0-4.9 – OR=2.15 (1.3-3.6) 
5.0 -9.9– OR=2.74 (1.5-5.2) 
≥10 – OR=4.12 (2.0-8.4) 
Tramacere, 
2012[35] 
EAC 
(risk) 
MEDLINE 
(inception-2010) 
 
Citation tracking 
MeSH terms ‘alcohol drinking’ or ‘alcoholic beverages’ and 
‘stomach neoplasms’ or ‘esophageal neoplasms’ 
 
Restricted to studies published in English 
24 
 
4 cohort 
20 case–control 
No Drinkers vs. non drinkers 
RR=0.87 (0.74-1.01), n=13, I2=35.7% 
 
Heavy alcohol drinkers (≥ 4 drinks per day) vs. non 
drinkers 
RR=1.10 (0.80-1.50), n=7 
Bagnardi, 2013[24] ESCC 
(risk) 
MEDLINE, 
WEB OF 
SCIENCE, 
EMBASE 
(inception-2010) 
 
Citation tracking 
((ethanol) OR (alcohol drinking)) AND lip neoplasm OR 
tongue neoplasm OR salivary gland neoplasm  OR gingival 
neoplasm OR mouth neoplasm OR pharynx neoplasm OR 
Laryngeal neoplasm OR esophageal neoplasm OR 
Intestinal neoplasm OR Colorectal neoplasm OR Breast 
neoplasm OR liver neoplasm 
 
27 
 
9 cohort 
18 case-control 
No Light drinking 
All studies – RR=1.30 (1.09-1.56), n=27, I2=67% 
 
ACCORDING TO SEX 
Men – RR=1.46 (1.19-1.80), n=14 
Women – RR=1.28 (0.84-1.96), n=5 
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Restricted to studies published in English ACCORDING TO STUDY DESIGN 
Cohort – RR=1.34 (0.96-1.87), n=9 
Case-control – RR=1.28 (1.04-1.59), n=18 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.05 (0.79-1.38), n=7 
North America – RR=1.21 (0.96-1.54), n=8 
Asia – RR=1.49 (1.12-1.98), n=10 
Prabhu, 2013[32] ESCC 
(risk) 
MEDLINE 
(1948-2013), 
EBM reviews 
(inception-
2013), 
EMBASE 
(1947-2011), 
ISI Web of 
Knowledge 
(inception-
2013), 
BIOSIS preview 
(1926-2013) 
Key index terms for our literature review included 
{esophageal carcinoma, esophageal neoplasm or 
[esophagus and (squamous cell carcinoma, carcinoma, 
cancer, neoplasms, adenosquamous carcinoma or 
basosquamous carcinoma)]} and (risk factors, tobacco, 
tobacco smokeless, tobacco use disorder, tobacco smoke 
pollution, smoke, smoking, marijuana smoking, cigarette, 
cigar, alcohols, alcohol, alcohol drinking, alcoholism, 
alcohol abuse, ethanol, alcoholic beverages, liquor, beer, 
wine, spirits, or alcoholic intoxication), also using the 
alternative spelling ‘oesophageal’ or ‘oesophagus’ 
 
No language restrictions 
18 
 
5 cohort 
13 case-control 
Newcastle-
Ottawa Scale 
 
6 highest 
quality studies 
≥200 g of alcohol/week vs. never drinkers 
All studies – OR=4.65 (3.61-5.99), n=18, I2=71% 
Only highest quality studies – OR=3.49 (2.82-4.32), 
n=6, I2=37% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=3.51 (3.09-4.00), n=5, I2=0% 
Case-control – OR=5.20 (3.30-8.18), n=13, I2=80% 
 
ACCORDING TO RACE/CONTINENT 
Asia – OR=5.80 (3.64-9.24), n=8, I2=77% 
(East Asia – OR=6.15 (3.80-9.96), n=7, I2=77%) 
Europe – OR=3.87 (2.57-5.82), n=8, I2=56% 
(Southern Europe – OR=5.93 (3.18-11.06), n=4, 
I2=40%) 
(Northern Europe – OR=2.92 (1.88-4.53), n=4, 
I2=43%) 
 
 
<200 g of alcohol/week vs. never drinkers 
All studies – OR=1.71 (1.22-2.42), n=18, I2=89% 
Li, 2014[18] EC 
(mortality) 
MEDLINE 
(inception-
2013), 
ISI Web of 
Knowledge 
(inception-2013) 
 
Citation tracking 
(alcohol OR alcoholic beverages) AND cancer AND 
mortality AND (prospective OR cohort OR case-control OR 
case-cohort) 
 
No language restrictions 
10 
 
8 cohort 
1 nested case-
control 
1 case-control 
Jin et al., 2013 Drinking vs. non/occasional 
RR/OR=1.86 (1.40-2.47), n=8, I2=72.2% 
 
Light drinking (≤12.5 g/day)  vs. non/occasional 
RR/OR=1.43 (1.09-1.87), n=5, I2=61.0% 
 
Moderate drinking (12.5-50 g/day) vs. 
non/occasional 
RR/OR=1.92 (1.25-2.96), n=7, I2=81.2% 
 
Heavy drinking (≥50 g/day) vs. non/occasional 
RR/OR=3.37 (2.30-4.93), n=8, I2=71.1% 
 
No evidence of publication bias 
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Bagnardi, 2015[25] ESCC 
(risk) 
MEDLINE 
(inception-
2012), 
ISI Web of 
Knowledge 
(inception-
2012), 
EMBASE 
(inception-2012) 
 
Citation tracking 
MeSH terms search 
1.   ethanol 
2.   alcohol drinking 
3.  lip neoplasms OR tongue neoplasms OR salivary gland 
neoplasms  OR gingival neoplasms OR mouth neoplasms 
OR pharyngeal neoplasms OR esophageal neoplasms OR 
intestinal neoplasms OR stomach neoplasms OR colorectal 
neoplasms OR liver neoplasms OR gallbladder neoplasms 
OR pancreatic neoplasms OR laryngeal neoplasms OR lung 
neoplasms OR carcinoma, basal cell OR melanoma OR 
carcinoma, squamous cell  OR breast neoplasms OR 
uterine cervical neoplasms OR endometrial neoplasms OR 
ovarian neoplasms OR prostatic neoplasms OR kidney 
neoplasms OR renal cell carcinoma OR urinary bladder 
neoplasms OR thyroid neoplasms OR brain neoplasms OR 
Non-Hodgkin lymphoma OR Hodgkin disease OR 
neoplasms 
4. ((1) OR (2)) AND 3 
 
Direct keyword search 
5.  alcohol 
6.  alcoholic beverages 
7.  (1) 
8.  (2) 
9.  (3) 
10. lip cancer OR tongue cancer OR salivary gland cancer  
OR gingival cancer OR mouth cancer OR pharyngeal 
cancer OR esophageal cancer OR intestinal cancer OR 
stomach cancer OR colorectal cancer OR liver cancer OR 
gallbladder cancer OR pancreatic cancer OR laryngeal 
cancer OR lung cancer OR skin cancer OR basal cell 
carcinoma OR squamous cell carcinoma OR melanoma OR 
breast cancer OR uterine cervical cancer OR endometrial 
cancer OR ovarian cancer OR prostatic cancer OR kidney 
cancer OR renal cell carcinoma OR urinary bladder cancer 
OR thyroid cancer OR brain cancer OR Non-Hodgkin 
lymphoma OR Hodgkin disease OR cancer 
11. ((5) OR (6) OR (7) OR (8)) AND ((9) OR (10)) 
12. (4) OR (11) 
 
No language restrictions 
54 
 
13 cohort 
41 case-control 
No Light drinking vs. non and occasional drinkers 
All studies – RR=1.26 (1.06-1.50), n=34, I2=68% 
Adjusted estimates only – RR=1.34 (1.12-1.58) 
Estimates that did not consider occasional drinkers 
in the reference category – RR=1.30 (1.08-1.55) 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.20 (0.84-1.71), n=10, I2=84% 
Case-control – RR=1.29 (1.07-1.55), n=24, I2=49% 
 
ACCORDING TO SEX 
Men – RR=1.39 (1.11-1.74), n=16, I2=61% 
Women – RR=1.14 (0.87-1.49), n=8, I2=43% 
 
ACCORDING TO POPULATION GROUP 
European – RR=1.05 (0.79-1.38), n=7, I2=22% 
North American – RR=1.07 (0.84-1.37), n=12, I2=32% 
Asian – RR=1.54 (1.18-2.00), n=11, I2=71% 
 
 
Moderate drinking vs. non and occasional drinkers 
RR=2.23 (1.87-2.65), n=53, I2=85% 
Adjusted estimates only – RR=2.56 (2.05-3.20) 
Estimates that did not consider occasional drinkers 
in the reference category – RR=2.16 (1.72-2.71) 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.92 (1.44-2.58), n=13, I2=83% 
Case-control – RR=2.34 (1.87-2.92), n=40, I2=86% 
 
ACCORDING TO SEX 
Men – RR=2.25 (1.78-2.85), n=28, I2=85% 
Women – RR=2.18 (1.42-3.35), n=8, I2=72% 
 
ACCORDING TO POPULATION GROUP 
European – RR=1.91 (1.32-2.77), n=10, I2=71% 
North American – RR=2.95 (2.38-3.67), n=13, I2=37% 
Asian – RR=2.20 (1.65-2.94), n=23, I2=91% 
 
 
Heavy drinking vs. non and occasional drinkers 
RR=4.95 (3.86-6.34), n=41, I2=91% 
Adjusted estimates only – RR=5.45 (3.80-7.83) 
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Estimates that did not consider occasional drinkers 
in the reference category – RR=4.53 (3.39-6.05) 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=3.56 (2.25-5.64), n=9, I2=91% 
Case-control – RR=5.43 (4.04-7.32), n=32, I2=91% 
 
ACCORDING TO SEX 
Men – RR=4.69 (3.49-6.31), n=24, I2=88% 
Women – RR=8.32 (2.95-23.45), n=3, I2=72% 
 
ACCORDING TO POPULATION GROUP 
European – RR=4.76 (2.69-8.41), n=8, I2=85% 
North American – RR=7.63 (5.34-10.91), n=10, 
I2=59% 
Asian – RR=4.24 (2.93-6.14), n=18, I2=93% 
Drahos, 2015[34] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 8 case-control NA Ever vs. never drinkers 
All age groups – OR=0.78 (0.64-0.96) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.95 (0.42-2.13) 
50-59 years – OR=0.73 (0.45-1.17) 
60-69 years – OR=1.00 (0.70-1.42) 
≥ 70 years – OR=0.62 (0.45-0.85) 
 
> 0 - < 0.5 drinks per day vs. none 
All age groups – OR=0.78 (0.62-0.98) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=1.05 (0.43-2.58) 
50-59 years – OR=0.72 (0.42-1.24) 
60-69 years – OR=0.99 (0.66-1.48) 
≥ 70 years – OR=0.63 (0.43-0.92) 
 
0.5 - < 1.0 drinks per day vs. none 
All age groups – OR=0.55 (0.42-0.72) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.44 (0.14-1.36) 
50-59 years – OR=0.47 (0.25-0.88) 
60-69 years – OR=0.72 (0.45-1.13) 
≥ 70 years – OR=0.53 (0.34-0.82) 
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1 - <3 drinks per day vs. none 
All age groups – OR=0.74 (0.58-0.93) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.85 (0.35-2.07) 
50-59 years – OR=0.71 (0.42-1.20) 
60-69 years – OR=0.84 (0.56-1.26) 
≥ 70 years – OR=0.66 (0.45-0.96) 
 
3 - <5 drinks per day vs. none 
All age groups – OR=0.69 (0.52-0.91) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.93 (0.34-2.53) 
50-59 years – OR=0.51 (0.27-0.94) 
60-69 years – OR=0.90 (0.56-1.45) 
≥ 70 years – OR=0.55 (0.33-0.89) 
 
≥ 7 drinks per day vs. none 
All age groups – OR=0.93 (0.66-1.30) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=1.55 (0.47-5.10) 
50-59 years – OR=0.85 (0.41-1.74) 
60-69 years – OR=1.34 (0.76-2.36) 
≥ 70 years – OR=0.48 (0.24-0.97) 
Fahey, 2015[28] ESCC, EAC 
(mortality) 
MEDLINE 
(inception-
2014), 
EMBASE 
(inception-2014) 
 
Citation tracking 
("Esophagus"[Mesh] OR “Esophagus"[Title/Abstract] OR 
"Oesophagus"[Title/Abstract] OR 
"Esophageal"[Title/Abstract] OR 
"Oesophageal"[Title/Abstract]) AND ("Neoplasms"[Mesh] 
OR "Neoplasm"[Title/Abstract] OR 
"Cancer*"[Title/Abstract] OR "Carcinoma"[Title/Abstract] 
OR "Adenocarcinoma"[Title/Abstract]) AND (("Survival" 
[Mesh]) OR ("Prognosis" [Mesh]) OR ("survival" 
[Title/Abstract]) OR ("prognosis" [Title/Abstract]) OR 
("prognostic" [Title/Abstract])) AND (("smoking" 
[Title/Abstract]) OR ("tobacco" [Title/Abstract]) OR 
("alcohol" [Title/Abstract]) OR ("physical activity" 
[Title/Abstract]) OR ("exercise" [Title/Abstract]) OR 
("sedentary lifestyle"[Title/Abstract]) OR ("body mass 
index"[Title/Abstract]) OR ("BMI" [Title/Abstract]) OR 
("obesity" [Title/Abstract]) OR ("Aspirin"[ Title/Abstract]) 
OR ("Non-Steroidal Anti-Inflammatory"[Title/Abstract]) OR 
9 JAMA Ever vs. never drinkers 
 
ESCC 
HR=1.36 (1.15-1.61), n=6, I2=67.9% 
 
EAC 
HR=1.08 (0.85-1.37), n=2, I2=0.0% 
 
 
Highest vs. lowest alcohol consumption category 
 
ESCC 
HR=1.40 (1.07-1.82), n=4, I2=54.0% 
 
EAC 
HR=0.97 (0.73-1.30), n=2, I2=0.0% 
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("NSAID"[Title/Abstract]) OR ("health 
behavior"[Title/Abstract]) OR ("health 
behaviour"[Title/Abstract]) OR ("life style"[ Title/Abstract]) 
OR ("lifestyle"[ Title/Abstract]) OR ("life-style"[ 
Title/Abstract]) OR ("Smoking"[Mesh]) OR ("Alcohol 
Drinking"[Mesh]) OR ("Motor Activity"[Mesh]) OR 
("Exercise"[Mesh]) OR ("Sedentary Lifestyle"[Mesh]) OR 
("Body Mass Index"[Mesh]) OR ("Obesity"[Mesh]) OR 
("Health Behavior"[Mesh]) OR ("Life Style"[Mesh]) OR 
("Aspirin"[Mesh]) OR ("Anti-Inflammatory Agents, Non-
Steroidal"[Mesh])) 
 
Restricted to studies published in English 
No evidence of publication bias 
Roerecke, 2015[21] EC 
(risk) 
IARC 
monographs 
(2010, 2012), 
MEDLINE 
(inception-2014) 
 
Citation tracking 
“alcohol or ethanol” and “cohort” and “cancer” and 
“japan” and “review” and “mortality” 
 
Restricted to studies conducted in Japan after 1980 
7 
 
3 cohort 
4 case-control 
No Per 100 g/day of pure alcohol intake 
Cohort – RR=11.71 (2.67-51.32), n=3, I2=60% 
Case-control – RR=33.11 (8.15-134.43), n=4, I2=89% 
SMOKING       
Castellsagué, 
1999[26] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ever vs. never smokers 
Men – OR=4.1 (2.7-6.0) 
Women – OR=2.4 (1.5-3.7) 
 
Current vs. never smokers 
Men – OR=5.1 (3.4-7.6) 
Women – OR=3.1 (1.8-5.3) 
 
Ex- vs. never smokers 
Men – OR=2.8 (1.8-4.3) 
Women – OR=1.6 (0.8-3.1) 
 
Average number of cigarettes/day 
Men 
1-7 – OR=2.2 (1.3-3.5) 
8-14 – OR=4.1 (2.6-6.4) 
15-24 – OR=5.3 (3.4-8.1) 
≥ 25 – OR=5.0 (3.2-7.7) 
Women 
1-14 – OR=2.1 (1.2-3.7) 
≥ 15 – OR=2.8 (1.4-5.4) 
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Years of cigarette smoking 
Men 
1-29 – OR=2.6 (1.7-4.2) 
30-39 – OR=3.6 (2.3-5.6) 
40-49 – OR=4.7 (3.0-7.2) 
≥ 50 – OR=6.0 (3.8-9.5) 
Women 
1-29 – OR=1.5 (0.8-2.9) 
30-39 – OR=2.0 (0.9-4.4) 
≥ 40 – OR=4.4 (2.2-9.0) 
 
Age at starting smoking 
Men 
14-16 – OR=0.7 (0.5-0.96) 
17-20 – OR=0.8 (0.6-1.0) 
≥ 21 – OR=0.6 (0.4-0.9) 
Women 
14-16 – OR=1.6 (0.3-7.5) 
17-20 – OR=0.6 (0.2-2.4) 
≥ 21 – OR=0.2 (0.1-0.7) 
 
Age at quitting smoking 
Men 
44-53 – OR=0.8 (0.5-1.3) 
54-62 – OR=1.0 (0.6-1.7) 
≥ 63 – OR=1.5 (0.9-2.7) 
Women 
≥ 54 – OR=7.6 (0.7-84.2) 
 
Years since quitting smoking 
Men 
1-4 – OR=0.7 (0.5-1.0) 
5-9 – OR=0.5 (0.3-0.8) 
≥ 10 – OR=0.5 (0.4-0.7) 
Women 
1-9 – OR=1.0 (0.3-3.1) 
≥ 10 – OR=0.4 (0.1-1.2) 
 
Type of tobacco 
Men 
Mixed – OR=1.3 (0.8-1.9) 
Black only – OR=2.0 (1.5-2.7) 
Women 
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Black only – OR=3.4 (0.9-13.0) 
 
Use of filter 
Men 
Ever – OR=0.8 (0.6-0.98) 
Women 
Ever – OR=1.5 (0.5-4.4) 
Castellsagué, 
2000b[27] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ex- vs. current smokers 
Men – OR=0.5 (0.4-0.7) 
 
Never vs. current smokers 
Men – OR=0.2 (0.1-0.4) 
 
Years since quitting smoking 
Men 
1-2 – OR=0.7 (0.4-1.0) 
3-7 – OR=0.6 (0.4-1.0) 
8-12 – OR=0.4 (0.3-0.6) 
13-23 – OR=0.5 (0.4-0.8) 
≥ 24 – OR=0.5 (0.3-0.7) 
 
Trend per cessation year 
Men – OR=0.98 (0.97-0.99) 
Zeka, 2003[23] EC, ESCC, EAC 
(risk) 
MEDLINE 
(1966-2001) 
Not stated 8 case-control No Trend estimation (per 100g/week of consumption) 
 
Esophageal cancer 
β=0.28 (SE: 0.07), n=8, I2=50% 
 
Esophageal adenocarcinoma 
β=0.24 (SE: 0.07), n=2, I2=0% 
 
Esophageal squamous cell carcinoma 
β=0.22 (SE: 0.04), n=2, I2=0% 
 
Mixed esophageal carcinoma 
β=0.33 (SE: 0.07), n=4, I2=74% 
Ishikawa, 2006[17] EC 
(incidence) 
Pooled analysis 
of prospective 
cohort studies 
conducted in 
Miyagi 
Prefecture, 
Japan 
NA 2 cohort NA Former vs. never smokers 
HR=2.07 (0.66-6.57) 
 
Current (1-19 cigarettes/day) vs. never smokers 
HR=5.00 (1.70-14.66) 
 
Current (≥20 cigarettes/day) vs. never smokers 
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HR=5.09 (1.80-14.40) 
Gandini, 2008[39] EC 
(risk) 
Not stated Not stated 22 
 
5 cohort 
17 case-control 
Not stated Current vs. never smokers 
RR=2.50 (2.00-3.13), n=22, I2=81%, no evidence of 
publication bias 
 
ACCORDING TO SEX 
Men – RR=2.52 (1.81-3.52), n=7 
Women – RR=2.28 (1.51-3.44), n=14 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=2.30 (1.34-3.95), n=5 
Case-control – RR=2.55 (1.94-3.36), n=17 
 
ACCORDING TO ETHNIC GROUP 
African-Americans – RR=3.49 (1.49-8.20), n=1 
Asians – RR=1.62 (1.14-2.31), n=6 
Caucasians – RR=3.35 (1.89-5.92), n=5 
 
ACCORDING TO GEOGRAPHIC AREA 
Western countries – RR=3.05 (2.23-4.17), n=11 
Not Western countries – RR=2.08 (1.52-2.83), n=11 
 
ACCORDING TO ADJUSTMENT FOR ALCOHOL 
INTAKE 
Adjusted – RR=3.00 (2.18-4.12), n=11 
Not adjusted – RR=2.10 (1.52-2.88), n=11 
 
 
Former vs. never smokers 
RR=2.03 (1.77-2.33), n=21, I2=20% 
Ansary-
Moghaddam, 
2009a[36] 
EC 
(risk) 
MEDLINE, 
EMBASE 
 
Citation tracking 
MeSH terms (all exploded): "esophageal", "laryngeal", 
"pharyngeal", or "oral cavity" together with "neoplasm", 
"squamous cell", "adenocarcinoma", or "cancer" together 
with "cohort study" or "case-control study" 
Not specified for EC No After correction for publication bias 
 
Current vs. never smokers 
RR=2.52 (2.14-2.95) 
 
Dose-response analysis 
<20 cigarettes/day – RR=2.36 (1.66-3.37) 
≥20 cigarettes/day – RR=2.97 (2.01-4.40) 
Ansary-
Moghaddam, 
2009b[37] 
EC 
(mortality) 
Asia Pacific 
Cohort Studies 
Collaboration 
NA 26 NA <20 cigarettes/day vs. never smokers 
HR=2.52 (1.25-5.07) 
 
≥20 cigarettes/day vs. never smokers 
HR=3.40 (1.71-6.76) 
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Ex- vs. current smokers 
HR=1.03 (0.66-1.63) 
 
Current vs. never smokers (adjusted for age and 
alcohol) 
HR=2.84 (1.72-4.68) 
Akl, 2010[44] EC 
(risk) 
MEDLINE 
(1950-2008), 
EMBASE 
(1988-2008), 
WEB OF SCIENCE 
(inception-2008) 
 
Citation tracking 
MEDLINE: Waterpipe_.mp., ‘‘water pipe_’’.mp., 
shisha_.mp., sheesha_.mp., hooka_.mp., huqqa_.mp., 
guza_.mp., goza_.mp., narghil_.mp., nargil_.mp., 
arghil_.mp, argil_.mp, (hubbl_ adj3 bubbl_).mp., or/1–13 
EMBASE: Waterpipe_.mp., ‘‘water pipe_’’.mp., 
shisha_.mp., sheesha_.mp., hooka_.mp., huqqa_.mp., 
guza_.mp., goza_.mp., narghil_.mp., nargil_.mp., 
arghil_.mp, argil_.mp, (hubbl_ adj3 bubbl_).mp., or/1-13 
WEB OF SCIENCE: (waterpipe_ OR ‘‘water pipe_’’ OR 
shisha_ OR sheesha_ OR hooka_ OR huqqa_ OR guza_ OR 
goza_ OR narghil_ OR nargil_ OR argil_ OR arghil_ OR 
(hubbl_ SAME bubbl_)) AND (smoking OR smoke OR 
health OR disease OR cancer_ OR malignan_ OR lung_ OR 
pulmonary OR heart OR cardiac OR vascular OR stroke) (in 
Title or Topic) 
1 case-control for 
EC as outcome 
GRADE Waterpipe tobacco smoking vs. no smoking 
OR=1.85 (0.95-3.58), n=1 
Cook, 2010[38] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 12 
 
2 cohort 
10 case-control 
NA Analyses restricted to white non-Hispanic men and 
women 
 
Ever vs. never smokers 
OR=1.96 (1.64-2.34), I2=24% 
 
ACCORDING TO SEX 
Men – OR=2.10 (1.71-2.59) 
Women – OR=1.74 (1.21-2.51) 
 
 
Pack-years of smoking vs. never smokers 
<15 – OR=1.25 (1.02-1.53), I2=0% 
15-30 – OR=1.96 (1.58-2.45), I2=0% 
30-45 – OR=2.07 (1.66-2.58), I2=2% 
≥45 – OR=2.71 (2.16-3.40), I2=24% 
Tramacere, 
2011[41] 
EAC 
(risk) 
MEDLINE 
(inception-2010) 
 
Citation tracking 
MESH terms “smoking” and combinations of “esophageal 
neoplasms” or “stomach neoplasms” and 
“adenocarcinoma” 
 
Restricted to studies published in English 
15 
 
2 cohort 
13 case-control 
No Ever vs. never smokers 
All studies – RR=1.85 (1.59-2.15), n=15, I2=29.4% 
Cohort – RR=2.67 (1.94-3.67), n=2, I2=0% 
Case-control – RR=1.71 (1.50-1.95), n=13, I2=4.6% 
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Lubin, 2012[31] ESCC, EAC 
(risk) 
International 
BEACON 
Consortium 
NA 12 
 
2 nested case-
control 
10 case-control 
NA Pack-years of smoking (reference category: 0) 
 
Esophageal adenocarcinoma 
1-29 – OR=1.66 (1.1-2.4) 
30-39 – OR=1.45 (0.8-2.5) 
40-49 – OR=2.22 (1.2-4.0) 
50-59 – OR=1.92 (1.0-3.6) 
≥60 – OR=2.77 (1.4-5.6) 
 
Esophageal squamous cell carcinoma 
1-29 – OR=2.63 (1.8-4.0) 
30-39 – OR=2.69 (1.6-4.6) 
40-49 – OR=3.93 (2.2-7.1) 
50-59 – OR=4.62 (2.5-8.5) 
≥60 – OR=5.63 (2.7-11.7) 
 
 
Cigarettes/day (reference category: 1-9) 
 
Esophageal adenocarcinoma 
10-19 – OR=1.30 (0.8-2.2) 
20-29 – OR=1.33 (0.7-2.4) 
30-39 – OR=1.65 (0.8-3.4) 
≥40 – OR=1.34 (0.6-2.9) 
 
Esophageal squamous cell carcinoma 
10-19 – OR=1.42 (0.9-2.3) 
20-29 – OR=0.89 (0.5-1.6) 
30-39 – OR=1.03 (0.5-2.1) 
≥40 – OR=0.71 (0.3-1.5) 
Oze, 2012[40] EC 
(risk) 
MEDLINE 
(1950-2011), 
Ichushi 
(1983-2011) 
 
Citation tracking 
Using the following as keywords: cigarette, smoking, 
esophagus, esophageal cancer, cohort, follow-up, case-
control, Japan and Japanese 
 
Restricted to studies conducted on Japanese populations 
and published in English or Japanese. 
15 
 
4 cohort 
11 case-control 
No Ever vs. never smokers 
All studies – RR=3.01 (2.30-3.94), n=13, I2=72%, 
Egger test: p=0.148 
Only cohort studies – RR=2.97 (2.12-4.16), n=4 
Only adjusted estimates for alcohol drinking – 
RR=2.70 (1.64-4.45), n=6, I2=82% 
 
 
Current vs. never smokers 
All studies – RR=3.73 (2.16-6.43), n=7, I2=78% 
Only cohort studies – RR=4.20 (2.83-6.23), n=3 
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Former vs. never smokers 
All studies – RR=2.21 (1.60-3.06), n=7 
Prabhu, 2013[32] ESCC 
(risk) 
MEDLINE 
(1948-2013), 
EBM reviews 
(inception-
2013), 
EMBASE 
(1947-2011), 
ISI Web of 
Knowledge 
(inception-
2013), 
BIOSIS preview 
(1926-2013) 
Key index terms for our literature review included 
{esophageal carcinoma, esophageal neoplasm or 
[esophagus and (squamous cell carcinoma, carcinoma, 
cancer, neoplasms, adenosquamous carcinoma or 
basosquamous carcinoma)]} and (risk factors, tobacco, 
tobacco smokeless, tobacco use disorder, tobacco smoke 
pollution, smoke, smoking, marijuana smoking, cigarette, 
cigar, alcohols, alcohol, alcohol drinking, alcoholism, 
alcohol abuse, ethanol, alcoholic beverages, liquor, beer, 
wine, spirits, or alcoholic intoxication), also using the 
alternative spelling ‘oesophageal’ or ‘oesophagus’ 
 
No language restrictions 
29 
 
8 cohort 
21 case-control 
Newcastle-
Ottawa Scale 
 
13 highest 
quality studies 
Current vs. never smokers 
All studies – OR=3.13 (2.53-3.86), n=29, I2=87% 
Only highest quality studies – OR=2.95 (2.20-3.96), 
n=13, I2=88% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=2.74 (1.88-3.99), n=8, I2=92% 
Case-control – OR=3.30 (2.62-4.16), n=21, I2=76% 
 
ACCORDING TO RACE/CONTINENT 
Asia – OR=2.31 (1.78-2.99), n=12, I2=86% 
(East Asia – OR=2.33 (1.73-3.15), n=10, I2=87%) 
Europe – OR=4.21 (3.13-5.66), n=12, I2=71% 
(Southern Europe – OR=3.69 (2.81-4.84), n=5, 
I2=27%) 
(Northern Europe – OR=4.71 (2.37-9.37), n=5, 
I2=86%) 
South America – OR=3.29 (1.75-6.18), n=3, I2=56% 
 
 
Ex- vs. never smokers 
All studies – OR=1.68 (1.44-1.96), n=27, I2=58% 
 
 
≥20 cigarettes/day vs. never smokers 
All studies – OR=3.66 (2.73-4.90), n=21, I2=86% 
Only highest quality studies – OR=2.89 (1.78-4.71), 
n=8, I2=89% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=2.11 (1.33-3.33), n=6, I2=86% 
Case-control – OR=4.62 (3.42-6.24), n=15, I2=75% 
 
ACCORDING TO RACE/CONTINENT 
Asia – OR=2.52 (1.78-3.57), n=9, I2=81% 
(East Asia – OR=2.63 (1.78-3.88), n=8, I2=84%) 
Europe – OR=4.42 (3.23-6.06), n=9, I2=61% 
(Southern Europe – OR=4.99 (3.42-7.28), n=5, 
I2=52%) 
 
 
Papers | 137 
<20 cigarettes/day vs. never smokers 
All studies – OR=1.84 (1.46-2.32), n=21, I2=70% 
 
 
≥20 years of smoking vs. never smokers 
All studies – OR=2.81 (2.06-3.83), n=13, I2=87% 
Only highest quality studies – OR=2.46 (1.35-4.48), 
n=3, I2=96% 
Case-control studies – OR=2.92 (2.26-3.77), n=11, 
I2=63% 
 
ACCORDING TO RACE/CONTINENT 
Asia – OR=2.34 (1.57-3.50), n=6, I2=90% 
(East Asia – OR=2.92 (1.14-7.46), n=3, I2=92%) 
Europe – OR=3.31 (2.15-5.10), n=6, I2=56% 
(Southern Europe – OR=3.57 (1.76-7.25), n=3, 
I2=72%) 
 
 
<20 years of smoking vs. never smokers 
All studies – OR=1.67 (1.29-2.17), n=14, I2=63% 
Drahos, 2015[34] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 8 case-control NA Current vs. never smokers 
All age groups – OR=2.65 (2.17-3.24) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=2.72 (1.11-6.65) 
50-59 years – OR=3.75 (2.46-5.69) 
60-69 years – OR=1.81 (1.30-2.54) 
≥ 70 years – OR=2.80 (1.93-4.07) 
 
Former vs. never smokers 
All age groups – OR=2.36 (1.94-2.88) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=2.44 (0.88-6.74) 
50-59 years – OR=2.95 (1.89-4.62) 
60-69 years – OR=1.86 (1.33-2.60) 
≥ 70 years – OR=2.51 (1.80-3.49) 
 
< 14 pack-years vs. never smokers 
All age groups – OR=1.27 (1.05-1.55) 
 
ACCORDING TO AGE GROUP 
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< 50 years – OR=2.02 (1.10-3.68) 
50-59 years – OR=1.47 (0.96-2.25) 
60-69 years – OR=0.98 (0.69-1.38) 
≥ 70 years – OR=1.39 (0.99-1.96) 
 
14 - > 30 pack-years vs. never smokers 
All age groups – OR=2.01 (1.66-2.45) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=3.62 (2.04-6.42) 
50-59 years – OR=2.13 (1.41-3.23) 
60-69 years – OR=1.79 (1.28-2.50) 
≥ 70 years – OR=1.66 (1.14-2.42) 
 
30 - >45 pack-years vs. never smokers 
All age groups – OR=2.00 (1.63-2.45) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=2.88 (1.35-6.14) 
50-59 years – OR=2.35 (1.54-3.59) 
60-69 years – OR=1.42 (1.00-2.01) 
≥ 70 years – OR=2.11 (1.45-3.07) 
 
≥ 45 pack-years vs. never smokers 
All age groups – OR=2.50 (2.09-3.00) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=2.68 (1.10-6.53) 
50-59 years – OR=3.41 (2.29-5.07) 
60-69 years – OR=1.84 (1.36-2.48) 
≥ 70 years – OR=2.61 (1.92-3.54) 
Fahey, 2015[28] ESCC, EAC 
(mortality) 
MEDLINE 
(inception-
2014), 
EMBASE 
(inception-2014) 
 
Citation tracking 
("Esophagus"[Mesh] OR “Esophagus"[Title/Abstract] OR 
"Oesophagus"[Title/Abstract] OR 
"Esophageal"[Title/Abstract] OR 
"Oesophageal"[Title/Abstract]) AND ("Neoplasms"[Mesh] 
OR "Neoplasm"[Title/Abstract] OR 
"Cancer*"[Title/Abstract] OR "Carcinoma"[Title/Abstract] 
OR "Adenocarcinoma"[Title/Abstract]) AND (("Survival" 
[Mesh]) OR ("Prognosis" [Mesh]) OR ("survival" 
[Title/Abstract]) OR ("prognosis" [Title/Abstract]) OR 
("prognostic" [Title/Abstract])) AND (("smoking" 
[Title/Abstract]) OR ("tobacco" [Title/Abstract]) OR 
("alcohol" [Title/Abstract]) OR ("physical activity" 
12 JAMA Ever vs. never smokers 
 
ESCC 
HR=1.19 (1.04-1.36), n=6, I2=47.0% 
 
EAC 
HR=0.96 (0.82-1.12), n=4, I2=0.0% 
 
 
Highest vs. lowest pack-years 
 
ESCC 
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[Title/Abstract]) OR ("exercise" [Title/Abstract]) OR 
("sedentary lifestyle"[Title/Abstract]) OR ("body mass 
index"[Title/Abstract]) OR ("BMI" [Title/Abstract]) OR 
("obesity" [Title/Abstract]) OR ("Aspirin"[ Title/Abstract]) 
OR ("Non-Steroidal Anti-Inflammatory"[Title/Abstract]) OR 
("NSAID"[Title/Abstract]) OR ("health 
behavior"[Title/Abstract]) OR ("health 
behaviour"[Title/Abstract]) OR ("life style"[ Title/Abstract]) 
OR ("lifestyle"[ Title/Abstract]) OR ("life-style"[ 
Title/Abstract]) OR ("Smoking"[Mesh]) OR ("Alcohol 
Drinking"[Mesh]) OR ("Motor Activity"[Mesh]) OR 
("Exercise"[Mesh]) OR ("Sedentary Lifestyle"[Mesh]) OR 
("Body Mass Index"[Mesh]) OR ("Obesity"[Mesh]) OR 
("Health Behavior"[Mesh]) OR ("Life Style"[Mesh]) OR 
("Aspirin"[Mesh]) OR ("Anti-Inflammatory Agents, Non-
Steroidal"[Mesh])) 
 
Restricted to studies published in English 
HR=1.55 (1.24-1.94), n=4, I2=0.0% 
 
 
No evidence of publication bias 
SMOKELESS 
TOBACCO 
      
Boffetta, 2008[47] EC 
(risk) 
Studies included 
in IARC 
Monograph, plus 
MEDLINE and 
PubMed 
(2004-2007) 
 
Citation tracking 
(“snus”, “snuff” OR “smokeless tobacco”) AND (“cancer” 
OR “neoplasm”) 
5 
 
2 cohort 
3 case-control 
Not stated Ever vs. never smokeless tobacco users 
All studies – RR=1.6 (1.1-2.3), n=5 
 
ACCORDING TO GEOGRAPHIC AREA 
USA – RR=1.2 (0.1-13.0), n=1 
Nordic countries – RR=1.6 (1.1-2.4), n=4 
Lee, 2009[48] EC 
(risk) 
MEDLINE 
(inception-2008) 
 
Citation tracking 
“cancer” AND (“smokeless tobacco” OR “chewing tobacco” 
OR “snuff” OR “alcohol”) 
 
Restricted to studies conducted in Europe and North 
America 
14 
 
4 cohort 
10 case-control 
No Smokeless tobacco (any type) 
Overall data – RR=1.25 (1.03-1.51), n=10, I2=13.0% 
Smoking adjusted – RR=1.13 (0.95-1.36), n=7, 
I2=0.0% 
Never smokers – RR=1.91 (1.15-3.17), n=4, I2=0.0% 
 
Smokeless tobacco (any type in USA) 
Overall data – RR=1.56 (1.11-2.19), n=6, I2=4.6% 
Smoking adjusted – RR=1.89 (0.84-4.25), n=3, 
I2=0.0% 
Never smokers – RR=1.89 (0.84-4.25), n=3, I2=0.0% 
 
Smokeless tobacco (snuff in Scandinavia) 
Overall data – RR=1.10 (0.92-1.33), n=4, I2=0.0% 
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Smoking adjusted – RR=1.10 (0.92-1.33), n=4, 
I2=0.0% 
Never smokers – RR=1.92 (1.00-3.68), n=1 
Lee, 2011[46] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-2010) 
 
Citation tracking 
“cancer” AND (“smokeless tobacco” OR “chewing tobacco” 
OR “snuff” OR “snus”) 
 
All studies conducted in Sweden and one in Norway 
4 
 
2 cohort 
2 case-control 
No Ever vs. never snus users 
Whole population – RR=1.10 (0.92-1.33), n=4 
 
ACCORDING TO HISTOLOGICAL TYPE 
EAC – RR=1.0 (0.6-1.5) 
ESCC – RR=1.0 (0.8-1.4) 
 
Never smokers – RR=1.92 (1.00-3.68), n=1 
 
ACCORDING TO HISTOLOGICAL TYPE 
EAC – RR=0.2 (0.0-1.9) 
ESCC – RR=3.5 (1.6-7.6) 
Akhtar, 2013[45] ESCC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2012) 
 
Citation tracking 
using the search terms case–control and/or cohort study, 
areca nut, betel nut, betel quid without tobacco, combined 
with oesophageal squamous-cell carcinoma, oesophageal 
cancer, chewing, and Asia 
 
No language restrictions 
12 case-control No Areca nut chewing in Asians 
OR=3.05 (2.41-3.87), n=12, I2=55%, Egger test: 
p=0.289 
 
ACCORDING TO SEX 
Only men – OR=2.99 (1.83-4.88), n=4, I2=61% 
Men and women – OR=3.09 (2.32-4.11), n=8, I2=62% 
 
 
Additive interaction between areca nut chewing and 
tobacco smoking 
OR=6.79 (4.71-9.79), n=6 
Siddiqi, 2015[49] EC 
(risk) 
MEDLINE, 
EMBASE, 
PsycINFO, 
CINAHL Plus, 
ISI Web of 
Knowledge, 
SCOPUS, 
COCHRANE, 
AJOL, 
LILACS, 
WHO, 
PakMediNet, 
IndMED, 
ProQuest, 
EThOS, 
Open Grey 
by combining an exhaustive list of terms for smokeless 
tobacco with terms for specific cancers and cardiovascular 
disease outcomes 
 
No language restrictions 
12 
 
2 cohort 
10 case-control 
Newcastle-
Ottawa Scale 
Ever vs. never smokeless tobacco use 
All studies – OR=2.17 (1.70-2.78), n=12, I2=76% 
 
ACCORDING TO GEOGRAPHIC AREA 
India – OR=2.57 (2.20-3.00), n=7, I2=22% 
Pakistan – OR=8.20 (2.45-27.47), n=2, I2=67% 
Norway – OR=1.40 (0.61-3.21), n=1 
Sweden – OR=1.26 (1.02-1.56), n=5, I2=0% 
North America – OR=1.20 (0.10-14.40), n=1 
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(inception-2015) 
 
Citation tracking 
SMOKING AND 
ALCOHOL 
      
Castellsagué, 
1999[26] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Joint effects 
 
Never drinkers/Ever smokers 
All – OR=1.95 (1.35-2.82) 
Men – OR=4.45 (2.09-9.47) 
Women – OR=1.57 (0.89-2.75) 
 
Ever drinkers/Never smokers 
All – OR=1.75 (1.17-2.63) 
Men – OR=4.03 (1.76-9.21) 
Women – OR=1.42 (0.82-2.48) 
 
Ever drinkers/Ever smokers 
All – OR=8.00 (5.67-11.27) 
Men – OR=17.0 (8.36-34.78) 
Women – OR=7.26 (3.68-14.33) 
Ansary-
Moghaddam, 
2009a[36] 
EC 
(risk) 
MEDLINE, 
EMBASE 
 
Citation tracking 
MeSH terms (all exploded): "esophageal", "laryngeal", 
"pharyngeal", or "oral cavity" together with "neoplasm", 
"squamous cell", "adenocarcinoma", or "cancer" together 
with "cohort study" or "case-control study" 
Not specified for EC No Current vs. never smokers 
Non-drinkers 
RR=2.45 (2.06-2.91) 
Drinkers 
RR=6.01 (3.82-9.44) 
 
Joint effects 
RR=10.0 (4.08-24.5) 
Prabhu, 2014[4] ESCC 
(risk) 
MEDLINE 
(1948-2013), 
EBM reviews 
(inception-
2013), 
EMBASE 
(1947-2013), 
ISI Web of 
Knowledge 
(inception-
2013), 
BIOSIS 
(1926-2013) 
 
((esophageal or esophagus or esophageal neoplasm) and 
(squamous cell carcinoma, carcinoma, cancer, neoplasm, 
adenosquamous carcinoma, or basosquamous 
carcinoma)) and (risk factors, tobacco, tobacco smokeless, 
tobacco use disorder, tobacco smoke pollution, smoke, 
smoking, marijuana smoking, cigarette, cigar, alcohols, 
alcohol, alcohol drinking, alcoholism, alcohol abuse, 
ethanol, alcoholic beverages, liquor, beer, wine, spirits, 
alcoholic intoxication) 
 
No language restrictions 
5 
 
2 cohort 
3 case-control 
Newcastle-
Ottawa Scale 
Synergy factors 
 
Alcohol non-use/Tobacco use 
OR=1.36 (1.14-1.61), n=5, I2=0.00% 
 
Alcohol use/Tobacco non-use 
OR=1.21 (0.81-1.81), n=5, I2=34.41% 
 
Alcohol use/Tobacco use 
OR=3.28 (2.11-5.08), n=5, I2=55.30% 
Cohort – OR=4.47 (2.62-7.63), n=3, I2=0.00% 
Case-control – OR=3.53 (1.71-7.27), n=2, I2=39.21% 
SF=1.85 (1.45-2.38), n=5, I2=11.15% 
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Citation tracking 
SMOKING, 
ALCOHOL AND 
GREEN TEA 
      
Ishikawa, 2006[17] EC 
(incidence) 
Pooled analysis 
of prospective 
cohort studies 
conducted in 
Miyagi 
Prefecture, 
Japan 
NA 2 cohort NA Currently smoking, Daily alcohol drinking, Daily 
consumption of ≥ 3 cups/day of green tea 
-/+/- : HR=2.61 (0.42-16.07) 
-/-/+: HR=1.65 (0.29-9.19) 
+/+/-: HR=9.23 (2.10-40.60) 
+/-/+: HR=4.99 (1.11-22.43) 
-/+/+: HR=2.97 (0.53-16.58) 
+/+/+: HR=11.1 (2.63-46.51) 
HELICOBACTER 
PYLORI INFECTION 
      
Rokkas, 2007[51] ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2007) 
 
Citation tracking 
helicobacter pylori AND (esophageal cancer OR 
esophageal neoplasms OR Barrett’s esophagus OR 
adenocarcinoma OR squamous cell carcinoma) 
 
Restricted to studies published in English 
18 
 
9 cohort 
9 case-control 
No EAC 
 
H. pylori infected vs. uninfected 
OR=0.52 (0.37-0.73), n=10, I2=34.6%, Begg test: 
p=0.37 
 
CagA infected vs. uninfected 
OR=0.51 (0.31-0.82), n=6, I2=0.0%, Begg test: p=0.26 
 
 
ESCC 
 
H. pylori infected vs. uninfected 
OR=0.86 (0.56-1.33), n=5, I2=84.7%, Begg test: 
p=0.80 
 
CagA infected vs. uninfected 
OR=1.22 (0.70-2.13), n=3, I2=73.4%, Begg test: 
p=0.30 
Islami, 2008[50] ESCC, EAC 
(risk) 
MEDLINE, 
WEB OF SCIENCE 
(inception-2008) 
 
Citation tracking 
("Helicobacter pylori" [MeSH] OR (Campylobacter pylori) 
OR (H Pylori) OR (H. Pylori)) AND ("Esophageal 
Neoplasms"[MeSH] OR (Cancer of Esophagus) OR (Cancer 
of the Esophagus) OR (Esophageal Cancer) OR (Esophagus 
Cancer) OR (Esophagus Neoplasm) OR (Neoplasms, 
Esophageal)); the search was repeated by replacing 
Esophagus with Oesophagus, and Esophageal with 
Oesophageal 
19 case-control No EAC 
 
H. pylori infected vs. uninfected 
All studies – OR=0.56 (0.46-0.68), n=13, I2=15%, 
Egger test: p=0.71, Begg test: p=0.76 
Large studies – OR=0.58 (0.47-0.73), n=8, I2=27% 
Population-based studies – OR=0.58 (0.43-0.76), 
n=6, I2=32% 
Western studies – OR=0.57 (0.47-0.70), n=12, 
I2=17% 
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Eastern studies – OR=0.32 (0.10-1.02), n=1 
Serologic studies – OR=0.59 (0.48-0.73), n=10, 
I2=10% 
Adjusted results – OR=0.50 (0.34-0.74), n=7, I2=28% 
 
CagA infected vs. uninfected 
OR=0.41 (0.28-0.62), n=5, I2=16% 
 
 
ESCC 
 
H. pylori infected vs. uninfected 
All studies – OR=1.10 (0.78-1.55), n=9, I2=73%, Egger 
test: p=0.84, Begg test: p=0.47 
Large studies – OR=1.10 (0.78-1.55), n=9, I2=73% 
Population-based studies – OR=1.00 (0.62-1.60), 
n=6, I2=82% 
Western studies – OR=1.17 (0.71-1.95), n=4, I2=63% 
Eastern studies – OR=1.05 (0.63-1.77), n=5, I2=81% 
Serologic studies – OR=1.10 (0.78-1.55), n=9, I2=73% 
Adjusted results – OR=0.99 (0.67-1.45), n=7, I2=56% 
 
CagA infected vs. uninfected 
OR=1.01 (0.80-1.27), n=4, I2=0% 
Zhuo, 2008[53] EC, ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE, 
CNKI 
(1989-2007) 
 
Citation tracking 
Helicobacter pylori and oesophageal cancer 
 
No language restrictions 
12 case-control No EAC 
 
H. pylori infected vs. uninfected 
OR=0.58 (0.48-0.70), n=9, I2=40.6%, Egger test: 
p=0.69 
 
CagA infected vs. uninfected 
OR=0.54 (0.40-0.73), n=6, I2=0.0% 
 
 
ESCC 
 
H. pylori infected vs. uninfected 
OR=0.80 (0.45-1.43), n=5, I2=85.1% 
 
CagA infected vs. uninfected 
OR=1.20 (0.45-3.18), n=2, I2=90.4% 
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EC 
 
CagA infected vs. uninfected 
OR=0.69 (0.45-1.05), n=7, I2=67.9% 
Xie, 2013[52] ESCC, EAC 
(risk) 
MEDLINE 
(inception-2013) 
 
Citation tracking 
“Helicobacter pylori” [MeSH] OR (Campylobacter pylori) 
OR (H. pylori) OR (H. pylori) AND (“Esophageal 
Neoplasms” [MeSH] OR (Cancer of Esophagus) OR (Cancer 
of the Esophagus) OR (Esophageal Cancer) OR (Esophagus 
Cancer) OR (Esophagus Neoplasm) OR (Neoplasms, 
Esophageal) 
27 case-control No EAC 
 
H. pylori infected vs. uninfected 
All studies – OR=0.59 (0.51-0.68), n=15, I2=29.9%, 
Egger test: p=0.371, Begg test: p=0.621 
Population-based studies – OR=0.62 (0.52-0.73), 
n=8, I2=40.9% 
Clinical-based studies – OR=0.53 (0.40-0.68), n=7, 
I2=14.5% 
Eastern studies – OR=0.32 (0.10-1.02), n=1 
Western studies – OR=0.60 (0.52-0.68), n=14, 
I2=31.0% 
Adjusted results – OR=0.51 (0.40-0.61), n=8, 
I2=28.6% 
 
CagA infected vs. uninfected 
All/Western studies – OR=0.56 (0.45-0.70), n=8, 
I2=39.9% 
 
 
ESCC 
 
H. pylori infected vs. uninfected 
All studies – OR=0.83 (0.63-1.03), n=16, I2=74.5%, 
Egger test: p=0.424, Begg test: p=0.753 
Population-based studies – OR=0.79 (0.59-1.00), 
n=14, I2=76.0% 
Clinical-based studies – OR=1.49 (0.66-2.31), n=2, 
I2=0.0% 
Eastern studies – OR=0.66 (0.43-0.89), n=8, I2=79.5% 
Western studies – OR=1.02 (0.80-1.25), n=8, I2=1.2% 
Adjusted results – OR=0.84 (0.56-1.12), n=11, 
I2=80.5% 
 
CagA infected vs. uninfected 
All studies – OR=0.97 (0.76-1.24), n=9, I2=52.0% 
Eastern studies – OR=0.77 (0.65-0.92), n=3, I2=35.0% 
Western studies – OR=1.26 (0.97-1.63), n=6, I2=3.6% 
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Nie, 2014[54] ESCC, EAC 
(risk) 
MEDLINE, 
ISI WEB OF 
KNOWLEDGE, 
CBD, WANFANG, 
CNKI 
(inception-2013) 
 
Citation tracking 
Using the key words ‘Helicobacter pylori’, ‘H. pylori’, or 
‘HP’, and ‘esophageal neoplasm’, ‘esophageal carcinoma’, 
‘esophageal tumor’, ‘esophageal cancer’, ‘esophageal 
squamous cell carcinoma’, ‘esophageal squamous 
carcinoma’, ‘ESCC’, ‘esophageal adenocarcinoma’, 
‘adenocarcinoma of the esophagus’, or ‘EAC’ 
 
Restricted to studies published in English or Chinese 
28 case-control Newcastle-
Ottawa scale 
ESCC 
 
H. pylori infected vs. uninfected 
OR=1.16 (0.83-1.60), n=19, I2=85.7%, 
Egger test: p=0.280 
 
CagA infected vs. uninfected 
OR=1.01 (0.73-1.40), n=7, I2=49.7% 
Egger test: p=0.496 
 
 
EAC 
 
H. pylori infected vs. uninfected 
OR=0.57 (0.44-0.73), n=13, I2=53.3% 
Egger test: p=0.216 
 
CagA infected vs. uninfected 
OR=0.64 (0.52-0.79), n=7, I2=0.0% 
Egger test: p=0.170 
GERD       
Rubenstein, 
2010[55] 
EAC 
(risk) 
MEDLINE 
(1950-2008), 
EMBASE 
(1947-2008), 
WEB OF SCIENCE 
(1900-2008), 
COCHRANE 
(2008), 
BIOSIS 
(1926-2008), 
DARE 
(2008), 
ACP (1991-2008) 
 
Citation tracking 
[‘gastroesophageal reflux’, or ‘GERD’, or ‘oesophageal 
reflux’, or ‘oesophagitis’, or ‘heartburn’, or ‘pyrosis’, or 
‘regurgitation’] and [‘oesophageal neoplasm’, or 
‘adenocarcinoma’, or ‘carcinoma’, or ‘Barrett*’, or 
‘metaplasia’, or ‘metaplastic’] 
5 case-control No Weekly gastro-oesophageal reflux symptoms vs. less 
frequent or no symptoms 
OR=4.92 (3.90-6.22), n=5, I2=60% 
Men – OR=4.3 (3.3-5.7), n=1 
Women – OR=3.5 (1.9-6.6), n=1 
 
Daily gastro-oesophageal reflux symptoms vs. 
symptoms less than weekly or no symptoms 
OR=7.40 (4.94-11.1), n=5, I2=71% 
 
Symptoms of at least 20 years of duration 
OR=5.41 (2.45-11.9), n=4, I2=89% 
 
Symptoms of less than 10-15 years of duration 
OR=3.05 (1.53-6.08), n=4, I2=84% 
Cook, 2014[56] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 5 case-control NA Recurrent vs. not-recurrent heartburn 
OR=4.64 (3.28-6.57), I2=74% 
 
Recurrent vs. not-recurrent regurgitation 
OR=4.57 (3.43-6.08), I2=55% 
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Recurrent vs. not-recurrent heartburn or 
regurgitation 
OR=4.81 (3.39-6.82), I2=76% 
 
Heartburn duration (years) vs. never 
0.1-<10 – OR=2.80 (1.60-4.91), I2=68% 
10-<20 – OR=3.85 (2.93-5.07), I2=0% 
≥20 – OR=6.24 (3.37-11.55), I2=85% 
 
Regurgitation duration (years) vs. never 
0.1-<10 – OR=2.69 (1.49-4.83), I2=75% 
10-<20 – OR=4.18 (2.37-7.37), I2=71% 
≥20 – OR=4.39 (2.34-8.25), I2=84% 
 
Heartburn and regurgitation duration (years) vs. 
never 
0.1-<10 – OR=3.48 (1.56-7.73), I2=82% 
10-<30 – OR=3.97 (2.41-6.54), I2=72% 
≥30 – OR=6.08 (3.26-11.34), I2=83% 
 
Heartburn frequency vs. never 
<Monthly – OR=0.91 (0.68-1.21), I2=0% 
Monthly-<Weekly – OR=2.90 (1.78-4.72), I2=56% 
Weekly-<Daily – OR=4.20 (2.76-6.40), I2=68% 
≥Daily – OR=7.42 (4.23-13.02), I2=76% 
 
Regurgitation frequency vs. never 
<Monthly – OR=0.71 (0.48-1.04), I2=37% 
Monthly-<Weekly – OR=3.13 (2.14-4.58), I2=40% 
Weekly-<Daily – OR=5.07 (3.51-7.32), I2=55% 
≥Daily – OR=4.94 (3.37-7.24), I2=35% 
 
Heartburn and regurgitation frequency vs. never 
≤Weekly – OR=2.08 (1.14-3.79), I2=86% 
>Weekly-Daily – OR=5.07 (3.07-8.38), I2=75% 
>Daily – OR=7.96 (4.51-14.04), I2=73% 
Drahos, 2015[34] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 8 case-control NA Recurrent vs. not-recurrent heartburn 
All age groups – OR=4.52 (3.84-5.33) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=6.62 (3.66-11.97) 
50-59 years – OR=3.17 (2.19-4.60) 
60-69 years – OR=5.03 (3.82-6.64) 
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≥ 70 years – OR=5.21 (3.88-6.99) 
 
Recurrent vs. not-recurrent regurgitation 
All age groups – OR=4.45 (3.74-5.31) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=7.98 (4.26-14.96) 
50-59 years – OR=3.31 (2.20-4.98) 
60-69 years – OR=4.38 (3.27-5.85) 
≥ 70 years – OR=5.24 (3.81-7.19) 
 
Recurrent vs. not-recurrent heartburn or 
regurgitation 
All age groups – OR=4.70 (4.03-5.49) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=8.06 (4.52-14.37) 
50-59 years – OR=3.15 (2.22-4.45) 
60-69 years – OR=5.33 (4.08-6.95) 
≥ 70 years – OR=5.20 (3.95-6.85) 
 
Heartburn frequency – < monthly vs. never: 
All age groups – OR=0.88 (0.67-1.16) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.55 (0.21-1.49) 
50-59 years – OR=0.65 (0.39-1.11) 
60-69 years – OR=1.08 (0.68-1.71) 
≥ 70 years – OR=0.86 (0.51-1.44) 
 
Heartburn frequency – monthly to < weekly vs. 
never: 
All age groups – OR=2.74 (2.10-3.57) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=1.87 (0.61-5.75) 
50-59 years – OR=1.93 (1.14-3.27) 
60-69 years – OR=3.69 (2.35-5.80) 
≥ 70 years – OR=2.63 (1.63-4.26) 
 
Heartburn frequency – weekly to < daily vs. never: 
All age groups – OR=4.15 (3.35-5.15) 
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ACCORDING TO AGE GROUP 
< 50 years – OR=5.21 (2.45-11.06) 
50-59 years – OR=2.52 (1.51-4.18) 
60-69 years – OR=5.27 (3.64-7.61) 
≥ 70 years – OR=4.25 (2.93-6.15) 
 
Heartburn frequency – ≥ daily vs. never: 
All age groups – OR=7.04 (5.47-9.08) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=6.84 (2.92-16.02) 
50-59 years – OR=4.65 (2.72-7.94) 
60-69 years – OR=7.75 (5.02-11.97) 
≥ 70 years – OR=11.41 (7.04-18.48) 
 
Regurgitation frequency – < monthly vs. never: 
All age groups – OR=0.70 (0.55-0.91) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=0.52 (0.21-1.26) 
50-59 years – OR=0.56 (0.34-0.91) 
60-69 years – OR=0.73 (0.47-1.14) 
≥ 70 years – OR=0.75 (0.46-1.22) 
 
Regurgitation frequency – monthly to < weekly vs. 
never: 
All age groups – OR=2.82 (2.21-3.59) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=2.36 (0.88-6.32) 
50-59 years – OR=2.21 (1.31-3.74) 
60-69 years – OR=2.59 (1.70-3.92) 
≥ 70 years – OR=3.69 (2.43-5.62) 
 
Regurgitation frequency – weekly to < daily vs. 
never: 
All age groups – OR=5.03 (4.02-6.31) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=7.03 (3.22-15.33) 
50-59 years – OR=3.27 (1.95-5.49) 
60-69 years – OR=5.65 (3.87-8.23) 
≥ 70 years – OR=5.65 (3.77-8.46) 
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Regurgitation frequency – ≥ daily vs. never: 
All age groups – OR=4.83 (3.64-6.42) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=7.00 (2.53-19.40) 
50-59 years – OR=3.25 (1.65-6.40) 
60-69 years – OR=4.33 (2.70-6.94) 
≥ 70 years – OR=6.58 (3.99-10.86) 
 
Heartburn or regurgitation frequency – monthly to < 
weekly vs. never: 
All age groups – OR=1.28 (1.04-1.59) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=1.23 (0.57-2.65) 
50-59 years – OR=0.79 (0.51-1.21) 
60-69 years – OR=1.63 (1.11-2.39) 
≥ 70 years – OR=1.42 (0.97-2.07) 
 
Heartburn or regurgitation frequency – weekly to < 
daily vs. never: 
All age groups – OR=4.40 (3.57-5.44) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=7.05 (3.23-15.41) 
50-59 years – OR=2.25 (1.39-3.64) 
60-69 years – OR=5.95 (4.09-8.67) 
≥ 70 years – OR=4.56 (3.20-6.51) 
 
Heartburn or regurgitation frequency – ≥ daily vs. 
never: 
All age groups – OR=6.86 (5.41-8.70) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=9.59 (3.97-23.18) 
50-59 years – OR=4.01 (2.40-6.73) 
60-69 years – OR=8.16 (5.39-12.34) 
≥ 70 years – OR=9.55 (6.24-14.62) 
BARRETT’S 
ESOPHAGUS (BE) 
      
Thomas, 2007[57] EC, EAC 
(incidence) 
MEDLINE, 
EMBASE 
Using key words ‘ BO’, ‘short segment Barrett’s 
oesophagus’ (SSBO), ‘oesophageal (oesophageal) cancer’ 
41 cohort No EC 
Prev=4% (2.6-5.4), n=39 
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(1966-2004) 
 
Citation tracking 
(both American and British spellings used), ‘oesophageal ⁄ 
oesophageal neoplasm’ and ‘surveillance’ 
 
Restricted to studies published in English 
 
IR=7/1000 pyd (6-9), n=41 
Egger test: p=0.18; Begg test: p=0.17 
 
ACCORDING TO GEOGRAPHIC AREA 
USA – IR=7/1000 pyd (4-9), n=16 
UK – IR=7/1000 pyd (4-12), n=13 
Europe – IR=8/1000 pyd (5-12), n=10 
Australia/New Zealand – IR=5/1000 pyd (1-25), n=2 
 
EAC 
Short segment BE vs. conventional BE 
RR=0.55 (0.19-1.60), n=6 
BODY MASS INDEX 
(BMI) 
      
Hampel, 2005[61] EAC 
(risk) 
MEDLINE 
(inception-2004) 
 
Citation tracking 
Search terms included obesity or body mass or 
anthroprometry searched with reflux or heartburn, 
(o)esophagitis, Barrett’s or Barretts, and (o)esophageal 
cancer or (o)esophageal adenocarcinoma 
 
Restricted to studies published in English 
7 case-control No Overweight/Obese vs. Normal weight 
OR=2.02 (1.53-2.67), n=6, no evidence of 
publication bias 
 
Overweight vs. Normal weight 
OR=1.52 (1.15-2.01), n=6, no evidence of 
publication bias 
 
Obese vs. Normal weight 
OR=2.78 (1.85-4.16), n=6, no evidence of 
publication bias 
Kubo, 2006[63] EAC 
(risk) 
MEDLINE 
(1966-2005), 
WEB OF SCIENCE 
(not stated) 
 
Citation tracking 
[esophag* AND (adenocarcinoma OR carcinoma OR 
cancer)] combined with ‘‘body mass index OR BMI OR 
obesit.’; similar search was done using the word 
‘‘oesophagus,’’ a common British spelling for esophagus; 
identical searches were done using ‘‘cardia’’ AND 
(adenocarcinoma OR carcinoma OR cancer) 
 
No language restrictions 
7 
 
1 cohort 
6 case-control 
No Overweight/Obese vs. Normal weight 
All studies – OR=2.1 (1.7-2.4), n=7, Begg test: p=0.52 
 
ACCORDING TO SEX 
Men – OR=2.2 (1.8-2.7), n=4 
Women – OR=1.9 (1.5-2.5), n=5 
 
Overweight vs. Normal weight 
All studies – OR=1.9 (1.5-2.4), n=6 
 
ACCORDING TO SEX 
Men – OR=1.8 (1.5-2.2), n=3 
Women – OR=1.5 (1.1-2.2), n=3 
 
Obese vs. Normal weight 
All studies – OR=2.4 (2.0-2.8), n=6 
 
Papers | 151 
ACCORDING TO SEX 
Men – OR=2.4 (1.9-3.2), n=3 
Women – OR=2.1 (1.4-3.2), n=3 
WCRF, 2007[22] ESCC, EAC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
7 
 
1 cohort 
6 case-control 
No Per 1 Kg/m2 increment in BMI 
 
ESCC/Mixed/Unspecified 
Cohort – RR=1.07 (1.00-1.14), n=1 
Case-control – RR=0.98 (0.90-1.08), n=3, I2=90.4% 
 
EAC 
Case-control – RR=1.11 (1.07-1.15), n=5, I2=40.1% 
Renehan, 2008[59] ESCC, EAC 
(incidence) 
MEDLINE 
(inception-
2007), 
EMBASE 
(inception-2007) 
 
Citation tracking 
Our core search consisted of terms related to bodyweight 
(“obesity”, “adiposity”, “body mass index”, and “body 
size”), combined with specific terms for each cancer site 
 
No language restrictions 
6 
 
5 cohort 
1 nested case-
control 
Methodological 
quality was 
assessed 
according to 
three study 
components 
which might 
affect the 
strength of the 
association 
between BMI 
and cancer risk: 
length of 
follow-up; 
whether BMI 
was self-
reported or 
measured; and 
the extent of 
adjustments 
for potential 
confounding 
factors 
Increase of 5 Kg/m2 in BMI 
 
EAC 
 
ACCORDING TO SEX 
Men – RR=1.52 (1.33-1.74), n=5, I2=24% 
Women – RR=1.51 (1.31-1.74), n=3, I2=0% 
 
ESCC 
 
ACCORDING TO SEX 
Men – RR=0.71 (0.60-0.85), n=3, I2=49% 
Women – RR=0.57 (0.47-0.69), n=2, I2=60% 
Smith, 2008[60] ESCC, EAC 
(risk) 
MEDLINE 
(1980-2006), 
EMBASE 
(1980-2006) 
 
Not stated 
 
Restricted to studies published in English 
14 
 
5 cohort 
9 case-control 
No Increase of 5 Kg/m2 in BMI 
 
EAC 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.53 (1.30-1.79), n=1 
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Citation tracking Case-control – RR=1.54 (1.39-1.71), n=6 
 
ESCC 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.69 (0.63-0.75), n=3 
Case-control – RR=0.49 (0.44-0.55), n=7 
Guh, 2009[58] EC 
(incidence) 
MEDLINE, 
EMBASE 
(inception-2007) 
 
Citation tracking 
'Incidence, Prevalence, Risk, Risk Factors, Cohort Studies, 
Longitudinal Studies, Follow-up Studies, or Prospective 
Studies' in combination with 'Adipose Tissue, Obesity, Body 
Mass Index, or Body Composition' (all "exploded"); these 
same search terms were applied to each co-morbidity (also 
"exploded") 
 
Restricted to studies published in English 
1 cohort No Overweight vs. Normal weight 
Men – RR=1.13 (1.02-1.26), n=1 
Women – RR=1.15 (0.97-1.36), n=1 
 
Obese vs. Normal weight 
Men – RR=1.21 (0.97-1.52), n=1 
Women – RR=1.20 (0.95-1.53), n=1 
Hoyo, 2012[62] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 12 
 
2 cohort 
10 case-control 
NA Overweight vs. Normal weight 
All studies – OR=1.54 (1.26-1.88), n=12, I2=55% 
 
ACCORDING TO SEX 
Men – OR=1.63 (1.32-2.00), I2=51% 
Women – OR=1.24 (0.67-2.29), I2=56% 
 
ACCORDING TO GERD 
No – OR=1.12 (0.80-1.58), I2=0% 
Yes – OR=1.48 (1.07-2.05), I2=40% 
 
 
Obese Class I (30 ≤ BMI < 35) vs. Normal weight 
All studies – OR=2.39 (1.86-3.06), n=12, I2=42% 
 
ACCORDING TO SEX 
Men – OR=2.47 (1.94-3.13), I2=26% 
Women – OR=2.66 (1.59-4.46), I2=17% 
 
ACCORDING TO GERD 
No – OR=1.85 (0.91-3.73), I2=48% 
Yes – OR=2.21 (1.44-3.39), I2=37% 
 
 
Obese Class II (35 ≤ BMI < 40) vs. Normal weight 
All studies – OR=2.79 (1.89-4.12), n=11, I2=23% 
 
ACCORDING TO SEX 
Men – OR=2.87 (1.89-4.36), I2=17% 
Papers | 153 
Women – OR=1.38 (0.57-3.35), I2=0% 
 
ACCORDING TO GERD 
No – OR=2.08 (1.00-4.30), I2=0% 
Yes – OR=2.95 (1.15-7.59), I2=49% 
 
 
Obese Class III (BMI ≥ 40) vs. Normal weight 
All studies – OR=4.76 (2.96-7.66), n=9, I2=0% 
 
ACCORDING TO SEX 
Men – OR=4.47 (2.42-8.26), I2=0% 
Women – OR=5.88 (2.28-15.10), I2=0% 
 
ACCORDING TO GERD 
No – OR=6.45 (1.60-25.99), I2=100% 
Yes – OR=5.84 (2.72-12.55), I2=0% 
 
 
Increment of 1 Kg/m2 in BMI 
All studies – OR=1.09 (1.06-1.12), n=12, I2=76% 
 
ACCORDING TO SEX 
Men – OR=1.09 (1.06-1.13), I2=76% 
Women – OR=1.07 (1.04-1.10), I2=13% 
 
ACCORDING TO GERD 
No – OR=1.07 (1.03-1.11), I2=0% 
Yes – OR=1.08 (1.03-1.14), I2=71% 
 
Interactions with body mass index 
EAC 
Cigarette smoking – S=1.11 (0.87-1.40) 
Alcohol – S=1.31 (0.12-13.74) 
H. pylori (negative) – S=1.08 (0.37-3.20) 
Heartburn – S=1.42 (0.89-2.26) 
Reflux – S=1.20 (0.64-2.28) 
GERD – S=1.42 (1.04-1.94) 
Dobbins, 2013[66] EAC 
(risk) 
Renehan, 2008 
plus 
MEDLINE 
(2007-2011), 
EMBASE 
Our core search consisted of terms related to bodyweight 
(“obesity”, “adiposity”, “body mass index”, and “body 
size”), combined with specific terms for each cancer site 
 
No language restrictions 
7 based on the 
work of the 
Evidence-based 
Medicine 
Obese vs. Normal weight 
 
EAC 
 
ACCORDING TO SEX 
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(2007-2011) 
 
Citation tracking 
 
(replicated from Renehan, 2008) 
group at 
McMaster 
University 
Men – RR=1.23 (0.58-2.60), n=3, I2=75% 
Women – RR=2.04 (1.18-3.55), n=4, I2=78% 
Singh, 2013[65] EAC 
(risk) 
MEDLINE 
(1966-2013), 
EMBASE 
(1988-2013), 
WEB OF SCIENCE 
(1993-2013) 
 
Citation tracking 
Medical subject heading (MeSH) terms used in the search 
included a combination of “Obesity”, “Waist 
Circumference”, “Waist-Hip Ratio”, “Body Fat 
Distribution”, “Adiposity”, “Abdominal Fat”, “Obesity, 
Abdominal” AND “Esophagitis”, “Barrett esophagus” OR 
“esophageal neoplasm” 
 
No language restrictions 
6 
 
3 cohort 
3 case-control 
Newcastle-
Ottawa scale 
Central adiposity (highest vs. lowest category of 
exposure) 
OR=2.51 (1.56-4.04), n=5, I2=62%, Egger test: p=0.67 
 
BMI (highest vs. lowest category of exposure) 
OR=2.45 (1.84-3.28), n=5 
Turati, 2013[64] EAC 
(risk) 
MEDLINE 
(inception-2011) 
 
Citation tracking 
‘body mass index’ or ‘BMI’ or ‘obesity’ and combinations of 
‘esophageal neoplasms’ or ‘stomach neoplasms’ and 
‘adenocarcinoma’ 
 
Restricted to studies published in English 
18 
 
8 cohort 
10 case–control 
No Overweight vs. Normal weight 
RR=1.87 (1.61-2.17), n=17 
 
Obese vs. Normal weight 
RR=2.73 (2.16-3.46), n=10 
 
Increment of 5 Kg/m2 of BMI 
RR=1.13 (1.11-1.16), n=18 
Drahos, 2015[34] EAC 
(risk) 
International 
BEACON 
Consortium 
NA 8 case-control NA Overweight vs. Normal weight 
All age groups – OR=1.58 (1.37-1.82) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=1.64 (0.99-2.73) 
50-59 years – OR=1.61 (1.18-2.20) 
60-69 years – OR=1.93 (1.51-2.46) 
≥ 70 years – OR=1.19 (0.93-1.52) 
 
Obese vs. Normal weight 
All age groups – OR=2.83 (2.36-3.40) 
 
ACCORDING TO AGE GROUP 
< 50 years – OR=4.19 (2.23-7.87) 
50-59 years – OR=2.64 (1.81-3.84) 
60-69 years – OR=2.73 (1.99-3.74) 
≥ 70 years – OR=2.81 (2.00-3.94) 
Fahey, 2015[28] ESCC, EAC 
(mortality) 
MEDLINE 
(inception-
2014), 
EMBASE 
(inception-2014) 
 
Citation tracking 
("Esophagus"[Mesh] OR “Esophagus"[Title/Abstract] OR 
"Oesophagus"[Title/Abstract] OR 
"Esophageal"[Title/Abstract] OR 
"Oesophageal"[Title/Abstract]) AND ("Neoplasms"[Mesh] 
OR "Neoplasm"[Title/Abstract] OR 
"Cancer*"[Title/Abstract] OR "Carcinoma"[Title/Abstract] 
OR "Adenocarcinoma"[Title/Abstract]) AND (("Survival" 
5 JAMA Overweight/obese vs. Normal weight 
 
ESCC 
HR=0.80 (0.67-0.95), n=4, I2=64.9% 
 
EAC 
HR=0.80 (0.68-0.95), n=3, I2=52.1% 
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[Mesh]) OR ("Prognosis" [Mesh]) OR ("survival" 
[Title/Abstract]) OR ("prognosis" [Title/Abstract]) OR 
("prognostic" [Title/Abstract])) AND (("smoking" 
[Title/Abstract]) OR ("tobacco" [Title/Abstract]) OR 
("alcohol" [Title/Abstract]) OR ("physical activity" 
[Title/Abstract]) OR ("exercise" [Title/Abstract]) OR 
("sedentary lifestyle"[Title/Abstract]) OR ("body mass 
index"[Title/Abstract]) OR ("BMI" [Title/Abstract]) OR 
("obesity" [Title/Abstract]) OR ("Aspirin"[ Title/Abstract]) 
OR ("Non-Steroidal Anti-Inflammatory"[Title/Abstract]) OR 
("NSAID"[Title/Abstract]) OR ("health 
behavior"[Title/Abstract]) OR ("health 
behaviour"[Title/Abstract]) OR ("life style"[ Title/Abstract]) 
OR ("lifestyle"[ Title/Abstract]) OR ("life-style"[ 
Title/Abstract]) OR ("Smoking"[Mesh]) OR ("Alcohol 
Drinking"[Mesh]) OR ("Motor Activity"[Mesh]) OR 
("Exercise"[Mesh]) OR ("Sedentary Lifestyle"[Mesh]) OR 
("Body Mass Index"[Mesh]) OR ("Obesity"[Mesh]) OR 
("Health Behavior"[Mesh]) OR ("Life Style"[Mesh]) OR 
("Aspirin"[Mesh]) OR ("Anti-Inflammatory Agents, Non-
Steroidal"[Mesh])) 
 
Restricted to studies published in English 
 
 
Obese vs. Normal weight 
 
ESCC 
HR=1.05 (0.76-1.46), n=4, I2=0.0% 
 
EAC 
HR=0.85 (0.68-1.06), n=3, I2=22.7% 
PHYSICAL 
ACTIVITY 
      
Behrens, 2014[67] EC, ESCC, EAC 
(incidence or 
mortality) 
MEDLINE 
(inception-
2013), 
ISI Web of 
Knowledge 
(inception-2013) 
 
Citation tracking 
search strategy included the terms physical activity, 
exercise, cardiorespiratory fitness, cardiovascular fitness, 
lifestyle, stomach cancer, stomach carcinoma, gastric 
cancer, gastric carcinoma, esophageal cancer, esophageal 
carcinoma, cancer, risk, incidence, and mortality 
 
Restricted to studies published in English 
24 
 
9 cohort 
15 case-control 
Monninkhof et 
al. 
High vs. low level of physical activity 
 
EC 
All studies – RR=0.79 (0.60-1.02), n=21 
 
ACCORDING TO SEX 
Men – RR=0.70 (0.58-0.85), n=9 
Women – RR=0.43 (0.26-0.71), n=3 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.84 (0.71-0.99), n=7 
Case-control – RR=0.76 (0.51-1.12), n=14 
 
ACCORDING TO STUDY QUALITY 
Upper tertile – RR=0.78 (0.63-0.97), n=7 
Intermediate tertile – RR=0.90 (0.42-1.93), n=6 
Lower tertile – RR=0.73 (0.61-0.87), n=8 
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ACCORDING TO GEOGRAPHIC AREA 
North America – RR=0.77 (0.64-0.92), n=8 
Europe – RR=0.82 (0.54-1.24), n=4 
Australia – RR=0.72 (0.57-0.91), n=2 
Middle East – RR=0.48 (0.29-0.81), n=3 
Asia – RR=1.09 (0.37-3.22), n=4 
 
ACCORDING TO PHYSICAL ACTIVITY DOMAIN 
Total – RR=0.71 (0.44-1.15), n=3 
Recreational – RR=0.72 (0.63-0.83), n=10 
Occupational – RR=0.91 (0.46-1.81), n=8 
 
ESCC 
RR=0.94 (0.41-2.16), n=6 
 
EAC 
RR=0.79 (0.66-0.94), n=7 
Chen, 2014[68] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-2013) 
 
Citation tracking 
Core search consisted of terms related to physical activity 
(‘‘exercise,’’ ‘‘physical activity,’’ ‘‘walking,’’ and ‘‘motor 
activity,’’) These were combined with specific terms for 
cancer sites of interest (‘‘stomach,’’ ‘‘gastric,’’ ‘‘cardia,’’ 
‘‘esophagus,’’ and ‘‘esophageal’’) and with descriptions of 
cancer (‘‘cancer,’’ ‘‘neoplasm,’’ and ‘‘carcinoma’’) 
 
No language restrictions 
8 
 
3 cohort 
5 case-control 
Methodological 
quality was 
assessed using 
three study 
components 
that might 
affect the 
strength of the 
association 
between 
physical 
activity and the 
risk of 
esophageal 
cancer risk: 
study design; 
measurement 
of physical 
activity; and 
adjustment for 
confounding 
effects 
Most physically active vs. least active people 
 
EC 
All studies – RR=0.73 (0.56-0.97), n=8, I2=58.4% 
 
ACCORDING TO SEX 
Men – RR=0.81 (0.64-1.02), n=3, I2=26.8% 
Women – RR=0.35 (0.04-3.15), n=1 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.78 (0.66-0.92), n=3, I2=0.0% 
Case-control – RR=0.55 (0.28-1.10), n=5, I2=73.4% 
 
ACCORDING TO STUDY QUALITY 
Low risk of bias – RR=0.79 (0.58-1.08), n=3, I2=0.0% 
High risk of bias – RR=0.68 (0.46-1.02), n=5, 
I2=74.8% 
 
ACCORDING TO STUDY POPULATION 
Europe and America – RR=0.75 (0.62-0.90), n=6, 
I2=2.3% 
Asia – RR=0.23 (0.01-3.62), n=2, I2=91.3% 
 
ESCC 
RR=0.25 (0.01-4.97), n=2, I2=92.0% 
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EAC 
RR=0.79 (0.58-1.08), n=2, I2=0.0% 
Schmid, 2014[69] EC 
(risk) 
COCHRANE 
(inception-
2014), 
EMBASE 
(inception-
2014), 
MEDLINE 
(inception-
2014), 
SCISEARCH 
(inception-2014) 
 
Citation tracking 
Our search included the following terms for sedentary 
behavior: television (viewing, watching, usage, time, 
consumption), TV (viewing, watching, usage, time, 
consumption), video/video game (viewing, watching, 
usage, time, consumption), computer game (viewing, 
watching, usage, time, consumption), viewing time, screen 
time, sedentary (job, time, behavior, lifestyle), sitting (time, 
hours, behavior, occupational, office, prolonged), and 
physical inactivity. The search included the following terms 
for cancer: cancer, neoplasm, carcinoma, adenocarcinoma, 
tumor, leukemia, and lymphoma. We also searched for 
terms related to physical activity (eg, physical activity, 
motor activity, exercise) because several investigations of 
sedentary behavior were conducted within the context of 
physical activity studies. 
 
No language restrictions. 
3 
 
2 cohort 
1 case-control 
Newcastle-
Ottawa scale 
Sedentary behaviour 
RR=0.87 (0.57-1.34), n=3, I2=34.1% 
Singh, 2014[70] EC, ESCC, EAC 
(risk) 
MEDLINE 
(1966-2013), 
EMBASE 
(1988-2013), 
ISI WEB OF 
KNOWLEDGE 
(1993-2013) 
 
Citation tracking 
A combination of key words was used in the search: 
(exercise OR physical activity OR walking OR motor activity) 
AND (esophagus) AND (cancer OR neoplasm OR 
carcinoma). 
 
No language restrictions. 
10 
 
4 cohort 
6 case-control 
Boyle et al. Most physically active vs. least active people 
 
EC 
All studies – OR=0.71 (0.57-0.89), n=9, I2=47% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=0.84 (0.71-1.00), n=4, I2=0% 
Case-control – OR=0.59 (0.40-0.88), n=5, I2=51% 
 
ACCORDING TO STUDY QUALITY 
Low quality – OR=0.59 (0.40-0.88), n=5, I2=51% 
High quality – OR=0.84 (0.71-1.00), n=4, I2=0% 
 
ACCORDING TO STUDY LOCATION 
Western – OR=0.72 (0.58-0.89), n=7, I2=18% 
Asian – OR=0.43 (0.09-2.00), n=2, I2=84% 
 
ESCC 
OR=1.10 (0.21-5.64), n=3, I2=95% 
 
EAC 
OR=0.68 (0.55-0.85), n=4, I2=0% 
Fahey, 2015[28] ESCC, EAC 
(mortality) 
MEDLINE ("Esophagus"[Mesh] OR “Esophagus"[Title/Abstract] OR 
"Oesophagus"[Title/Abstract] OR 
2 JAMA Highest vs. lowest exercise category 
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(inception-
2014), 
EMBASE 
(inception-2014) 
 
Citation tracking 
"Esophageal"[Title/Abstract] OR 
"Oesophageal"[Title/Abstract]) AND ("Neoplasms"[Mesh] 
OR "Neoplasm"[Title/Abstract] OR 
"Cancer*"[Title/Abstract] OR "Carcinoma"[Title/Abstract] 
OR "Adenocarcinoma"[Title/Abstract]) AND (("Survival" 
[Mesh]) OR ("Prognosis" [Mesh]) OR ("survival" 
[Title/Abstract]) OR ("prognosis" [Title/Abstract]) OR 
("prognostic" [Title/Abstract])) AND (("smoking" 
[Title/Abstract]) OR ("tobacco" [Title/Abstract]) OR 
("alcohol" [Title/Abstract]) OR ("physical activity" 
[Title/Abstract]) OR ("exercise" [Title/Abstract]) OR 
("sedentary lifestyle"[Title/Abstract]) OR ("body mass 
index"[Title/Abstract]) OR ("BMI" [Title/Abstract]) OR 
("obesity" [Title/Abstract]) OR ("Aspirin"[ Title/Abstract]) 
OR ("Non-Steroidal Anti-Inflammatory"[Title/Abstract]) OR 
("NSAID"[Title/Abstract]) OR ("health 
behavior"[Title/Abstract]) OR ("health 
behaviour"[Title/Abstract]) OR ("life style"[ Title/Abstract]) 
OR ("lifestyle"[ Title/Abstract]) OR ("life-style"[ 
Title/Abstract]) OR ("Smoking"[Mesh]) OR ("Alcohol 
Drinking"[Mesh]) OR ("Motor Activity"[Mesh]) OR 
("Exercise"[Mesh]) OR ("Sedentary Lifestyle"[Mesh]) OR 
("Body Mass Index"[Mesh]) OR ("Obesity"[Mesh]) OR 
("Health Behavior"[Mesh]) OR ("Life Style"[Mesh]) OR 
("Aspirin"[Mesh]) OR ("Anti-Inflammatory Agents, Non-
Steroidal"[Mesh])) 
 
Restricted to studies published in English 
EAC 
HR=1.20 (0.91-1.58), n=2 
 
ESCC 
HR=0.80 (0.41-1.55), n=1 
DIETARY 
PATTERNS 
      
Liu, 2014[74] ESCC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-
2013), 
CNKI 
(inception-
2013), 
VJIP 
(inception-2013) 
 
Citation tracking 
Key words used for the literature search included 
‘oesophageal cancer’, ‘oesophageal squamous cell 
carcinoma’, ‘oesophageal neoplasm’, ‘dietary pattern’, 
‘nutrient pattern’, ‘food pattern’, ‘eating pattern’, ‘dietary 
habits’, ‘diet’, ‘dietary’, and ‘nutrients’ 
 
Restricted to studies published in English or Chinese 
9 case-control Newcastle-
Ottawa scale 
Western pattern 
OR=1.29 (0.83-1.75), n=9, I2=51.60% 
Egger test: p=0.853 
 
Healthy pattern 
OR=0.36 (0.23-0.49), n=9, I2=67.30% 
Egger test: p=0.071 
 
Drinker/alcohol pattern 
OR=2.34 (1.22-3.45), n=4, I2=48.70% 
Egger test: p=0.093 
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GLYCEMIC 
INDEX/LOAD 
      
Mulholland, 
2009[71] 
ESCC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2008) 
 
Citation tracking 
1) glyc(a)emic index, glyc(a)emic load, blood glucose, blood 
sugar(s); 2) diet, nutrition, dietary carbohydrate(s), 
carbohydrate(s), dietary fiber/fiber, fiber/fiber, dietary 
sugar(s), and dietary sucrose; and 3) cancer, neoplasm(s), 
neoplasia, adenoma, adenocarcinoma, or carcinoma 
 
No language restrictions 
1 case-control No Per each 10-unit/d increase in GI intake 
OR=1.1 (0.9-1.5), n=1 
 
Per each 100-unit/d increment in GL intake 
OR=1.2 (1.0-1.5), n=1 
Turati, 2015[72] ESCC 
(risk) 
MEDLINE 
(inception-2015) 
 
Citation tracking 
((cancer) OR (neoplasm) OR (carcinoma)) AND((glycemic 
index)OR (glycemic load) OR (glycaemic index) OR 
(glycaemic load)) 
 
No language restrictions 
4 
 
1 cohort 
3 case-control 
No Highest vs. lowest category of GI intake 
RR=1.46 (0.90-2.38), n=4, I2=83.4% 
 
Highest vs. lowest category of GL intake 
RR=1.25 (0.45-3.48), n=4, I2=95.1% 
ENERGY INTAKE       
Yu, 2012[73] EC 
(risk) 
MEDLINE 
(1966-2012), 
EMBASE 
(1985-2012), 
SCIE (1945-2012) 
 
Citation tracking 
energy intake combined with digestive system neoplasms 
 
Restricted to studies published in English 
Not specified for EC No Highest vs. lowest category of energy intake 
RR=0.96 (0.86-1.07) 
MEAT       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Almost daily/daily vs. never/1-3 per week 
Overall – OR=1.28 (1.02-1.61) 
Men – OR=1.46 (1.11-1.92) 
Women – OR=0.98 (0.62-1.53) 
Choi, 2013[92] EC, ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2012) 
 
Citation tracking 
“oesophageal or esophageal or esophagus or 
oesophagus” and “cancer or neoplasm or carcinoma” and 
“cohort or prospective or case-control” and “food or diet 
or meat” 
 
Restricted to studies published in English 
27 
 
4 cohort 
23 case-control 
Newcastle-
Ottawa scale  
Highest vs. lowest red meat intake 
All studies – RR=1.38 (1.17-1.64), n=22, I2=67.1% 
 
ACCORDING TO SEX 
Men – RR=1.26 (0.66-2.41), n=3 
Women – RR=1.31 (0.78-2.21), n=2 
Both – RR=1.42 (1.17-1.71), n=19 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.26 (1.00-1.59), n=4, I2=35.3%, Egger 
test: p=0.79 
Case-control – RR=1.44 (1.16-1.80), n=18, I2=72.8%, 
Egger test: p=0.34 
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ACCORDING TO TUMOR TYPE 
EAC – RR=1.42 (1.02-1.98), n=9 
ESCC – RR=1.55 (1.10-2.17), n=9 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.33 (1.09-1.62), n=6 
Europe – RR=1.33 (0.86-2.07), n=6 
USA – RR=1.32 (1.03-1.70), n=7 
South America – RR=2.20 (0.48-10.04), n=3 
 
ACCORDING TO STUDY QUALITY 
≥7– RR=1.60 (1.20-2.13), n=8 
<7 – RR=1.25 (1.02-1.54), n=14 
 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.32 (1.08-1.62), n=18, I2=58.4% 
 
ACCORDING TO SEX 
Men – RR=1.24 (0.58-2.65), n=2 
Women – RR=0.61 (0.33-1.13), n=1 
Both – RR=1.43 (1.15-1.77), n=16 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.25 (0.83-1.86), n=3, I2=63.4%, Egger 
test: p=0.65 
Case-control – RR=1.36 (1.07-1.74), n=15, I2=57.1%, 
Egger test: p=0.80 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=1.38 (1.07-1.78), n=8 
ESCC – RR=1.08 (0.80-1.44), n=7 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.09 (0.61-1.95), n=5 
Europe – RR=1.49 (0.99-2.23), n=7 
USA – RR=1.30 (1.08-1.57), n=5 
South America – RR=0.76 (0.51-1.13), n=1 
 
ACCORDING TO STUDY QUALITY 
≥7– RR=1.20 (0.88-1.62), n=6 
<7 – RR=1.43 (1.11-1.86), n=12 
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Per 100 g/d increment in processed meat intake 
Cohort – RR=1.37 (0.88-2.13), n=3, I2=33.5% 
Huang, 2013[99] EAC 
(risk) 
MEDLINE 
(1966-2012), 
EMBASE 
(1974-2012) 
 
Citation tracking 
[esophag* AND (adenocarcinomaORcarcinomaORcancer)] 
combined with ‘‘red meat OR processed meat OR 
preserved meat OR beef OR pork OR veal OR mutton OR 
lamb OR ham OR sausage OR bacon OR salted meat’’; a 
similar search was done using the word ‘‘oesophag*,’’ a 
common British spelling for esophagus 
 
Restricted to studies published in English 
10 
 
3 cohort 
7 case-control 
No Highest vs. lowest red meat intake 
All studies – RR=1.31 (1.05-1.64), n=9, I2=18.9%, 
Egger test: p=0.161 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.12 (0.88-1.41), n=3, I2=0.0% 
Case-control – RR=1.56 (1.14-2.14), n=6, I2=8.1% 
Population-based – RR=1.50 (1.07-2.11), n=5, 
I2=14.0% 
Hospital-based – RR=2.40 (0.87-6.50), n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.60 (0.77-3.29), n=3, I2=71.5% 
USA – RR=1.26 (1.01-1.58), n=6, I2=0.0% 
 
Increase in red meat intake of 100 g/day 
RR=1.45 (1.09-1.93), n=7, I2=61.8% 
 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.41 (1.09-1.83), n=9, I2=39.4%, 
Egger test: p=0.359 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.35 (0.78-2.33), n=3, I2=75.9% 
Case-control – RR=1.54 (1.15-2.07), n=6, I2=0.0% 
Population-based – RR=1.44 (1.06-1.97), n=5, 
I2=0.0% 
Hospital-based – RR=2.80 (1.09-7.16), n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.58 (0.75-3.35), n=3, I2=74.8% 
USA – RR=1.29 (1.03-1.62), n=6, I2=5.0% 
 
Increase in processed meat intake of 50 g/day 
RR=1.37 (1.03-1.81), n=7, I2=71.0% 
Qu, 2013[93] ESCC 
(risk) 
MEDLINE 
(1966-2012), 
EMBASE 
(1974-2012) 
(o)esophageal OR (o)esophagus; cancer OR carcinoma OR 
neoplasia; and red meat OR processed meat OR preserved 
meat OR beef OR pork OR veal OR mutton OR lamb OR 
ham OR sausage OR bacon OR salted meat 
21 
 
2 cohort 
19 case-control 
No Highest vs. lowest red meat intake 
All studies – RR=1.57 (1.26-1.95), n=16, I2=56.0% 
Only ESCC – RR=1.42 (1.14-1.75), n=7, I2=6.6% 
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Citation tracking 
 
No language restrictions 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.52 (1.03-2.25), n=2, I2=0.0% 
Case-control – RR=1.59 (1.24-2.04), n=14, I2=60.6% 
Population-based – RR=1.11 (0.93-1.33), n=2, 
I2=0.0% 
Hospital-based – RR=1.78 (1.35-2.35), n=12, 
I2=48.8% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.50 (0.95-2.38), n=5, I2=46.7% 
USA – RR=1.52 (1.01-2.57), n=3, I2=53.2% 
South America – RR=2.57 (1.49-4.42), n=3, I2=52.5% 
Asia – RR=1.20 (1.03-1.39), n=5, I2=0.0% 
 
Increase in red meat intake of 100 g/day 
RR=1.41 (1.16-1.70), n=11, I2=51.7% 
 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.55 (1.22-1.97), n=15, I2=45.3% 
Only ESCC – RR=1.41 (1.11-1.78), n=8, I2=0.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.28 (0.88-1.86), n=2, I2=0.0% 
Case-control – RR=1.62 (1.22-2.16), n=13, I2=51.0% 
Population-based – RR=1.97 (1.24-3.12), n=4, 
I2=25.2% 
Hospital-based – RR=1.51 (1.05-2.15), n=9, I2=57.9% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.73 (0.97-3.08), n=5, I2=69.6% 
USA – RR=1.57 (1.05-2.34), n=2, I2=17.0% 
South America – RR=1.73 (1.21-2.48), n=2, I2=0.0% 
Asia – RR=1.43 (1.01-2.14), n=6, I2=47.3% 
 
Increase in processed meat intake of 50 g/day 
RR=1.81 (1.32-2.48), n=13, I2=56.5% 
Salehi, 2013[82] EC, ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE, 
WEB OF SCIENCE 
(1990-2011) 
 
Citation tracking 
“meat” or “foods” or “diet” combined with “esophageal 
cancer,” “esophageal neoplasm,” “esophagus cancer,” or 
“esophagus neoplasm”; the search was repeated using 
British spelling 
 
Restricted to studies published in English 
35 
 
4 cohort 
31 case-control 
Critical 
Appraisal Skills 
Programme 
(CASP) 
Highest vs. lowest total meat intake 
All studies – RR=0.99 (0.85-1.15), n=21, I2=49.7%, 
Egger test: p=0.40 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.90 (0.59-1.38), n=3 
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Population-based case-control – RR=1.33 (0.99-
1.81), n=8 
Hospital-based case-control – RR=0.95 (0.79-1.14), 
n=10 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=1.09 (0.92-1.29), n=6 
ESCC – RR=0.89 (0.69-1.14), n=8 
 
ACCORDING TO GEOGRAPHIC AREA 
Asian – RR=0.77 (0.67-0.88), n=9 
European – RR=1.02 (0.77-1.34), n=7 
American – RR=1.16 (0.98-1.36), n=5 
 
Increase in total meat intake of 100 g/day 
RR=1.01 (0.99-1.01), n=9, I2=33.8% 
 
 
Highest vs. lowest red meat intake 
All studies – RR=1.40 (1.09-1.81), n=14, Egger test: 
p=0.15 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.32 (1.03-1.71), n=2 
Population-based case-control – RR=1.17 (0.87-
1.58), n=5, I2=0.0% 
Hospital-based case-control – RR=1.66 (1.02-2.69), 
n=7, I2=82.0% 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=1.19 (0.98-1.44), n=6 
ESCC – RR=1.63 (1.00-2.63), n=7, I2=79.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
European – RR=1.57 (1.03-2.38), n=5 
American – RR=1.34 (0.97-1.85), n=9 
 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.41 (1.13-1.76), n=17, I2=62.0%, 
Egger test: p=0.75 
 
ACCORDING TO STUDY DESIGN 
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Cohort – RR=1.87 (0.62-5.64), n=2 
Population-based case-control – RR=1.32 (1.01-
1.72), n=7, I2=0.0% 
Hospital-based case-control – RR=1.43 (0.99-2.06), 
n=8, I2=62.0% 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=1.37 (1.05-1.78), n=6 
ESCC – RR=1.17 (0.90-1.51), n=6 
 
ACCORDING TO GEOGRAPHIC AREA 
Asian – RR=0.78 (0.51-1.19), n=3 
European – RR=1.86 (1.20-2.90), n=6 
American – RR=1.43 (1.09-1.89), n=8 
 
Increase in processed meat intake of 50 g/day 
RR=1.57 (1.22-2.01), n=8 
 
 
Highest vs. lowest barbecued meat intake 
All studies – RR=1.68 (0.88-3.21), n=3 
 
ACCORDING TO STUDY DESIGN 
Population-based case-control – RR=0.99 (0.62-
1.59), n=1 
Hospital-based case-control – RR=2.37 (1.41-3.98), 
n=2 
 
 
Highest vs. lowest white meat intake 
All studies – RR=0.71 (0.59-0.86), n=4, I2=6.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.80 (0.63-1.00), n=1 
Population-based case-control – RR=0.51 (0.23-
1.13), n=1 
Hospital-based case-control – RR=0.64 (0.48-0.85), 
n=2 
 
 
Highest vs. lowest poultry meat intake 
All studies – RR=0.87 (0.60-1.24), n=9, Egger test: 
p=0.81 
Papers | 165 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.93 (0.99-3.76), n=1 
Population-based case-control – RR=0.88 (0.65-
1.19), n=4 
Hospital-based case-control – RR=0.68 (0.35-1.30), 
n=4 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=1.02 (0.52-2.00), n=3 
ESCC – RR=0.66 (0.31-1.40), n=3 
 
ACCORDING TO GEOGRAPHIC AREA 
Asian – RR=1.42 (0.62-3.25), n=1 
European – RR=0.74 (0.34-1.74), n=4 
American – RR=0.89 (0.64-1.24), n=4 
Zhu, 2014[83] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-
2013), 
COCHRANE 
(inception-2013) 
 
Citation tracking 
The search strategy included terms of outcome 
(esophageal cancer, oesophageal cancer, esophageal 
neoplasms, esophageal squamous cell carcinoma, and 
esophageal adenocarcinoma) and exposure (meat, red 
meat, processed meat, white meat, poultry, fish, beef, 
pork, lamb, and goat). 
 
No language restrictions 
35 
 
7 cohort 
28 case-control 
Newcastle-
Ottawa scale 
EC 
 
Highest vs. lowest total meat intake 
All studies – RR=1.19 (0.98-1.46), n=24, I2=73.3%, 
Egger test: p=0.009; Begg test: p=0.107 
 
High-quality studies – RR=1.26 (0.98-1.63), n=16, 
I2=77.8% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.94 (0.67-1.32), n=4, I2=60.5% 
Case-control – RR=1.24 (0.99-1.57), n=20, I2=70.7% 
Population-based case-control – RR=1.54 (1.13-
2.10), n=10, I2=76.1% 
Hospital-based case-control – RR=0.87 (0.73-1.04), 
n=11, I2=17.3% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=0.92 (0.75-1.12), n=11, I2=50.4% 
Europe – RR=0.93 (0.73-1.18), n=6, I2=49.2% 
USA – RR=1.85 (0.89-3.85), n=4, I2=79.9% 
South America – RR=0.87 (0.47-1.63), n=2, I2=0.0% 
Australia – RR=2.19 (1.66-2.90), n=1 
 
Highest vs. lowest red meat intake 
All studies – RR=1.55 (1.22-1.96), n=15, I2=63.6%, 
Egger test: p=0.326; Begg test: p=0.132 
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High-quality studies – RR=1.52 (1.15-2.02), n=12, 
I2=68.5% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.21 (0.98-1.50), n=3, I2=40.9% 
Case-control – RR=1.78 (1.30-2.44), n=12, I2=68.3% 
Population-based case-control – RR=1.42 (1.02-
1.98), n=4, I2=0.0% 
Hospital-based case-control – RR=2.01 (1.28-3.16), 
n=8, I2=78.5% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.42 (1.07-1.87), n=2, I2=0.0% 
Europe – RR=1.32 (0.93-1.87), n=6, I2=52.1% 
USA – RR=1.36 (1.09-1.68), n=4, I2=0.0% 
South America – RR=2.64 (0.88-7.89), n=3, I2=84.6% 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.33 (1.04-1.69), n=15, I2=61.5%, 
Egger test: p=0.159; Begg test: p=0.345 
 
High-quality studies – RR=1.35 (1.03-1.78), n=12, 
I2=66.9% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.25 (0.83-1.86), n=3, I2=63.4% 
Case-control – RR=1.29 (1.00-1.93), n=12, I2=63.4% 
Population-based case-control – RR=1.37 (1.00-
1.88), n=5, I2=0.0% 
Hospital-based case-control – RR=1.44 (0.84-2.50), 
n=7, I2=78.7% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.00 (0.52-1.94), n=2, I2=0.0% 
Europe – RR=1.57 (0.95-2.58), n=6, I2=72.6% 
USA – RR=1.23 (1.00-1.50), n=4, I2=0.0% 
South America – RR=1.07 (0.48-2.41), n=3, I2=80.0% 
 
Highest vs. lowest white meat intake 
All studies – RR=0.72 (0.60-0.86), n=4, I2=0.0%, 
Egger test: p=0.332; Begg test: p=0.624 
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ACCORDING TO STUDY DESIGN 
Cohort – RR=0.80 (0.64-1.00), n=1 
Case-control – RR=0.58 (0.42-0.80), n=3, I2=0.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.51 (0.23-1.13), n=1 
USA – RR=0.80 (0.64-1.00), n=1 
South America – RR=0.60 (0.42-0.84), n=2, I2=0.0% 
 
Highest vs. lowest poultry intake 
All studies – RR=0.83 (0.72-0.96), n=12, I2=34.5%, 
Egger test: p=0.858; Begg test: p=0.956 
 
High-quality studies – RR=0.78 (0.57-1.07), n=7, 
I2=57.3% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.02 (0.64-1.62), n=2, I2=66.2% 
Case-control – RR=0.76 (0.63-0.91), n=10, I2=11.4% 
Population-based case-control – RR=0.83 (0.66-
1.04), n=5, I2=0.0% 
Hospital-based case-control – RR=0.64 (0.46-0.88), 
n=6, I2=6.7% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=0.85 (0.67-1.08), n=5, I2=0.0% 
Europe – RR=0.77 (0.34-1.74), n=4, I2=76.7% 
USA – RR=0.87 (0.70-1.07), n=3, I2=0.0% 
 
 
ESCC 
 
Highest vs. lowest total meat intake 
All studies – RR=0.92 (0.75-1.14), n=18, I2=68.5% 
 
High-quality studies – RR=0.87 (0.67-1.14), n=12, 
I2=72.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.65 (0.49-0.87), n=3, I2=64.8% 
Case-control – RR=1.05 (0.79-1.39), n=14, I2=66.2% 
Population-based case-control – RR=1.27 (0.80-
2.00), n=7, I2=75.6% 
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Hospital-based case-control – RR=0.83 (0.68-1.01), 
n=8, I2=21.1% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=0.92 (0.75-1.12), n=11, I2=50.4% 
Europe – RR=0.74 (0.55-0.99), n=3, I2=2.5% 
USA – RR=2.01 (0.82-4.95), n=1 
South America – RR=0.87 (0.47-1.63), n=2, I2=0.0% 
Australia – RR=2.84 (1.67-4.83), n=1 
 
Highest vs. lowest red meat intake 
All studies – RR=1.86 (1.31-2.66), n=10, I2=72.6%, 
Egger test: p=0.415; Begg test: p=0.621 
 
High-quality studies – RR=1.93 (1.23-3.03), n=8, 
I2=76.2% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.54 (1.04-2.27), n=2, I2=47.0% 
Case-control – RR=2.01 (1.28-3.16), n=8, I2=78.5% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.42 (1.07-1.87), n=2, I2=0.0% 
Europe – RR=1.87 (1.04-3.36), n=4, I2=66.3% 
USA – RR=1.79 (1.07-3.01), n=1 
South America – RR=2.64 (0.88-7.89), n=3, I2=84.6% 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.35 (0.92-2.00), n=10, I2=71.3% 
 
High-quality studies – RR=1.44 (0.92-2.26), n=8, 
I2=76.8% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.34 (0.62-2.92), n=2, I2=68.5% 
Case-control – RR=1.37 (0.84-2.24), n=8, I2=75.4% 
Population-based case-control – RR=0.93 (0.38-
2.29), n=1 
Hospital-based case-control – RR=1.44 (0.84-2.50), 
n=7, I2=78.7% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.00 (0.52-1.94), n=2, I2=0.0% 
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Europe – RR=1.84 (0.86-3.97), n=4, I2=79.4% 
USA – RR=1.32 (0.83-2.10), n=1 
South America – RR=1.07 (0.48-2.41), n=3, I2=80.0% 
 
Highest vs. lowest white meat intake 
All studies – RR=0.63 (0.48-0.83), n=3, I2=0.0%, 
Egger test: p=0.420; Begg test: p=0.117 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.69 (0.44-1.08), n=1 
Case-control – RR=0.60 (0.42-0.84), n=2, I2=0.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
USA – RR=0.69 (0.44-1.08), n=1 
South America – RR=0.60 (0.42-0.84), n=2, I2=0.0% 
 
Highest vs. lowest poultry intake 
All studies – RR=0.73 (0.60-0.89), n=9, I2=6.9%, 
Egger test: p=0.285; Begg test: p=0.421 
 
High-quality studies – RR=0.56 (0.40-0.77), n=4, 
I2=0.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.69 (0.42-1.13), n=1 
Case-control – RR=0.74 (0.60-0.91), n=8, I2=16.8% 
Population-based case-control – RR=0.83 (0.63-
1.09), n=3, I2=8.2% 
Hospital-based case-control – RR=0.64 (0.46-0.88), 
n=6, I2=6.7% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=0.85 (0.67-1.08), n=5, I2=0.0% 
Europe – RR=0.47 (0.31-0.73), n=3, I2=0.0% 
USA – RR=0.69 (0.42-1.13), n=1 
 
 
EAC 
 
Highest vs. lowest total meat intake 
All studies – RR=1.96 (1.26-3.03), n=6, I2=62.9%, 
Egger test: p=0.743; Begg test: p=0.851 
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High-quality studies – RR=1.96 (1.26-3.03), n=6, 
I2=62.9% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.79 (0.86-3.75), n=1 
Case-control – RR=1.99 (1.18-3.36), n=5, I2=70.2% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.54 (0.91-2.60), n=2, I2=0.0% 
USA – RR=2.24 (0.84-6.00), n=3, I2=83.7% 
Australia – RR=2.12 (1.30-3.46), n=1 
 
Highest vs. lowest red meat intake 
All studies – RR=1.20 (0.98-1.48), n=7, I2=1.9% 
 
High-quality studies – RR=1.15 (0.93-1.42), n=6, 
I2=0.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.09 (0.84-1.41), n=3, I2=30.0% 
Case-control – RR=1.42 (1.02-1.98), n=4, I2=0.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.02 (0.69-1.51), n=3, I2=26.9% 
USA – RR=1.28 (1.01-1.62), n=4, I2=0.0% 
 
Highest vs. lowest processed meat intake 
All studies – RR=1.23 (1.01-1.50), n=7, I2=40.9%, 
Egger test: p=0.289; Begg test: p=0.186 
 
High-quality studies – RR=1.20 (0.97-1.47), n=6, 
I2=44.5% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.21 (0.67-2.16), n=3, I2=69.3% 
Case-control – RR=1.45 (1.04-2.03), n=4, I2=0.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.31 (0.65-2.65), n=3, I2=68.0% 
USA – RR=1.21 (0.96-1.51), n=4, I2=0.0% 
 
Highest vs. lowest white meat intake 
All studies – RR=0.80 (0.63-1.02), n=2, I2=26.8% 
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Highest vs. lowest poultry intake 
All studies – RR=1.01 (0.69-1.46), n=4, I2=50.5% 
 
High-quality studies – RR=1.01 (0.69-1.46), n=4, 
I2=50.5% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.27 (0.64-2.50), n=2, I2=72.9% 
Case-control – RR=0.83 (0.55-1.26), n=2, I2=30.4% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.93 (0.99-3.76), n=1 
USA – RR=0.91 (0.72-1.15), n=3, I2=0.0% 
FISH       
Han, 2013[96] ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2012) 
 
Citation tracking 
(o)esophag*; cancer OR carcinoma OR neoplasia OR 
adenocarcinoma; fish OR shellfish OR seafood 
 
Restricted to studies published in English 
24 
 
3 cohort 
21 case-control 
No EAC 
 
Highest vs. lowest fish intake 
All studies – RR=0.86 (0.61-1.22), n=6, I2=58.4% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.78 (0.59-1.03), n=1 
Case-control – RR=0.86 (0.53-1.41), n=5, I2=64.4% 
Population-based case-control – RR=0.86 (0.53-
1.41), n=5, I2=64.4% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.32 (0.81-2.14), n=2, I2=0.0% 
USA – RR=0.72 (0.48-1.09), n=4, I2=62.9% 
 
 
ESCC 
 
Highest vs. lowest fish intake 
All studies – RR=0.81 (0.66-0.99), n=17, I2=51.9%, 
Egger test: p=0.773, Begg test: p=0.318 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.87 (0.60-1.27), n=3, I2=46.1% 
Case-control – RR=0.79 (0.62-1.02), n=14, I2=55.1% 
Population-based case-control – RR=1.58 (1.09-
2.29), n=3, I2=0.0% 
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Hospital-based case-control – RR=0.66 (0.55-0.80), 
n=11, I2=12.9% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.60 (0.42-0.86), n=4, I2=40.9% 
USA – RR=1.30 (0.71-2.39), n=2, I2=59.6% 
South America – RR=0.74 (0.43-1.28), n=3, I2=41.6% 
Asia – RR=0.86 (0.65-1.13), n=8, I2=43.3% 
 
Increase in fish intake of 1 serving/week 
RR=0.81 (0.73-0.89), n=6, I2=0.0% 
 
Increase in fish intake of 20 g/day 
RR=0.86 (0.58-1.27), n=3, I2=88.9% 
Salehi, 2013[82] EC, ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE, 
WEB OF SCIENCE 
(1990-2011) 
 
Citation tracking 
“meat” or “foods” or “diet” combined with “esophageal 
cancer,” “esophageal neoplasm,” “esophagus cancer,” or 
“esophagus neoplasm”; the search was repeated using 
British spelling 
 
Restricted to studies published in English 
35 
 
4 cohort 
31 case-control 
Critical 
Appraisal Skills 
Programme 
(CASP) 
Highest vs. lowest fish intake 
All studies – RR=0.80 (0.64-1.00), n=17, Egger test: 
p=0.47 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.59 (0.36-0.97), n=1 
Population-based case-control – RR=1.14 (0.82-
1.44), n=7 
Hospital-based case-control – RR=0.69 (0.52-0.91), 
n=9 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=0.90 (0.52-1.56), n=3 
ESCC – RR=0.71 (0.48-1.06), n=6 
 
ACCORDING TO GEOGRAPHIC AREA 
Asian – RR=0.98 (0.68-1.42), n=6 
European – RR=0.66 (0.49-0.88), n=7 
American – RR=0.87 (0.44-1.73), n=4 
 
Increase in fish intake of 50 g/day 
RR=0.62 (0.43-0.87), n=7 
Yu, 2014[100] EC 
(incidence) 
MEDLINE 
(1966-2013), 
EMBASE 
(1985-2013), 
SCIE 
(1945-2013) 
 
Using the Medical Subject Heading terms fish and 
gastrointestinal neoplasm, or esophageal neoplasm, or 
stomach neoplasm, or colorectal neoplasm, or 
hepatocellular neoplasm, or pancreatic neoplasm 
 
Restricted to studies published in English 
2 cohort No Fish consumers vs. non/lowest consumers 
RR=0.91 (0.83-0.99), n=2 
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Citation trackinh 
Zhu, 2014[83] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-
2013), 
COCHRANE 
(inception-2013) 
 
Citation tracking 
The search strategy included terms of outcome 
(esophageal cancer, oesophageal cancer, esophageal 
neoplasms, esophageal squamous cell carcinoma, and 
esophageal adenocarcinoma) and exposure (meat, red 
meat, processed meat, white meat, poultry, fish, beef, 
pork, lamb, and goat). 
 
No language restrictions 
25 
 
3 cohort 
22 case-control 
Newcastle-
Ottawa scale 
EC 
 
Highest vs. lowest fish intake 
All studies – RR=0.95 (0.76-1.19), n=25, I2=79.2%, 
Egger test: p=0.416; Begg test: p=0.368 
 
High-quality studies – RR=0.96 (0.73-1.25), n=16, 
I2=80.2% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.83 (0.68-1.01), n=3, I2=23.7% 
Case-control – RR=0.98 (0.74-1.28), n=22, I2=81.5% 
Population-based case-control – RR=1.31 (0.84-
2.05), n=10, I2=87.0% 
Hospital-based case-control – RR=0.77 (0.58-1.03), 
n=13, I2=68.4% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.18 (0.79-1.76), n=12, I2=86.4% 
Europe – RR=0.65 (0.53-0.81), n=7, I2=41.8% 
USA – RR=0.91 (0.66-1.26), n=5, I2=62.0% 
South America – RR=1.50 (0.60-4.00), n=1 
 
 
ESCC 
 
Highest vs. lowest fish intake 
All studies – RR=1.08 (0.80-1.46), n=19, I2=90.5% 
 
High-quality studies – RR=1.15 (0.78-1.69), n=12, 
I2=91.4% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.05 (0.51-2.14), n=3, I2=92.1% 
Case-control – RR=1.09 (0.77-1.55), n=16, I2=84.8% 
Population-based case-control – RR=1.82 (0.94-
3.53), n=7, I2=90.5% 
Hospital-based case-control – RR=0.79 (0.55-1.13), 
n=10, I2=72.9% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=1.18 (0.79-1.76), n=12, I2=86.4% 
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Europe – RR=0.62 (0.47-0.82), n=4, I2=36.7% 
USA – RR=1.30 (0.71-2.39), n=2, I2=59.6% 
South America – RR=1.50 (0.60-4.00), n=1 
 
 
EAC 
 
Highest vs. lowest fish intake 
All studies – RR=0.81 (0.54-1.20), n=5, I2=63.1% 
 
High-quality studies – RR=0.81 (0.54-1.20), n=5, 
I2=63.1% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.78 (0.69-1.03), n=1 
Case-control – RR=0.77 (0.42-1.43), n=4, I2=71.4% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=1.49 (0.72-3.10), n=1 
USA – RR=0.72 (0.48-1.09), n=4, I2=62.9% 
FRUITS       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA 1-3 per week or month vs. never/rarely 
Overall – OR=0.43 (0.31-0.58) 
Men – OR=0.39 (0.27-0.55) 
Women – OR=0.64 (0.28-1.45) 
 
Almost daily/daily vs. never/rarely 
Overall – OR=0.37 (0.27-0.51) 
Men – OR=0.31 (0.22-0.45) 
Women – OR=0.68 (0.30-1.52) 
Riboli, 2003[76] EC 
(risk, 
incidence, 
mortality) 
MEDLINE 
(1973-2001) 
 
Citation tracking 
Not stated 
 
Restricted to studies published in English 
13 
 
1 cohort 
12 case-control 
No Increase in fruits intake of 100 g/day 
All studies – RR=0.72 (0.62-0.83), n=15 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.82 (0.66-1.01), n=4 
United Sates – RR=0.80 (0.67-0.96), n=2 
Asia – RR=0.68 (0.43-1.06), n=5 
South America – RR=0.56 (0.38-0.82), n=4 
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
Not specifically stated 
 
No language restrictions 
8 case-control No Fruits (general) 
Per 100 g/d increment 
RR=0.56 (0.42-0.74), n=8, I2=78.6% 
 
Citrus fruit 
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CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Per 50 g/d increment 
RR=0.70 (0.56-0.88), n=7, I2=88.1% 
Soerjomataram, 
2010[77] 
EC 
(risk, 
incidence, 
mortality) 
Not stated Not stated 
 
Restricted to European studies published in English up to 
December 2008 
6 
 
1 cohort 
5 case-control 
No Per 1 g/d increment 
RR=0.995 (0.994-0.997), n=6 
Liu, 2013[79] ESCC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2012) 
 
Citation tracking 
[esophag* AND (neoplasm OR carcinoma OR cancer)] 
combined with “nutrition OR diet OR lifestyle OR fruit OR 
vegetable”; a similar search was done using the word 
“oesophag*,” a common British spelling for esophagus 
 
Restricted to studies published in English 
32 
 
5 cohort 
27 case-control 
No Highest vs. lowest fruits intake 
All studies – RR=0.53 (0.44-0.64), n=29, I2=73.7%, 
Egger test: p=0.128, Begg test: p=0.268 
Only ESCC – RR=0.51 (0.40-0.64), n=17, I2=66.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.68 (0.55-0.86), n=5, I2=25.1% 
Case-control – RR=0.51 (0.41-0.63), n=24, I2=71.5% 
Population-based case-control – RR=0.73 (0.58-
0.92), n=6, I2=0.0% 
Hospital-based case-control – RR=0.44 (0.34-0.57), 
n=18, I2=74.9% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.37 (0.22-0.63), n=7, I2=78.1% 
USA – RR=0.40 (0.18-0.92), n=3, I2=66.9% 
South America – RR=0.41 (0.29-0.56), n=3, I2=72.9% 
Asia – RR=0.67 (0.56-0.79), n=16, I2=49.7% 
 
 
Per 100 g/d increment in fruits intake 
All studies – RR=0.61 (0.52-0.72), n=18, I2=89.7% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.87 (0.82-0.91), n=4, I2=0.0% 
Case-control – RR=0.52 (0.40-0.67), n=14, I2=88.7% 
Li, 2014[80] EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-2013) 
 
With the following text words and/or Medical Subject 
Heading (MeSH) terms: (1) “esophag*” OR “oesophag*”; 
(2) “neoplasm” OR “carcinoma” OR “adenocarcinoma”; (3) 
“nutrition” OR “diet” OR “dietary” OR “lifestyle” OR “fruit” 
OR “vegetable”; and (4) “case–control” OR “cohort” 
 
9 
 
3 cohort 
6 case-control 
Newcastle-
Ottawa scale 
High vs. low fruit intake 
All studies – RR=0.73 (0.55-0.98), n=9, I2=52.9%, 
Egger test: p=0.062, Begg test: p=0.118 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.99 (0.72-1.36), n=3, I2=0.0% 
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Citation tracking Restricted to studies published in English Case-control – RR=0.59 (0.38-0.90), n=6, I2=62.6% 
Population-based case-control – RR=0.61 (0.37-
1.02), n=4, I2=62.6% 
Hospital-based case-control – RR=0.40 (0.09-1.92), 
n=2, I2=81.3% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.58 (0.36-0.93), n=6, I2=62.6% 
USA – RR=0.90 (0.65-1.25), n=2, I2=0.0% 
 
Dose-response analysis 
Per 100g/day increment – RR=0.87 (0.76-0.99), n=6, 
I2=71.0% 
VEGETABLES       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA 1-3 per week or month vs. never/rarely 
Overall – OR=0.60 (0.43-0.84) 
Men – OR=0.56 (0.39-0.82) 
Women – OR=0.62 (0.28-1.39) 
 
Almost daily/daily vs. never/rarely 
Overall – OR=0.62 (0.44-0.88) 
Men – OR=0.64 (0.44-0.95) 
Women – OR=0.48 (0.21-1.08) 
Riboli, 2003[76] EC 
(risk, 
incidence, 
mortality) 
MEDLINE 
(1973-2001) 
 
Citation tracking 
Not stated 
 
Restricted to studies published in English 
13 
 
1 cohort 
12 case-control 
No Increase in vegetables intake of 100 g/day 
All studies – RR=0.89 (0.82-0.97), n=13 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.79 (0.68-0.92), n=4 
United Sates – RR=0.81 (0.67-0.98), n=2 
Asia – RR=0.98 (0.91-1.05), n=5 
South America – RR=0.68 (0.32-1.43), n=2 
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
5 case-control No Per 50 g/d increment 
Non-starchy vegetables – RR=0.87 (0.72-1.05), n=5, 
I2=93.9% 
Raw vegetables – RR=0.69 (0.58-0.83), n=5, I2=86.3% 
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Islami, 2009[81] ESCC 
(risk) 
MEDLINE, 
WEB OF 
SCIENCE, 
J-EAST, 
INDMED, 
VIP, 
CNKI 
(inception-2009) 
 
Citation tracking 
(oesophageal OR oesophageal OR oesophagus OR 
oesophagus) AND (cancer OR carcinoma OR 
adenocarcinoma OR neoplasm OR neoplasia OR 
neoplastic) AND (pickle OR pickled OR moldy OR 
fermented) 
 
Restricted to studies published in English or Chinese 
34 
 
3 cohort 
31 case-control 
No Highest vs. lowest pickled vegetables intake 
All studies – OR=2.08 (1.66-2.60), n=34, I2=88%, 
Egger test: p=0.01, Begg test: p=0.30 
After excluding the three most influential studies – 
OR=2.32 (1.92-2.81), n=31, I2=75% 
Large studies – OR=2.09 (1.67-2.63), n=30, I2=89% 
Adjusted results – OR=2.15 (1.64-2.81), n=24, 
I2=88% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=1.52 (0.82-1.63), n=3, I2=81% 
Case-control – OR=2.18 (1.75-2.73), n=31, I2=83% 
Population-based case-control – OR=2.11 (1.56-
2.85), n=18, I2=91% 
Soerjomataram, 
2010[77] 
EC 
(risk, 
incidence, 
mortality) 
Not stated Not stated 
 
Restricted to European studies published in English up to 
December 2008 
6 
 
1 cohort 
5 case-control 
No Per 1 g/d increment 
RR=0.996 (0.994-0.998), n=6 
Liu, 2013[79] ESCC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2012) 
 
Citation tracking 
[esophag* AND (neoplasm OR carcinoma OR cancer)] 
combined with “nutrition OR diet OR lifestyle OR fruit OR 
vegetable”; a similar search was done using the word 
“oesophag*,” a common British spelling for esophagus 
 
Restricted to studies published in English 
32 
 
5 cohort 
27 case-control 
No Highest vs. lowest vegetables intake 
All studies – RR=0.56 (0.45-0.69), n=24, I2=75.8%, 
Egger test: p=0.832, Begg test: p=0.980 
Only ESCC – RR=0.57 (0.43-0.75), n=15, I2=78.5% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.80 (0.61-1.07), n=5, I2=36.2% 
Case-control – RR=0.52 (0.41-0.65), n=19, I2=64.6% 
Population-based case-control – RR=0.57 (0.31-
1.05), n=4, I2=68.8% 
Hospital-based case-control – RR=0.51 (0.40-0.65), 
n=15, I2=66.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.30 (0.15-0.60), n=5, I2=81.9% 
USA – RR=0.65 (0.43-0.98), n=3, I2=0.0% 
South America – RR=0.68 (0.54-0.87), n=4, I2=0.0% 
Asia – RR=0.63 (0.47-0.83), n=12, I2=74.8% 
 
 
Per 100 g/d increment in vegetables intake 
All studies – RR=0.84 (0.78-0.92), n=15, I2=82.0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.92 (0.84-1.01), n=4, I2=82.0% 
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Case-control – RR=0.78 (0.69-0.89), n=11, I2=83.0% 
Li, 2014[80] EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-2013) 
 
Citation tracking 
With the following text words and/or Medical Subject 
Heading (MeSH) terms: (1) “esophag*” OR “oesophag*”; 
(2) “neoplasm” OR “carcinoma” OR “adenocarcinoma”; (3) 
“nutrition” OR “diet” OR “dietary” OR “lifestyle” OR “fruit” 
OR “vegetable”; and (4) “case–control” OR “cohort” 
 
Restricted to studies published in English 
9 
 
3 cohort 
6 case-control 
Newcastle-
Ottawa scale 
High vs. low vegetables intake 
All studies – RR=0.76 (0.59-0.96), n=9, I2=40.4%, 
Egger test: p=0.629, Begg test: p=0.348 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.76 (0.54-1.05), n=3, I2=0.0% 
Case-control – RR=0.75 (0.53-1.06), n=6, I2=58.5% 
Population-based case-control – RR=0.71 (0.45-
1.11), n=5, I2=64.7% 
Hospital-based case-control – RR=0.90 (0.61-1.33), 
n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.73 (0.46-1.14), n=5, I2=52.2% 
USA – RR=0.82 (0.58-1.14), n=3, I2=22.0% 
 
Dose-response analysis 
Per 100g/day increment – RR=0.91 (0.83-0.99), n=6, 
I2=22.9% 
FRUITS AND 
VEGETABLES 
      
Lock, 2005[75] EC 
(risk) 
MEDLINE, 
EMBASE, 
COCHRANE 
(1980-2000) 
CAB Abstracts 
(1987-2000) 
 
Citation tracking 
“fruit” or “vegetables” and “coronary heart disease”, 
“cerebrovascular disorder”, “lung”, “colorectal”, 
“stomach” and “esophageal”, “neoplasms” and “cancer”; 
all search terms were linked to MESH headings and 
exploded 
 
Restricted to studies published in English 
32 
 
4 cohort 
28 case-control 
No Change per increase of 80 g per day in intake of fruit 
and vegetables, by age group 
15-29 years – RR=0.94 (0.88-1.01) 
30-44 years – RR=0.94 (0.88-1.01) 
45-59 years – RR=0.94 (0.88-1.01) 
60-69 years – RR=0.94 (0.88-1.01) 
70-79 years – RR=0.95 (0.89-1.02) 
≥ 80 years – RR=0.97 (0.91-1.04) 
Li, 2014[80] EAC 
(risk) 
MEDLINE 
(inception-
2013), 
EMBASE 
(inception-2013) 
 
Citation tracking 
With the following text words and/or Medical Subject 
Heading (MeSH) terms: (1) “esophag*” OR “oesophag*”; 
(2) “neoplasm” OR “carcinoma” OR “adenocarcinoma”; (3) 
“nutrition” OR “diet” OR “dietary” OR “lifestyle” OR “fruit” 
OR “vegetable”; and (4) “case–control” OR “cohort” 
 
Restricted to studies published in English 
5 
 
1 cohort 
4 case-control 
Newcastle-
Ottawa scale 
High vs. low fruits and vegetables intake 
All studies – RR=0.68 (0.49-0.93), n=5, I2=38.9% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=0.99 (0.61-1.61), n=1 
Case-control – RR=0.61 (0.44-0.84), n=4, I2=20.7% 
Population-based case-control – RR=0.65 (0.49-
0.86), n=3, I2=0.0% 
Hospital-based case-control – RR=0.25 (0.07-0.86), 
n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – RR=0.54 (0.32-0.82), n=3, I2=25.1% 
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USA – RR=0.99 (0.61-1.61), n=1 
 
Dose-response analysis 
Per 100g/day increment – RR=0.88 (0.78-0.98), n=4, 
I2=84.0% 
MILK AND DAIRY 
PRODUCTS 
      
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
5 
 
1 cohort 
4 case-control 
No Per 20 g/d increment 
Cohort – RR=0.90 (0.83-0.98), n=1 
Case-control – RR=0.89 (0.78-1.01), n=4, I2=64.6% 
EGGS       
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
5 
 
1 cohort 
4 case-control 
No Per 50 g/d increment 
Cohort – RR=1.18 (0.96-1.45), n=1 
Case-control – RR=1.28 (0.98-1.66), n=4, I2=82.2% 
FAT INTAKE       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Almost daily/daily vs. never/rarely 
Overall – OR=1.42 (1.03-1.94) 
Men – OR=1.57 (1.09-2.26) 
Women – OR=1.09 (0.56-2.10) 
BARBECUE       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
NA 5 case-control NA Almost daily/daily vs. never/rarely 
Overall – OR=1.22 (0.85-1.76) 
180 | Defining predictive models of the variation in esophageal cancer incidence 
based case-
control studies 
conducted in 
high-risk areas in 
South America 
Men – OR=1.44 (0.95-2.18) 
Women – OR=0.87 (0.35-2.15) 
CEREALS       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Almost daily/daily vs. never/rarely 
Overall – OR=0.64 (0.38-1.10) 
Men – OR=0.61 (0.33-1.12) 
Women – OR=0.49 (0.14-1.66) 
DIETARY FIBER       
Coleman, 2013[84] ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE, 
WEB OF SCIENCE 
(inception-2012) 
 
Citation tracking 
Dietary fibre/fiber,fibre/fiber,cellulose,cereal fibre/fiber, 
fruit fibre/fiber, vegetable fibre/fiber, soluble fibre/fiber, 
insoluble fibre/fiber; (o)esophageal neoplasm(s), 
(o)esophageal cancer, (o)esophageal adenocarcinoma, 
(o)esophageal squamous cell carcinoma, Barrett(’s) 
(o)esophagus, columnar lined epithelium, specialized 
intestinal metaplasia, (o)esophageal squamous dysplasia 
 
No language restrictions 
13 case-control No Highest vs. lowest total dietary fiber intake 
EAC – RR=0.66 (0.44-0.98), n=8, I2=83% 
ESCC – RR=0.61 (0.31-1.20), n=5, I2=87% 
Egger test: p=0.51 
SALT INTAKE       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Almost daily/daily vs. 1-3/week or month 
Overall – OR=1.94 (1.40-2.69) 
Men – OR=2.11 (1.48-3.01) 
Women – OR=1.17 (0.45-3.04) 
ZINC INTAKE       
Li, 2014[87] EC, ESCC, EAC 
(risk) 
MEDLINE, 
EMBASE 
(inception-2013) 
 
Citation tracking 
“zinc” OR “zn”; “colorectal” OR “colon” OR “rectal”; 
“gastric” OR “stomach”, “esophagus” OR “esophageal 
squamous cell carcinoma”, “cancer” OR “tumor” OR 
“carcinoma” OR “neoplasm” 
 
Restricted to studies published in English or Chinese 
6 case-control Newcastle-
Ottawa scale 
Highest vs. lowest zinc intake 
All studies – RR=0.72 (0.44-1.17), n=6, I2=74.5%, no 
publication bias 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=0.96 (0.57-1.62), I2=73.1% 
ESCC – RR=0.79 (0.43-1.47), I2=71.5% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – RR=0.43 (0.21-0.86), I2=44.1% 
America and Europe – RR=0.89 (0.55-1.45), I2=72.9% 
Papers | 181 
FOLATE       
Larsson, 2006[94] EC, ESCC, EAC 
(risk) 
MEDLINE 
(1966-2006) 
 
Citation tracking 
folate, folic acid, or MTHFR in combination with cancer, 
neoplasm, or the individual cancer sites 
 
No language restrictions 
7 case-control No Highest vs. lowest dietary intake 
All studies – RR=0.62 (0.53-0.72), n=7, I2=0%, Egger 
test: p=0.33 
 
ACCORDING TO TUMOR TYPE 
EAC – RR=0.50 (0.39-0.65), n=3, I2=0% 
ESCC – RR=0.66 (0.53-0.83), n=4, I2=0% 
 
ACCORDING TO STUDY DESIGN 
Population-based – RR=0.52 (0.42-0.65), n=3 
Hospital-based – RR=0.74 (0.59-0.92), n=4 
Liu, 2011[101] EC 
(risk) 
MEDLINE, 
EMBASE, 
CBD 
(inception-2011) 
Not specified 6 case-control No Highest vs. lowest dietary intake 
OR=0.60 (0.50-0.70), n=8 
Tio, 2014[95] EC, ESCC, EAC 
(risk) 
MEDLINE 
(1946-2013), 
EMBASE 
(1949-2013), 
CCC (1998-2013) 
 
Citation tracking 
folate, folic acid, or vitamin B9, and esophageal, gastric, 
stomach, or pancreatic cancer, neoplasm, squamous cell 
carcinoma, or adenocarcinoma 
9 case-control No Highest vs. lowest dietary intake 
Overall – OR=0.59 (0.51-0.69), n=9, I2=21.1%, Egger 
test: p=0.09 
ESCC – OR=0.63 (0.44-0.89), n=4, I2=47.7%, Egger 
test: p=0.12 
EAC – OR=0.57 (0.43-0.76), n=3, I2=44.9%, Egger 
test: p=0.85 
ACRYLAMIDE       
Pelucchi, 2011[86] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-
2009), 
Web site 
established by 
World Health 
Organization and 
Food and 
Agricultural 
Organization for 
acrylamide 
research 
 
Citation tracking 
(acrylamide OR glycidamide) AND (cancer OR neoplasm OR 
tumor) 
 
No language restrictions 
2 
 
1 cohort 
1 case-control 
No Highest vs. lowest level of intake 
RR=0.93 (0.66-1.31), n=2 
 
10 μg/day increase in exposure 
RR=0.98 (0.91-1.06), n=2 
EAC – RR=1.00 (0.85-1.17), n=1 
ESCC – RR=0.95 (0.78-1.16), n=1 
 
High vs. low intake of fried/baked potatoes 
RR=1.0 (0.7-1.5), n=1 
Pelucchi, 2015[85] EC 
(risk) 
MEDLINE, 
EMBASE 
(2009-2014) 
 
Citation tracking 
(acrylamide OR glycidamide) AND (cancer OR neoplasm 
OR tumor) AND (diet OR dietary OR food OR foods) 
 
No language restrictions 
4 
 
2 cohort 
2 case-control 
No Highest vs. lowest level of intake 
RR=1.14 (0.93-1.38), n=4 
Never/former smokers – RR=1.27 (0.91-1.77), n=3 
 
ACCORDING TO STUDY DESIGN 
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Cohort – RR=1.01 (0.71-1.43), n=2 
Case-control – RR=1.20 (0.94-1.53), n=2 
 
10 μg/day increase in intake 
RR=1.03 (0.99-1.07), n=4 
ANTIOXIDANTS       
Kubo, 2007[98] EAC 
(risk) 
MEDLINE 
(1966-2006), 
WEB OF SCIENCE 
 
Citation tracking 
medical subject headings (MeSH) or keywords “Esophag∗ 
AND (adenocarcinoma OR carcinoma OR cancer)” 
combined with any combination of the following terms: 
antioxidant, ascorbic acid, vitamin C, vitamin E, selenium, 
carotenoids, beta-carotene, or vitamin A; a similar search 
was performed using the word “oesophagus,” a common 
British spelling for esophagus; identical searches were 
performed using “gastric cardia and (adenocarcinoma OR 
carcinoma OR cancer)” 
 
No language restrictions 
5 case-control No Highest vs. lowest dietary intake 
Vitamin C – RR=0.49 (0.39-0.62), n=4 
Vitamin E – RR=0.80 (0.63-1.03), n=3 
Beta-carotene/Vitamin A – RR=0.46 (0.36-0.59), n=4 
CAROTENOIDS       
Ge, 2013[88] EC, ESCC, EAC 
(risk) 
MEDLINE, 
COCHRANE, 
WEB OF 
SCIENCE, 
SCOPUS, 
CNKI, 
CBM 
(inception-2012) 
 
Citation tracking 
“Esophageal Neoplasms”, “esophag*” and the British 
spelling form “oesophag*” with combination of any of the 
following terms: “cancer”, “tumor”, “carcinoma”, 
“neoplasm”, and “malignancy” OR “cancer of esophagus” 
AND carotenoids, including alpha-carotene, beta-
carotene, beta-cryptoxanthin, lutein, zeaxanthin, lycopene 
 
No language restrictions 
10 
 
1 cohort 
9 case-control 
No Highest vs. lowest beta-carotene intake 
All studies – OR=0.58 (0.44-0.77), n=10, I2=78.2% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=0.85 (0.38-1.90), n=1 
Population-based case-control – OR=0.48 (0.39-
0.57), n=5, I2=0.0%, Egger test: p=0.114, Begg test: 
p=0.142 
Hospital-based case-control – OR=0.71 (0.42-1.22), 
n=5, I2=88.3%, Egger test: p=0.800, Begg test: 
p=0.327 
 
ACCORDING TO TUMOR TYPE 
EAC – OR=0.46 (0.36-0.58), n=4, I2=0.0%, Egger test: 
p=0.962, Begg test: p=1.000 
ESCC– OR=0.69 (0.45-1.07), n=6, I2=85.2%, Egger 
test: p=0.801, Begg test: p=0.851 
 
ACCORDING TO GEOGRAPHIC AREA 
Europe – OR=0.49 (0.37-0.66), n=7, I2=43.9%, Egger 
test: p=0.198, Begg test: p=0.133 
Asia– OR=0.91 (0.61-1.36), n=2, I2=9.5%, Begg test: 
p=0.317 
North America– OR=0.45 (0.36-0.56), n=3, I2=0.0%, 
Egger test: p=0.210, Begg test: p=0.117 
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South America– OR=1.47 (1.07-2.02), n=1 
 
 
Highest vs. lowest alpha-carotene intake 
All studies – OR=0.81 (0.70-0.94), n=3, I2=0.0% 
ESCC – OR=0.82 (0.70-0.95), I2=0.0% 
 
 
Highest vs. lowest lycopene intake 
All studies – OR=0.75 (0.64-0.86), n=2, I2=0.0% 
ESCC – OR=0.74 (0.64-0.86), I2=0.0% 
 
Highest vs. lowest beta-cryptoxanthin intake 
All studies – OR=0.80 (0.66-0.97), n=3, I2=50.9% 
ESCC – OR=0.83 (0.72-0.97), I2=42.6% 
 
Highest vs. lowest lutein and zeaxanthin  intake 
All studies – OR=0.71 (0.59-0.87), n=2, I2=0.0% 
MATÉ       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ever vs. never maté drinker 
Overall – OR=1.52 (1.10-2.12) 
Men – OR=1.34 (0.92-1.96) 
Women – OR=2.20 (1.08-4.47) 
 
Ex- vs. never maté drinker 
Overall – OR=1.87 (1.25-2.80) 
Men – OR=1.91 (1.20-3.06) 
Women – OR=1.74 (0.73-4.11) 
 
Current vs. never maté drinker 
Overall – OR=1.47 (1.06-2.05) 
Men – OR=1.27 (0.87-1.87) 
Women – OR=2.30 (1.13-4.71) 
 
Maté amount (l/day) 
Overall 
0.01-0.50 – OR=1.39 (0.98-1.98) 
0.51-1.00 – OR=1.34 (0.95-1.90) 
1.01-1.50 – OR=1.96 (1.27-3.03) 
1.51-2.00 – OR=2.03 (1.32-3.13) 
> 2.00 – OR=3.04 (1.84-5.02) 
 
Men 
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0.01-0.50 – OR=1.23 (0.81-1.86) 
0.51-1.00 – OR=1.20 (0.80-1.79) 
1.01-1.50 – OR=1.69 (1.03-2.77) 
1.51-2.00 – OR=1.69 (1.03-2.77) 
> 2.00 – OR=2.30 (1.32-4.03) 
 
Women 
0.01-0.50 – OR=1.93 (0.92-4.08) 
0.51-1.00 – OR=1.86 (0.85-4.05) 
1.01-1.50 – OR=4.03 (1.47-11.04) 
1.51-2.00 – OR=3.95 (1.53-10.20) 
> 2.00 – OR=11.65 (2.96-45.79) 
 
Years of maté drinking 
Overall 
1-29 – OR=1.40 (0.91-2.13) 
30-39 – OR=1.39 (0.93-2.07) 
40-49 – OR=1.53 (1.06-2.21) 
50-59 – OR=1.47 (1.00-2.17) 
> 60 – OR=1.92 (1.25-2.96) 
 
Men 
1-29 – OR=1.23 (0.76-2.00) 
30-39 – OR=1.32 (0.85-2.07) 
40-49 – OR=1.38 (0.91-2.10) 
50-59 – OR=1.27 (0.81-1.98) 
> 60 – OR=1.61 (0.96-2.72) 
 
Women 
1-29 – OR=1.83 (0.69-4.88) 
30-39 – OR=1.28 (0.49-3.37) 
40-49 – OR=2.10 (0.91-4.87) 
50-59 – OR=2.39 (1.06-5.37) 
> 60 – OR=2.71 (1.18-6.22) 
 
Years since quitting 
Overall 
1-9 – OR=1.53 (1.07-2.19) 
≥ 10 – OR=0.90 (0.59-1.36) 
 
Men 
1-9 – OR=1.78 (1.16-2.74) 
≥ 10 – OR=1.07 (0.67-1.69) 
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Women 
1-9 – OR=1.11 (0.55-2.25) 
≥ 10 – OR=0.39 (0.14-1.09) 
 
Maté temperature 
Overall 
Hot – OR=1.11 (0.84-1.47) 
Very hot – OR=1.89 (1.24-2.86) 
 
Men 
Hot – OR=1.06 (0.77-1.45) 
Very hot – OR=1.77 (1.09-2.86) 
 
Women 
Hot – OR=1.33 (0.71-2.49) 
Very hot – OR=2.47 (1.03-5.91) 
 
Joint effects of maté amount and temperature 
(reference category: ≤0.50 l/day & Cold/warm/hot) 
≤0.50 & Very hot – OR=0.99 (0.48-2.02) 
0.51-1.00 & Cold/warm/hot – OR=0.91 (0.71-1.16) 
0.51-1.00 & Very hot – OR=1.59 (0.96-2.63) 
1.01-1.50 & Cold/warm/hot – OR=1.50 (1.05-2.14) 
1.01-1.50 & Very hot – OR=0.73 (0.24-2.26) 
>1.50 & Cold/warm/hot – OR=1.38 (1.00-1.90) 
>1.50 & Very hot – OR=4.14 (2.24-7.67) 
 
Ever vs. never any very hot beverage (other than 
maté) 
Overall – OR=2.45 (1.72-3.49) 
Men – OR=2.28 (1.48-3.50) 
Women – OR=3.21 (1.66-6.23) 
 
Ever vs. never any very hot beverage (including 
maté) 
Overall – OR=2.07 (1.55-2.76) 
Men – OR=2.10 (1.49-2.96) 
Women – OR=2.18 (1.20-3.94) 
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
Not specifically stated 
 
No language restrictions 
5 case-control No Per 1 cup/d increment 
RR=1.16 (1.07-1.25), n=5, I2=88.7% 
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BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Andrici, 2013[97] ESCC 
(risk) 
MEDLINE (1946-
2012), EMBASE 
(1949-2012), 
CCC (1998-2012) 
 
Citation tracking 
‘Ilex paraguariensis’ OR ‘maté’ OR ‘yerba maté’ OR ‘erva 
maté’ OR ‘chimarraõ’ OR ‘cimarrón’ AND ‘cancer’ OR 
‘neoplasms’ 
 
No language restrictions 
9 case-control No Ever vs. never maté intake 
All studies – OR=2.57 (1.66-3.98), n=9, I2=65.4%, 
Egger test: p=0.229 
Adjusted results – OR=2.95 (1.70-5.13), n=5, 
I2=49.4% 
Unadjusted results – OR=2.31 (1.18-4.54), n=5, 
I2=74.0% 
 
 
Highest vs. lowest maté intake 
All studies – OR=2.76 (1.33-5.73), n=6, I2=74.3% 
TEA       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ever vs. never tea drinker 
Overall – OR=0.81 (0.62-1.06) 
Men – OR=0.80 (0.58-1.10) 
Women – OR=0.74 (0.45-1.22) 
 
Highest amount vs. never tea drinker 
Overall – OR=0.62 (0.40-0.96) 
Men – OR=0.53 (0.32-0.88) 
Women – OR=0.96 (0.39-2.34) 
 
Highest vs. lowest tea temperature 
Overall – OR=3.73 (1.41-9.89) 
Men – OR=8.73 (1.95-39.10) 
Women – OR=2.20 (0.42-11.56) 
Ishikawa, 2006[17] EC 
(incidence) 
Pooled analysis 
of two 
prospective 
cohort studies 
conducted in 
Miyagi 
Prefecture, 
Japan 
NA 2 cohort NA 1-2 cups/day vs. never or occasionally green tea 
consumption 
HR=1.03 (0.46-2.28) 
 
3-4 cups/day vs. never or occasionally green tea 
consumption 
HR=1.13 (0.53-2.42) 
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≥ 5 cups/d vs. never or occasionally green tea 
consumption 
HR=1.67 (0.89-3.16) 
WCRF, 2007[22] EC 
(risk, 
incidence, 
mortality) 
MEDLINE, 
WEB OF 
SCIENCE, 
CINAHL, 
BIOSIS, 
CAB Abstracts, 
LILACS, 
EMBASE 
COCHRANE 
(inception-2006) 
 
Citation tracking 
Not specifically stated 
 
No language restrictions 
7 case-control No Per 1 cup/d increment 
RR=0.95 (0.88-1.02), n=7, I2=60.6% 
Zheng, 2012[104] EC 
(risk) 
MEDLINE (1966-
2012), EMBASE 
(1980-2012), SCI 
(1945-2012), 
CBD (1981-
2012), 
WANFANG 
(1980-2012) 
 
Citation tracking 
“tea”, “food”, “diet”, “beverage”, “drinking” or “tea 
polyphenol” combined with “esophageal”, “oesophageal”, 
or “esophagus” 
 
Restricted to studies published in English or Chinese 
10 
 
2 cohort 
8 case-control 
No Highest vs. lowest green tea intake 
RR=0.76 (0.49-1.02), n=10, I2=73%, Egger test: 
p=0.16, Begg test: p=0.37 
 
ACCORDING TO SEX 
Men – RR=1.04 (0.48-1.60), n=2, I2=73% 
Women – RR=0.32 (0.10-0.54), n=2, I2=0% 
 
ACCORDING TO STUDY DESIGN 
Cohort – RR=1.67 (0.46-2.87), n=2, I2=0% 
Case-control – RR=0.72 (0.45-0.98), n=8, I2=76% 
Population-based case-control – RR=0.71 (0.43-
0.98), n=7, I2=78% 
Hospital-based case-control – RR=0.92 (0.49-2.32), 
n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
Japan – RR=1.67 (0.46-2.87), n=2, I2=0% 
China – RR=0.73 (0.44-1.02), n=7, I2=79% 
Northern Iran – RR=0.65 (0.32-1.31), n=1 
Sang, 2013[103] EC 
(risk) 
MEDLINE, 
EMBASE, 
COCHRANE 
(inception-2012) 
 
 
(tea OR catechin OR green tea OR beverages OR diet OR 
drinking OR lifestyle OR dietary) AND (esophageal OR 
digestive) AND (cancer OR tumor OR neoplasm OR 
carcinoma) 
 
Restricted to studies published in English 
12 
 
2 cohort 
10 case-control 
No Highest vs. lowest green tea intake 
All studies – RR=1.09 (0.76-1.55), n=12, I2=75.6%, 
Egger test: p=0.94, Begg test: p=0.945 
 
ACCORDING TO SEX 
Men – RR=1.06 (0.75-1.52), n=7, I2=74% 
Women – RR=0.46 (0.28-0.74), n=2, I2=0% 
Both – RR=1.34 (0.88-2.03), n=5, I2=51.4% 
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ACCORDING TO STUDY DESIGN 
Cohort – RR=1.68 (0.89-3.16), n=2, I2=0% 
Case-control – RR=1.01 (0.68-1.50), n=10, I2=79.1% 
Population-based case-control – RR=0.80 (0.41-
1.56), n=4, I2=81.1% 
Hospital-based case-control – RR=1.24 (0.65-2.37), 
n=5, I2=83.2% 
Nested-based case-control – RR=0.87 (0.38-2.01), 
n=1 
 
ACCORDING TO GEOGRAPHIC AREA 
China – RR=1.01 (0.63-1.62), n=8, I2=83.6% 
Japan – RR=1.42 (0.88-2.28), n=3, I2=0% 
Iran – RR=0.89 (0.38-2.09), n=1 
Zheng, 2013[89] EC, ESCC 
(risk) 
MEDLINE, WEB 
OF SCIENCE, 
CNKI, VIP 
(inception-2011) 
 
Citation tracking 
(tea OR polyphenol OR catechin, OR coffee OR caffeine OR 
beverages OR diet OR drinking) AND (esophageal OR 
esophagus OR oesophagus OR oesophageal) AND (cancer 
OR neoplasm OR tumor OR carcinoma) 
 
Restricted to studies published in English or Chinese 
24 
 
4 cohort 
20 case-control 
No Highest vs. lowest green tea intake 
All studies – OR=0.77 (0.57-1.04), n=16, I2=72.0%, 
Egger test: p=0.05 
Adjusted for tea temperature – OR=0.69 (0.49-0.96), 
n=3, I2=69.9% 
Adjusted for alcohol drinking or smoking – OR=0.81 
(0.59-1.09), n=13, I2=68.8% 
 
ACCORDING TO SEX 
Men – OR=1.07 (0.75-1.52), n=5, I2=54.0% 
Women – OR=0.32 (0.17-0.59), n=2, I2=0.0% 
Both – OR=0.70 (0.45-1.10), n=9, I2=75.4% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=1.68 (0.89-3.16), n=2, I2=0.0% 
Case-control – OR=0.70 (0.51-0.96), n=14, I2=73.8% 
Population-based case-control – OR=0.64 (0.43-
0.95), n=11, I2=79.3% 
Hospital-based case-control – OR=0.86 (0.58-1.25), 
n=3, I2=0.0% 
Case control from China – OR=0.64 (0.44-0.95), 
n=11, I2=79.4% 
Case-control out of China – OR=0.85 (0.57-1.25), 
n=3, I2=0.0% 
 
ACCORDING TO GEOGRAPHIC AREA 
China – OR=0.64 (0.44-0.95), n=11, I2=79.4% 
Japan – OR=1.10 (0.71-1.72), n=4, I2=29.7% 
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Iran – OR=0.89 (0.38-2.09), n=1 
 
ACCORDING TO TUMOR TYPE 
ESCC – OR=0.66 (0.33-1.33), n=5, I2=71.5% 
Not reported – OR=0.79 (0.56-1.12), n=11, I2=74.0% 
 
 
Per 2 cups/d increase in green tea intake 
OR=0.97 (0.87-1.08) 
 
 
Highest vs. lowest black tea intake 
All studies – OR=1.35 (0.86-2.11), n=3, I2=0.0%, 
Egger test: p=0.925 
COFFEE       
Castellsagué, 
2000a[78] 
ESCC 
(risk) 
Pooled analysis 
of hospital-
based case-
control studies 
conducted in 
high-risk areas in 
South America 
NA 5 case-control NA Ever vs. never coffee drinker 
Overall – OR=1.04 (0.83-1.30) 
Men – OR=1.09 (0.84-1.41) 
Women – OR=0.89 (0.53-1.49) 
 
Highest amount vs. never coffee drinker 
Overall – OR=1.26 (0.88-1.81) 
Men – OR=1.19 (0.80-1.78) 
Women – OR=1.68 (0.72-3.93) 
 
Highest vs. lowest coffee temperature 
Overall – OR=1.01 (0.52-1.98) 
Men – OR=0.76 (0.35-1.64) 
Women – OR=3.46 (0.45-26.57) 
 
 
Ever vs. never coffee with milk drinker 
Overall – OR=1.15 (0.94-1.42) 
Men – OR=1.09 (0.86-1.38) 
Women – OR=1.44 (0.90-2.29) 
 
Highest amount vs. never coffee with milk drinker 
Overall – OR=1.31 (0.89-1.95) 
Men – OR=1.14 (0.72-1.81) 
Women – OR=2.12 (0.91-4.93) 
 
Highest vs. lowest coffee with milk temperature 
Overall – OR=2.29 (1.37-3.81) 
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Men – OR=2.22 (1.20-4.10) 
Women – OR=2.82 (0.94-8.45) 
Turati, 2011[90] ESCC, EAC 
(risk) 
MEDLINE 
(inception-2009) 
 
Citation tracking 
(coffee OR caffeine OR beverages OR diet OR drinking) 
AND (oral OR pharyngeal OR oropharyngeal OR 
oropharynx OR pharynx OR mouth OR hypopharyngeal OR 
hypopharynx OR laryngeal OR larynx OR head OR neck OR 
esophagus OR oesophagus OR esophageal OR 
oesophageal OR aerodigestive) AND (cancer OR carcinoma 
OR tumor OR neoplasm) AND risk 
 
Restricted to studies published in English 
9 
 
1 cohort 
8 case-control 
No Highest vs. lowest coffee intake 
EAC – RR=1.18 (0.81-1.71), n=3, I2=43.7% 
ESCC – RR=0.87 (0.65-1.17), n=7, I2=74.6% 
ESCC (case-control studies) – RR=0.92 (0.67-1.27), 
n=6 
ESCC (cohort studies) – RR=0.60 (0.37-0.97), n=1 
Yu, 2011[102] EC 
(incidence) 
MEDLINE (1966-
2010), EMBASE 
(1985-2010), 
SCIE (1945-2010) 
 
Citation tracking 
coffee combined with cancer or neoplasm or carcinoma 
 
Restricted to studies published in English 
2 cohort No Highest vs. lowest coffee intake 
RR=0.55 (0.37-0.74), n=2, I2=0.0% 
Zheng, 2013[89] EC, ESCC, EAC 
(risk) 
MEDLINE, WEB 
OF SCIENCE, 
CNKI, VIP 
(inception-2011) 
 
Citation tracking 
(tea OR polyphenol OR catechin, OR coffee OR caffeine OR 
beverages OR diet OR drinking) AND (esophageal OR 
esophagus OR oesophagus OR oesophageal) AND (cancer 
OR neoplasm OR tumor OR carcinoma) 
 
Restricted to studies published in English or Chinese 
24 
 
4 cohort 
20 case-control 
No Highest vs. lowest coffee intake 
All studies – OR=0.88 (0.76-1.01), n=17, I2=38.4%, 
Egger test: p=0.53 
Adjusted for alcohol drinking or smoking – OR=0.89 
(0.77-1.03), n=16, I2=37.6% 
 
ACCORDING TO SEX 
Men – OR=0.82 (0.58-1.15), n=4, I2=48.6% 
Women – OR=1.68 (0.72-3.93), n=1 
Both – OR=0.88 (0.75-1.04), n=12, I2=36.6% 
 
ACCORDING TO STUDY DESIGN 
Cohort – OR=0.88 (0.65-1.19), n=5, I2=31.3% 
Case-control – OR=0.88 (0.74-1.04), n=12, I2=44.8% 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – OR=0.67 (0.55-0.82), n=7, I2=0.0% 
Europe – OR=0.95 (0.78-1.15), n=6, I2=38.5% 
Others – OR=1.13 (0.82-1.57), n=4, I2=40.3% 
 
ACCORDING TO TUMOR TYPE 
EAC – OR=0.88 (0.67-1.17), n=3, I2=55.5% 
ESCC – OR=1.00 (0.80-1.25), n=8, I2=44.1% 
Not reported – OR=0.69 (0.56-0.87), n=6, I2=0.0% 
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Per 2 cups/d increase in coffee intake 
OR=1.00 (0.89-1.12) 
SOFT DRINKS       
Boyle, 2014[91] EC, ESCC, EAC 
(risk) 
MEDLINE, 
ISI WEB OF 
KNOWLEDGE 
(inception-2012) 
 
Citation tracking 
With the key words ‘carbonated beverages’, ‘carbonated 
soda’, ‘carbonated sodas’, ‘coca cola’, ‘coca-cola’, ‘soft 
drinks’, ‘carbonated drinks’, ‘carbonated soft drinks’, ‘soft 
drink consumption’, ‘cola beverages’, ‘sweetened 
beverages’, ‘sugar-sweetened’, ‘sports drinks’, ‘soda pop’, 
‘fizzy drinks’, ‘tonic’, ‘cancer’, ‘neoplasms’ 
 
No language restrictions. 
5 
 
1 cohort 
4 case-control 
No Highest vs. lowest intake 
 
EC 
RR=0.82 (0.57-1.20), n=4, I2=0% 
 
EAC 
RR=0.80 (0.45-1.41), n=4, I2=55% 
 
ESCC 
RR=0.73 (0.46-1.15), n=4, I2=18% 
HOT BEVERAGES 
AND FOODS 
      
Chen, 2015[105] EC, ESCC, EAC 
(risk) 
MEDLINE 
(inception-
2014), 
EMBASE 
(inception-
2014), 
ISI WEB OF 
KNOWLEDGE 
(inception-2014) 
 
Citation tracking 
using the string ‘(esophageal OR oesophageal) AND 
(cancer OR carcinoma OR neoplasm) AND (tea OR maté 
OR coffee OR beverage OR liquid OR alcohol OR food OR 
diet)’ 
 
Restricted to studies published in English 
39 case-control Newcastle-
Ottawa scale 
Hot beverages and/or foods 
EC 
All studies – OR=1.82 (1.53-2.17), n=39, I2=90.3%, 
Egger test: p=0.121, Begg test: p=0.557 
 
ACCORDING TO SEX 
Men – OR=2.36 (1.53-3.65), n=8, I2=87.6% 
Women – OR=2.45 (1.51-3.98), n=7, I2=85.6% 
Both – OR=1.78 (1.49-2.16), n=37, I2=89.3% 
 
ACCORDING TO STUDY QUALITY 
Score ≥ 7 – OR=2.73 (2.06-3.62), n=2, I2=12.9% 
Score < 7 – OR=1.78 (1.49-2.14), n=45, I2=90.4 
 
ACCORDING TO GEOGRAPHIC AREA 
Asia – OR=2.06 (1.62-2.61), n=28, I2=91.7% 
South America – OR=1.52 (1.25-1.85), n=13, 
I2=66.7% 
Europe – OR=0.95 (0.68-1.34), n=5, I2=62.4% 
Africa – OR=12.78 (6.95-23.50), n=1 
 
ACCORDING TO TUMOR TYPE 
ESCC – OR=1.60 (1.29-2.00), n=26, I2=88.7% 
EAC – OR=0.79 (0.53-1.16), n=4, I2=50.3% 
Not reported – OR=2.35 (1.90-2.91), n=20, I2=80.7% 
 
Hot beverages 
All studies – OR=1.77 (1.39-2.25), n=23, I2=92.8% 
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Tea – OR=1.88 (1.16-3.07), n=8, I2=94.3% 
Maté – OR=1.72 (1.43-2.07), n=10, I2=47.5% 
 
Hot foods 
All studies – OR=2.09 (1.71-2.56), n=10, I2=57.8% 
 
Hot beverages and foods 
All studies – OR=1.73 (1.18-2.53), n=7, I2=68.2% 
EC: esophageal cancer; EAC: esophageal adenocarcinoma; ESCC: esophageal squamous cell carcinoma; NA: Not available; CI: confidence interval; n: number of studies; I2: heterogeneity statistic (percentage of variance in 
a meta-analysis that is attributable to study heterogeneity); RR: relative risk; OR: odds ratio; HR: hazard ratio; IR: incidence rate; S: synergy index (ratio of the observed excess risk in individuals exposed to both factors 
relative to the expected excess risk assuming that both exposures are independent risk factors). 
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Supplementary Table 2: Quality assessment of the studies included in the systematic review, using the AMSTAR tool. For each 
question, answer “yes” was marked with a plus, “no” with a cross, and “not applicable” with a triangle. 
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Supplementary Figure 1: Flow-chart of the systematic review. 
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Supplementary Figure 2: Forests plots of overall and sex-specific associations between alcohol drinking cessation (A) and tobacco 
smoking cessation (B) and the occurrence of esophageal cancer. RR: relative risk, CI: confidence interval, ESCC: esophageal squamous 
cell carcinoma, EC: esophageal cancer. 
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Supplementary Figure 3: Forest plot of overall and sex-specific associations between BMI and the occurrence of esophageal cancer, 
by histological subtype. RR: relative risk, CI: confidence interval, ESCC: esophageal squamous cell carcinoma, EAC: esophageal 
adenocarcinoma. 
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Supplementary Figure 4: Forest plot of overall and sex-specific associations between fruit and vegetable consumption and the 
occurrence of esophageal cancer, by histological subtype. RR: relative risk, CI: confidence interval, ESCC: esophageal squamous cell 
carcinoma, EAC: esophageal adenocarcinoma. 
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ABSTRACT 
Background: Variations in the exposure to risk factors may be used to explain past cancer trends 
and to predict its future burden. This study aimed to develop a model able to describe and 
predict the variation of esophageal cancer incidence in 1995-2005, taking into account changes 
in exposures to risk factors in different countries. 
Methods: We adapted an existing model to calculate the expected variation in the number of 
esophageal cancer cases, between 1995 and 2005, in Australia, Japan, Italy, Portugal, the United 
Kingdom (UK) and the United States of America, due to changes in exposures to risk factors, 
taking into account the corresponding lag times. Analyses were based on country-specific data 
of cancer incidence and exposures to risk factors. We computed 95% credibility intervals for 
each estimate through Monte Carlo simulation methods. 
Results: Absolute deviations between the number of cases predicted and those observed in 2005 
ranged between 1.8% in Japan and 23.6% in the UK among men; 0.0% in Japan and 18.0% in 
Australia among women. In Italy and Japan, deviations did not exceed 3%. The UK registered the 
worst model performance. The variation in esophageal cancer incidence was mainly influenced 
by changes in fruit and red meat intake, and body mass index. For nearly half of the sex- and 
histological type-specific predictions performed, the credibility intervals included the observed 
number of cases. 
Conclusion: This study proposes a framework for the analysis of the contribution of changes in 
exposure to different factors to esophageal cancer incidence trends and for long-term 
predictions at a population level. 
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INTRODUCTION 
Esophageal cancer is one of the most lethal cancers[1], with relatively small differences in survival 
across the most developed countries and over time[2, 3]. Squamous cell carcinoma (ESCC) and 
adenocarcinoma (EAC) are the major histological types of esophageal cancer. These show 
markedly different incidence and mortality trends, reflecting essentially differences in the 
contribution of the different risk factors to their occurrence in distinct settings[4]. While smoking 
and a low consumption of fruits and vegetables increase the risk of both subtypes, alcohol 
drinking increases ESCC risk, but not EAC, which is associated with overweight/obesity and 
gastroesophageal reflux (GERD)[5-8]. 
Some studies have evaluated the impact of the exposure to risk factors on esophageal cancer 
incidence/mortality rates at a given time through the corresponding population attributable 
fractions (PAFs)[9, 10]. However, to our knowledge, the relation between the trends in the 
exposures to all major determinants of esophageal cancer and the variation in its incidence has 
not been comprehensively assessed. Furthermore, the most widely used models to predict 
future cancer rates incorporate age, period and/or cohort effects[11-14], instead of the actual 
variations in the exposure to risk factors. 
This study aimed to develop a model able to describe and predict the variation of esophageal 
cancer incidence by histological type in different countries, namely Australia, Italy, Japan, 
Portugal, the United Kingdom (UK) and the United States of America (USA), taking into account 
the changes in the exposures to risk factors in each setting. 
 
METHODS 
We adapted an existing model (IMPACT), which was originally developed to explain the trends 
in mortality from a non-communicable disease other than cancer, namely coronary heart 
disease; after its validation, this model has been used in several countries[15, 16]. Briefly, it 
calculates the number of deaths prevented or postponed which are explained by changes in past 
exposures to different risk factors and treatments, and then provides a combined overall 
estimate. 
Using a similar methodological approach, we developed a model to explain and predict 
esophageal cancer incidence. We calculated the number of esophageal cancer cases prevented 
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(CP) between 1995 and 2005, in individuals aged 15 years or older, based on past exposures to 
risk factors, as summarized in Figure 1; positive figures for CP indicate that the number of cases 
decreased due to the variation in exposure to the risk factors, whereas negative values reflect 
an increase in incidence. The risk factors considered in the present study were the following: 
tobacco smoking, body mass index (BMI), and fruit, vegetable and red meat consumption for 
both histological subtypes; Helicobacter pylori (H. pylori) infection for EAC alone; and alcohol 
drinking and its interaction with smoking for ESCC alone. 
 
 
Figure 1: Data required for the proposed model and methods for the calculation of the number of cases prevented (CP) due to 
variations in exposure to risk factors. 
 
Association between modifiable exposures and esophageal cancer 
Estimates of the magnitude of association between these factors and ESCC and/or EAC were 
obtained from published meta-analyses, by sex, whenever available, or overall, otherwise. 
Regarding fruit and vegetable intake, estimates were obtained by geographical area (Asia, 
Europe and the USA), for esophageal cancer as a whole[17]; no specific estimate was found for 
Australia, so the overall relative risks (RR) estimates were used[17]. Cohort studies included in the 
selected meta-analyses were assessed to estimate the most likely lags between exposure and 
outcome, based on the magnitude of the effects found in studies with different follow-up 
periods. The RR estimates, the lag periods considered for each combination of risk factor and 
the respective outcome, as well as the corresponding sources of information are summarized in 
Supplemental Table 1. 
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Prevalence of exposure to risk factors 
Data on the prevalence of exposure to risk factors were collected, by sex and age group (15-44, 
45-54, 55-64, 65-74 and 75+), from the World Health Organization (WHO) Global Infobase[18], 
country-specific national health and nutrition surveys, and literature searches, for two time 
periods (1995 and 2005, minus the lag time considered for each determinant). When data was 
not available for the specific years of interest, we estimated the levels of exposure after a linear 
regression analysis using observed values for at least two other periods. Since data on the joint 
consumption of alcohol and tobacco are scarce and not usually evaluated in national health 
surveys, a single paper with representative data from the general population in each country 
was used to estimate the sex-specific proportion of alcohol drinkers among smokers; this 
proportion was assumed constant over time and it was applied to the prevalence of ever 
smokers and that of ever drinkers, as applicable, to yield estimates of separate and joint 
consumption. For H. pylori infection, we selected all population-based studies assessing the 
infection through serologic methods in each of the considered countries among those identified 
in a previous systematic review[19], and performed linear regression analyses to estimate the 
prevalence of exposure for the years of interest, by age group. Estimates of the levels of 
exposure in the adult population in each of the selected countries and the corresponding data 
sources are summarized in Supplemental Table 2; trends in the exposures to risk factors were 
very heterogeneous across countries, with various patterns being observed according to the risk 
factor and by sex. 
 
Esophageal cancer incidence by subtype 
Esophageal cancer incidence data were obtained from the Cancer Incidence in Five Continents 
online database, CI5-plus[20], for Australia, Italy, Japan, the UK and the USA; these countries were 
chosen to represent different ratios of the number of incident cases of the main histological 
types of esophageal cancer and a small proportion of cases of unspecified subtype, and to 
include distinct patterns of variation in ESCC and EAC incidence rates. Data from different cancer 
registries in these countries were aggregated to ensure the highest geographic coverage. For 
Portugal, data were retrieved from the North Region Cancer Registry, which covers 
approximately 30% of the national population and has reported the highest esophageal cancer 
incidence rates in the country[21]. 
The number of cases diagnosed in 1995 and 2005 in each country was estimated as the average 
of the 1994-1996 and 2004-2006 periods, respectively, to increase stability in the results. Data 
were collected by sex, age group (15-44, 45-54, 55-64, 65-74 and 75+ years) and histological 
type. Population figures for those periods were those presented by each cancer registry. The 
years 1995 and 2005 were chosen based on cancer data availability, as information provided by 
CI5-plus covers the years up to 2007.  
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Between 1995 and 2005, the esophageal cancer age-standardized (World standard 
population[22]) incidence rates (ASIR) increased for both sexes in Japan and the UK, while they 
increased among men and decreased among women in Australia, Portugal and the USA; in Italy, 
rates decreased among men and were stable among women. Patterns by subtype were very 
heterogeneous; for ESCC, Australia, Italy and the USA had decreasing ASIR for both sexes, Japan 
presented opposite trends, Portugal had increasing ASIR among men and decreasing among 
women, while the UK presented stable ASIR for both sexes. For EAC, ASIR increased in all settings 
among men, while among women they increased in Australia and the UK, but remained stable 
for other countries, with values below 0.5 per 100 000 (Figure 2). 
 
 
UK: United Kingdom; USA: United States of America. 
Figure 2: Age-standardized (World standard population) incidence rates (ASIR) per 100 000 of esophageal cancer in 1995 and 2005, 
by histological type, country and sex.  
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Calculation of the number of cases prevented (CP) 
For continuous variables, namely BMI, and fruit, vegetable and red meat consumption, the 
number of CP was calculated as the product of three variables: the number of cases expected in 
2005 (if 1995 rates persisted), the absolute reduction in the mean exposure between 1995 and 
2005, and the regression coefficient quantifying the increase in risk of developing the disease by 
a unit increase in the exposure. For dichotomous variables, namely smoking, alcohol drinking 
and H. pylori infection, PAFs were calculated, for 1995 and 2005, as (P×(RR−1))/(1+P×(RR−1)), 
where P is the prevalence of the risk factor (in each year minus the lag time) and RR is the relative 
risk for that exposure. The number of CP was then estimated as the number of cases expected 
in 2005 if 1995 rates had persisted, multiplied by the difference between the PAFs in 2005 and 
that in 1995. Thus, CPs should be interpreted as the number of cases that were prevented (as 
compared to the number of cases expected had rates in 1995 persisted) due to variations in 
exposures to risk factors. 
The numbers of CP as a result of risk factor changes were quantified for each histological type 
(ESCC and EAC), by sex and by age group (15-44, 45-54, 55-64, 65-74, 75+), to account for 
potential differences in effects across these strata. Estimates were then added to obtain CP at 
all ages, for ESCC and EAC (separately and combined), by sex. 
 
Predictions for 2005 
The number of cases predicted for 2005 by the model based on the trends in the exposure to 
risk factors (named henceforth the “risk factors’ model”) was estimated as the difference 
between the number of expected cases for 2005, had the 1995 rates persisted (named 
henceforth the “naive model”), and the number of CP. For each country, we computed the 
percent difference between the number of cases predicted by the models for 2005 and the ones 
observed, by sex and histological type; this reflects the deviation between the incident cases 
predicted by the models and those observed. When the number of predicted cases was lower 
than that of the observed cases, a negative value was presented for this proportion. We then 
compared the deviations obtained by the risk factors’ model with those obtained by the naive 
model. 
 
Precision of the estimates 
We computed 95% credibility intervals for each estimate, through Monte Carlo simulation 
methods[23], by using 95% confidence intervals, when available, or ±20% otherwise, of both the 
prevalence of (for categorical variables) or mean (for continuous variables) exposures and the 
corresponding RR or regression coefficient, as applicable. We generated 1000 replicates 
assuming Normal distributions for the ln RR and for the regression coefficients.  
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RESULTS 
Table 1 depicts the comparison between the subtype- and sex-specific numbers of cases 
observed in 2005 with the ones expected by the naive model, and the ones predicted by the risk 
factors’ model. When combining the estimates for both subtypes, absolute deviations between 
the number of cases predicted and those observed in 2005 ranged between 1.8% (1220 
predicted vs. 1242 observed, in Japan) and 23.6% (2293 vs. 3003, in the UK) among men, and 
between 0.0% (30 vs. 30, in Japan) and 18.0% (373 vs. 316, in Australia) among women. For 
ESCC, the deviations ranged between 1.0% in Japan and 22.5% in Portugal among men, and 
between 0.0% in Portugal and 25.3% in Australia among women; for EAC, corresponding values 
were 5.1% in Australia and 29.7% in Italy among men, and 0.0% in Portugal and 31.5% in the 
USA among women. 
 
Table 1: Number of esophageal cancer cases observed, expected (had the 1995 rates persisted – “naive model”) and predicted for 
2005 (based on trends in the exposure to risk factors – “risk factors’ model”), by subtype, country and sex. 
    
Cases  
observed  
1995 
Cases  
observed  
2005 
Cases  
expected  
2005 
Cases  
prevented  
(CP) 
CP  
explained  
by model 
Cases  
predicted  
2005 
95% credibility 
interval 
% difference  
expected vs.  
observed  
% difference  
predicted vs.  
observed  
Esophageal cancer               
  Australia                   
     Men 526 704 689 -15 -43 732 681 ; 801 -2.1 4.0 
     Women 295 316 373 57 0 373 351 ; 411 18.0 18.0 
  Italy                   
     Men 105 114 121 7 4 117 109 ; 123 6.1 2.6 
     Women 32 36 38 2 1 37 35 ; 41 5.6 2.8 
  Japan                   
     Men 830 1242 1099 -143 -121 1220 1158 ; 1332 -11.5 -1.8 
     Women 157 210 210 0 -5 215 205 ; 227 0.0 2.4 
  Portugal                   
     Men 96 141 115 -26 7 108 100 ; 117 -18.4 -23.4 
     Women 29 30 36 6 6 30 27 ; 33 20.0 0.0 
  UK                   
     Men 2017 3003 2476 -527 183 2293 2079 ; 2462 -17.5 -23.6 
     Women 1306 1618 1493 -125 84 1409 1285 ; 1490 -7.7 -12.9 
  USA                   
     Men 694 884 849 -35 87 762 724 ; 817 -4.0 -13.8 
     Women 256 278 297 19 23 274 253 ; 289 6.8 -1.4 
ESCC             
  Australia                   
     Men 247 256 324 68 17 307 277 ; 334 26.6 19.9 
     Women 232 221 293 72 16 277 254 ; 305 32.6 25.3 
  Italy                   
     Men 80 77 92 15 1 91 82 ; 95 19.5 18.2 
     Women 26 28 31 3 1 30 28 ; 34 10.7 7.1 
  Japan                   
     Men 799 1183 1057 -126 -114 1171 1110 ; 1283 -10.7 -1.0 
     Women 150 200 200 0 -3 203 194 ; 216 0.0 1.5 
  Portugal                   
     Men 82 120 99 -21 6 93 86 ; 101 -17.5 -22.5 
     Women 25 24 31 7 7 24 21 ; 27 29.2 0.0 
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  UK                   
     Men 643 784 791 7 103 688 625 ; 734 0.9 -12.2 
     Women 831 959 951 -8 103 848 766 ; 905 -0.8 -11.6 
  USA                   
     Men 339 285 415 130 110 305 278 ; 337 45.6 7.0 
     Women 191 167 222 55 24 198 180 ; 212 32.9 18.6 
EAC             
  Australia                   
     Men 279 448 365 -83 -60 425 383 ; 487 -18.5 -5.1 
     Women 63 95 80 -15 -16 96 87 ; 115 -15.8 1.1 
  Italy                   
     Men 25 37 29 -8 3 26 24 ; 30 -21.6 -29.7 
     Women 6 8 7 -1 0 7 6 ; 8 -12.5 -12.5 
  Japan                   
     Men 31 59 42 -17 -7 49 41 ; 60 -28.8 -16.9 
     Women 7 10 10 0 -2 12 9 ; 14 0.0 20.0 
  Portugal                   
     Men 14 21 16 -5 1 15 12 ; 19 -23.8 -28.6 
     Women 4 6 5 -1 -1 6 4 ; 7 -16.7 0.0 
  UK                   
     Men 1374 2219 1685 -534 80 1605 1400 ; 1766 -24.1 -27.7 
     Women 475 659 542 -117 -19 561 483 ; 622 -17.8 -14.9 
  USA                   
     Men 355 599 434 -165 -23 457 428 ; 500 -27.5 -23.7 
     Women 65 111 75 -36 -1 76 68 ; 84 -32.4 -31.5 
ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma, UK: United Kingdom; USA: United States of America. 
 
In Australia, in analyses performed by subtype and by sex the risk factors’ model showed lower 
deviations from what was observed in 2005 than the naive model; when combining both 
subtypes, the differences between the two models were attenuated (Table 1). In Italy, for ESCC, 
the risk factors’ model had a better performance than the naive model, but not for EAC. In Japan, 
the risk factors’ model presented lower deviations from what was observed, except for EAC 
among women, who presented a much lower number of incident cases. In Italy and Japan, when 
considering both subtypes combined, the risk factors’ model yielded deviations that did not 
exceed 3%. In Portugal, the cases estimated by the risk factors’ model were closer to the 
observed among women, but not among men. Globally, the worst performance of the risk 
factors’ model was found in the UK, where the risk factors’ model only presented a lower 
deviation than the naive model (14.9% vs. 17.8%) for EAC among women. For the USA, the risk 
factors’ model performed better than the naive model when considering each subtype 
separately, although the differences between the observed and the predicted number of cases 
were still high, especially for EAC (23.7% among men, 31.5% among women); for both subtypes 
combined, the risk factors’ model had lower deviations than the naive among women (1.4% vs. 
6.8%), but not among men (13.8% vs. 4.0%). 
In Japan, the credibility intervals obtained for predictions using the risk factors’ model always 
included the number of cases observed in 2005, while the opposite was verified in the UK (Table 
1). In the remaining countries, when considering subtype-specific data, the credibility intervals 
did not always include the number of cases observed in 2005.  
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The contribution of each risk factor to the number of CP explained by the model varied widely 
between countries, sexes and cancer subtypes (Figure 3, Supplemental Tables 3 and 4). For both 
subtypes combined, CP explained by the model were mainly influenced by changes in the mean 
daily intake of fruits (24% in Australia and Japan, 28% in Portugal) and red meat (35% in Australia, 
30% in Japan, 32% in the USA), among men, and in mean BMI (from 17% in Italy and Japan to 
44% in Portugal), among women. For ESCC, the largest contributors to the number of CP 
explained were mean daily fruit and red meat intake among men and mean BMI among women, 
though among Italian men the separate and joint consumption of alcohol and tobacco 
accounted for 84% of CP explained by the model for ESCC. For EAC, the most relevant changes 
in exposures were related to H. pylori infection in both sexes, red meat intake among men and 
BMI among women. Due to the much lower incidence of EAC than that of ESCC in Italy, Japan 
and Portugal, very few cases were explained by the risk factors’ model. In Italy, the number of 
CP was -1 and the model yielded no variations in EAC due to changes in the exposure to risk 
factors among women. In Portugal, the model predicted a decrease of one EAC case among men 
due to an increasing consumption of fruits, and an increase in the same amount among women 
due to the increasing mean BMI. 
 
ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma; UK: United Kingdom; USA: United States of America H. pylori: 
Helicobacter pylori; BMI: Body mass index. 
 
Figure 3: Proportion of cases prevented between 1995 and 2005 due to changes in the exposure to risk factors, by cancer subtype 
and by sex.  
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DISCUSSION 
This study quantified the contribution of a comprehensive set of risk factors to the observed 
changes in esophageal cancer incidence, by adapting the methods used by the IMPACT model. 
In general, the proposed model yielded closer predictions to the observed number of cases than 
the naive assumption of constant rates over the years, which is relevant, since the latter will 
always have a good fit when the rates remain relatively constant. Nearly half of the sex- and 
histological type-specific predictions of the risk factors’ model had a 95% credibility interval 
including the observed number of cases, regardless of the patterns of variation in esophageal 
cancer incidence. The performance of the model was consistently better for Japan, and worse 
for the UK. 
The ability of a model to explain cancer incidence trends and to perform predictions depends on 
the extent to which its underlying assumptions are met. The understanding of the etiology of 
multifactorial conditions and the accurate quantification of the relation between the different 
risk factors and the disease of interest is essential. In the present study, we assessed the current 
knowledge on the etiology of esophageal cancer, using several systematic reviews and meta-
analyses to accurately quantify the association between each risk factor and the occurrence of 
esophageal cancer’s major histological types. The use of RR estimates specific by geographical 
area, sex and histological type is expected to have contributed to improve the fit of the proposed 
model. An example is the use of very different RR estimates for Japan and the other countries 
regarding the separate and joint consumption of alcohol and tobacco; alcohol consumption in 
Asia is much lower than that in Western countries[24], and therefore the lower RR estimates from 
Asian populations[25] hindered an overestimation of prevented cases between 1995 and 2005 
due to these risk factors, which ultimately led to a good model fit in that country. For red meat 
consumption, a more recent meta-analysis than the one we used reported separate RR 
estimates according to geographical area, yielding a higher risk of ESCC in Europe than in Asia, 
and a higher risk of EAC in the USA than in Europe[26]; however, these estimates could not be 
used in our model since they did not report the change in risk due to increases/decreases in 
consumption, but rather the comparison between the highest and lowest categories of 
exposure. Processed meat has been increasingly mentioned as a risk factor for esophageal 
cancer, with meta-analyses suggesting a higher risk of ESCC with its consumption than the one 
observed for red meat[27, 28]. In the present study, this risk factor could not be included since data 
on daily per capita consumption is not routinely collected in national health surveys and there 
is no proxy data such as availability from the Food and Agriculture Organization balance 
sheets[29]. However, part of its effect is likely included in the results obtained for red meat and 
the inclusion of both risk factors would probably yield an overestimation of cases attributable 
to these risk factors. A relevant risk factor for EAC that could not be considered in the model 
was GERD. Data on the exposure to GERD were scarce and methodologically heterogeneous, 
mainly because of the multiplicity of definitions across studies. Even though some systematic 
reviews have been performed on the prevalence of GERD, aiming to describe worldwide trends 
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on this exposure[30, 31], there were few population-based studies, and even fewer reported 
prevalence based on the same definition. Furthermore, as studies included in those reviews 
were mainly performed since the 1990’s and changes in GERD-related therapies have been 
observed in more recent years[32, 33], current exposure trends might not allow a reasonably 
accurate estimation of the levels of exposure in the period relevant for this study.  Nevertheless, 
although the variation in the frequency of GERD cannot be accurately quantified, an increase 
could be expected[30], which would have contributed for a greater number of cases of EAC, and 
therefore a better fit of the model in most countries. 
In addition to the knowledge on cancer etiology, the performance of a prediction method relies 
heavily on the quality of the data included in the analyses. The quality of information regarding 
the exposure to risk factors is crucial and was probably the most important determinant of the 
yielding of the risk factors’ model. As we selected several countries with different patterns of 
incidence trends regarding esophageal cancer’s major histological types, they also show various 
trends of exposure to risk factors. When data on exposure to a risk factor could not be obtained 
for the years of interest, we used linear regression analyses with other periods of observation, 
which may have led to bias in the estimated CP since the observed changes in more recent years 
may not have been verified in the past. The direction of this bias is not straightforward as it 
depends on the risk factor, varying across countries and between sexes. An assumption of a 
linear trend in the period of analysis is also needed[15]. Finally, as cancer onset is preceded by an 
often long latency period, which is imprecisely estimated, the observed changes in exposures to 
risk factors in a 10-year period may not suffice to be reflected in cancer incidence estimates, 
which further compromises the yielding of the model. 
When the risk factors’ model yielded better predictions for 2005 than the naive model, the 
changes in risk factors that most contributed to changes in incidence were mean BMI, and red 
meat and fruit intake for ESCC, and the prevalence of H. pylori and mean BMI for EAC. For ESCC, 
this may seem surprising given that alcohol drinking and tobacco smoking are commonly 
referred to as the most relevant risk factors of ESCC, with more than 90% of ESCC cases being 
attributed to these risk factors in some Western countries[5]. However, our results were 
consistent with these values, with PAFs among men regarding the interaction between drinking 
and smoking in 2005 ranging between 80.6% in Portugal and 90.1% in the UK (values not shown). 
Since there were no large differences in PAFs between 1995 and 2005, the contribution of 
alcohol and tobacco to changes in incidence in that period was smaller than that of the 
aforementioned risk factors in most settings. 
Regarding the outcomes considered in this study, namely the number of incident cases of 
esophageal cancer by subtype, data for most countries were derived from CI5-plus[20]. This 
database aggregates annual data from selected cancer registries included in consecutive CI5 
publications to allow for time trends analyses using high-quality information. For Portugal, data 
was retrieved from the North Region Cancer Registry; although data from this registry are not 
available in CI5-plus, they were included in CI5-IX[34], which covers the period 1998-2002, a 
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similar time frame to the one used in the present study, ensuring the quality of the data used. 
Furthermore, with the exception of Japan, where the proportion of cases of unspecified subtype 
(20.7% in 1994-1996, 15.5% in 2004-2006) was above that of EAC (2.9% in 1994-1996, 3.8% in 
2004-2006), a low proportion of unspecified cases was observed in all countries, regardless of 
the predominant subtype in each setting. Nevertheless, the potential misclassification of gastric 
cardia tumors for EAC, which may have contributed to the increase in EAC rates observed in 
some countries[35], cannot be ignored, as it may lead to a spuriously higher difference between 
the observed and expected cases of EAC for 2005 and, ultimately, to a spuriously poor 
performance in some settings. This may be an explanation for the greater deviations between 
the number of predicted and observed cases in the UK, as cardia cancer cases comprise the 
majority of gastric tumors of specified location in the country[36]. 
This study adds to previous research on this topic a framework for analysis of the contribution 
of the variation in the exposure to different factors known to be associated with esophageal 
cancer, as well as for long-term predictions of ESCC and EAC at a population level. 
Nearly half of the strata-specific predictions of the risk factors’ model had a 95% credibility 
interval including the observed number of cases, regardless of the patterns of variation in 
esophageal cancer incidence. These results show the potential of this model for the planning of 
interventions and to define cancer control policies, but future studies, taking into account a 
wider period of time between exposure assessments, while also using more accurate estimates 
of the variation in the exposure to the risk factors, are expected to improve the accuracy of the 
predictions. 
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Supplemental Table 1: Relative risk (RR) estimates, corresponding 95% confidence intervals (95%CI) and lag times for the association between risk factors and incidence of esophageal cancer, by histological type. 
 
Outcome Risk factor 
Lag time 
(years) 
Categories of exposure Subgroup RR 95%CI 
Source of information 
on RR (author, year) 
ESCC Alcohol 15 Ever drinkers and never smokers vs. Men (non-Asian) 4.03 1.76-9.21 Castelsague, 1999[37] 
 never drinkers and never smokers Women (non-Asian) 1.42 0.82-2.48 Castelsague, 1999[37] 
   Asian 1.21 0.81-1.81 Prabhu, 2014[25] 
Tobacco 20 Ever smokers and never drinkers vs. 
never smokers and never drinkers 
Men (non-Asian) 4.45 2.09-9.47 Castelsague, 1999[37] 
  Women (non-Asian) 1.57 0.89-2.75 Castelsague, 1999[37] 
    Asian 1.36 1.14-1.61 Prabhu, 2014[25] 
 Alcohol x smoking 15 Ever drinkers and ever smokers vs. never 
drinkers and never smokers 
Men (non-Asian) 17.00 8.36-34.78 Castelsague, 1999[37] 
  Women (non-Asian) 7.26 3.68-14.33 Castelsague, 1999[37] 
    Asian 3.28 2.11-5.08 Prabhu, 2014[25] 
 Body mass index 10 Increasing risk per 5 kg/m2 Men 0.71 0.60-0.85 Renehan, 2008[8] 
 Women 0.57 0.47-0.69 Renehan, 2008[8] 
 Red meat consumption 10 Per 100g/day increase Overall 1.41 1.16-1.70 Qu, 2013[93] 
EAC H. pylori infection 20 Infected vs. non-infected Overall 0.57 0.44-0.73 Nie, 2014[38] 
 Tobacco 20 Ever vs. never smokers Men 2.10 1.71-2.59 Cook, 2010[39] 
  Ever vs. never smokers Women 1.74 1.21-2.51 Cook, 2010[39] 
 Body mass index 10 Per 5 kg/m2 increase Men 1.52 1.33-1.74 Renehan, 2008[8] 
  Women 1.51 1.31-1.74 Renehan, 2008[8] 
 Red meat consumption 10 Per 100g/day increase Overall 1.45 1.09-1.93 Huang, 2013[40] 
Esophageal cancer 
(irrespective of subtype) 
Fruit consumption 15 Per 100g/day increase Overall 0.72 0.62-0.83 Riboli, 2003[17] 
   Asia 0.68 0.43-1.06 Riboli, 2003[17] 
   Europe 0.82 0.66-1.01 Riboli, 2003[17] 
   USA 0.80 0.67-0.96 Riboli, 2003[17] 
Vegetable consumption 15 Per 100g/day increase Overall 0.89 0.82-0.97 Riboli, 2003[17] 
   Asia 0.98 0.91-1.05 Riboli, 2003[17] 
   Europe 0.79 0.68-0.92 Riboli, 2003[17] 
   USA 0.81 0.67-0.98 Riboli, 2003[17] 
ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma; H. pylori : Helicobacter pylori; USA: United States of America. 
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Supplemental Table 2: Estimates of exposure to risk factors, in 1995 and 2005 minus the lag times considered for each risk factor, 
by country and sex, in individuals aged 15 years or over. 
  
  
Men Women 
Sources of data 
  1995-lag 2005-lag 1995-lag 2005-lag 
Australia 
  Prevalence of ever drinkers and never smokers, % 44.7 45.2 53.9 55.3 [41, 42] 
  Prevalence of ever smokers and never drinkers, % 8.6 8.5 13.9 13.4 [41, 42] 
  Prevalence of ever drinkers and ever smokers, % 48.5 48.2 31.8 30.6 [41] 
  Prevalence of ever smokers, % 57.2 56.8 46.2 44.6 [42] 
  Prevalence of Helicobacter pylori infection, % 60.8 45.8 60.8 45.8 [19] 
  Mean body mass index, kg/m2 25.0 26.1 23.9 25.3 [43, 44]* 
  Mean fruit intake, g/d 175.9 158.2 206.5 157.6 [45] 
  Mean vegetable intake, g/d 299.3 289.2 242.9 233.1 [45] 
  Mean red meat intake, g/d 105.1 73 63.9 37.0 [46] 
Italy 
  Prevalence of ever drinkers and never smokers, % 30.1 38.2 56.9 54.5 [47-50] 
  Prevalence of ever smokers and never drinkers, % 5.7 4.5 5.2 5.6 [47, 51-53]* 
  Prevalence of ever drinkers and ever smokers, % 46.5 37.6 12.5 13.1 [47] 
  Prevalence of ever smokers, % 56.6 44.7 17.3 18.5 [51-53]* 
  Prevalence of Helicobacter pylori infection, % 50.3 46.1 50.3 46.1 [19] 
  Mean body mass index, kg/m2 26.0 26.4 26.3 25.6 [53, 54]* 
  Mean fruit intake, g/d 201.4 200.1 164.9 185.7 [55, 56] 
  Mean vegetable intake, g/d 209.9 219.2 219.7 217.4 [55, 56] 
  Mean red meat intake, g/d 68.0 66.0 59.0 55.0 [55, 56] 
Japan 
  Prevalence of ever drinkers and never smokers, % 10.1 11.8 1.3 2.8 [57, 58]* 
  Prevalence of ever smokers and never drinkers, % 15.6 14.6 4.1 5.5 [57, 58]* 
  Prevalence of ever drinkers and ever smokers, % 45.2 42.2 3.2 4.1 [57] 
  Prevalence of ever smokers, % 62.3 58.2 6.9 9.1 [58]* 
  Prevalence of Helicobacter pylori infection, % 76.2 65.2 76.2 65.2 [19]† 
  Mean body mass index, kg/m2 22.9 23.1 22.6 22.4 [59] 
  Mean fruit intake, g/d 133.2 116.3 163.3 146.2 [60] 
  Mean vegetable intake, g/d 323.6 307.5 289.3 283.1 [60] 
  Mean red meat intake, g/d 46.5 57.2 27.3 36.7 [60] 
Portugal 
  Prevalence of ever drinkers and never smokers, % 53.4 55.7 51.3 52.5 [61-64] 
  Prevalence of ever smokers and never drinkers, % 11.8 10.9 1.1 3.3 [61-67] 
  Prevalence of ever drinkers and ever smokers, % 34.1 31.5 1.4 3.1 [61] 
  Prevalence of ever smokers, % 49.3 44.9 4.2 6.9 [62-67] 
  Prevalence of Helicobacter pylori infection, % 80.1 78.5 80.1 78.5 [19]† 
  Mean body mass index, kg/m2 25.0 25.4 23.9 24.7 [62-64] 
  Mean fruit intake, g/d 209.1 230.6 246.1 270.7 [68, 69] 
  Mean vegetable intake, g/d 421.8 396.3 418.8 404.4 [68, 69] 
  Mean red meat intake, g/d 69.8 77.3 57.8 63.7 [68, 69] 
UK 
  Prevalence of ever drinkers and never smokers, % 51.6 56.3 56.8 61.9 [70, 71] 
  Prevalence of ever smokers and never drinkers, % 7.7 6.5 19.2 17.6 [70, 71] 
  Prevalence of ever drinkers and ever smokers, % 63.2 54.8 36.4 34.1 [70] 
  Prevalence of ever smokers, % 76.8 65.4 53.9 50.4 [71] 
  Prevalence of Helicobacter pylori infection, % 46.2 46.1 46.2 46.1 [19]† 
  Mean body mass index, kg/m2 25.1 25.6 24.7 25.6 [72, 73]* 
  Mean fruit intake, g/d 103.9 103.4 107.4 108.6 [74, 75] 
  Mean vegetable intake, g/d 73.1 110.1 55.5 97.7 [74, 75] 
  Mean red meat intake, g/d 86.7 85.7 43.1 48.1 [74, 75] 
USA 
  Prevalence of ever drinkers and never smokers, % 31.3 27.6 16.5 22.5 [76-78] 
  Prevalence of ever smokers and never drinkers, % 7.0 6.4 13.7 13.7 [76, 79, 80] 
  Prevalence of ever drinkers and ever smokers, % 60.2 54.5 32.1 31.9 [76] 
  Prevalence of ever smokers, % 70.0 63.7 45.8 45.7 [79, 80] 
  Prevalence of Helicobacter pylori infection, % 44.0 39.3 44.0 39.3 [19]† 
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  Mean body mass index, kg/m2 26.3 26.9 26.1 26.9 [81]* 
  Mean fruit intake, g/d 200.2 190.3 113.1 134.9 [82] 
  Mean vegetable intake, g/d 360.5 326.7 281.4 262.4 [83] 
  Mean red meat intake, g/d 100.0 83.3 57.5 46.9 [84] 
UK: United Kingdom; USA: United States of America. 
* Data retrieved from the World Health Organization Global Infobase[18].  
† Exposure for the year of interest estimated through regression analyses. 
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 Supplemental Table 3: Number of esophageal cancer cases prevented (n) between 1995 and 2005 due to changes in the exposure 
to risk factors, and corresponding 95% credibility intervals (CI), by histological type, among men. 
    Australia Italy Japan Portugal UK USA 
    n (95%CI) n (95%CI) n (95%CI) n (95%CI) n (95%CI) n (95%CI) 
Esophageal cancer             
  Prevalence of ever drinkers and never smokers -19 -8 -14 -2 -18 76 
    (-29 ; -6) (-10 ; -3) (-41 ; 4) (-5 ; 1) (-44 ; 8) (46 ; 92) 
  Prevalence of ever smokers and never drinkers 4 4 7 3 6 -1 
    (-6 ; 14) (2 ; 7) (-2 ; 14) (0 ; 5) (-17 ; 26) (-11 ; 9) 
  Prevalence of ever drinkers and ever smokers 2 4 36 2 5 0 
    (-3 ; 6) (2 ; 7) (-3 ; 76) (0 ; 5) (-4 ; 16) (-5 ; 5) 
  Prevalence of ever smokers 5 3 1 0 19 0 
    (-9 ; 17) (1 ; 4) (-1 ; 3) (0 ; 1) (-43 ; 85) (-16 ; 15) 
  Prevalence of H. pylori infection -46 0 -5 0 0 -14 
    (-95 ; -11) (-3 ; 1) (-15 ; 2) (-3 ; 3) (-135 ; 143) (-43 ; 11) 
  Mean body mass index -11 -1 -32 4 -63 -8 
    (-23 ; 3) (-1 ; 1) (-74 ; 3) (3 ; 7) (-111 ; -24) (-18 ; 2) 
  Mean fruit intake -52 0 -51 7 20 -15 
    (-84 ; -34) (-3 ; 3) (-113 ; 0) (3 ; 12) (-32 ; 83) (-32 ; -2) 
  Mean vegetable intake 0 2 0 -5 163 -9 
    (-3 ; 9) (0 ; 5) (-11 ; 7) (-9 ; -3) (136 ; 256) (-18 ; -2) 
  Mean red meat intake 74 0 -63 -2 51 58 
    (55 ; 93) (0 ; 2) (-96 ; -49) (-4 ; -1) (22 ; 80) (44 ; 76) 
ESCC             
  Prevalence of ever drinkers and never smokers -19 -8 -14 -2 -18 76 
    (-29 ; -6) (-10 ; -3) (-41 ; 4) (-5 ; 1) (-44 ; 8) (46 ; 92) 
  Prevalence of ever smokers and never drinkers 4 4 7 3 6 -1 
    (-6 ; 14) (2 ; 7) (-2 ; 14) (0 ; 5) (-17 ; 26) (-11 ; 9) 
  Prevalence of ever drinkers and ever smokers 2 4 36 2 5 0 
    (-3 ; 6) (2 ; 7) (-3 ; 76) (0 ; 5) (-4 ; 16) (-5 ; 5) 
  Mean body mass index 24 -1 -34 4 37 22 
    (16 ; 33) (-1 ; 1) (-75 ; 2) (3 ; 7) (22 ; 54) (15 ; 29) 
  Mean fruit intake -24 0 -49 6 7 -7 
    (-45 ; -12) (-3 ; 3) (-112 ; 1) (2 ; 11) (-17 ; 32) (-19 ; 1) 
  Mean vegetable intake 0 2 0 -5 52 -4 
    (-2 ; 5) (0 ; 4) (-11 ; 7) (-9 ; -2) (36 ; 87) (-10 ; 1) 
  Mean red meat intake 30 0 -60 -2 14 24 
    (24 ; 44) (0 ; 2) (-93 ; -47) (-4 ; -1) (7 ; 26) (20 ; 37) 
EAC             
  Prevalence of ever smokers 5 3 1 0 19 0 
    (-9 ; 17) (1 ; 4) (-1 ; 3) (0 ; 1) (-43 ; 85) (-16 ; 15) 
  Prevalence of H. pylori infection -46 0 -5 0 0 -14 
    (-95 ; -11) (-3 ; 1) (-15 ; 2) (-3 ; 3) (-135 ; 143) (-43 ; 11) 
  Mean body mass index -35 0 2 0 -100 -30 
    (-45 ; -25) (0 ; 0) (0 ; 3) (-1 ; 0) (-142 ; -64) (-37 ; -23) 
  Mean fruit intake -28 0 -2 1 13 -8 
    (-49 ; -13) (-1 ; 1) (-4 ; 0) (0 ; 2) (-33 ; 74) (-20 ; 2) 
  Mean vegetable intake 0 0 0 0 111 -5 
    (-3 ; 6) (0 ; 1) (0 ; 0) (-1 ; 0) (81 ; 190) (-11 ; 0) 
  Mean red meat intake 44 0 -3 0 37 34 
    (25 ; 56) (0 ; 0) (-4 ; -1) (0 ; 0) (9 ; 64) (19 ; 44) 
ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma; H. pylori: Helicobacter pylori; UK: United 
Kingdom; USA: United States of America. 
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Supplemental Table 4: Number of esophageal cancer cases prevented (n) between 1995 and 2005 due to changes in the exposure 
to risk factors, and corresponding 95% credibility intervals (CI), by histological type, among women. 
    Australia Italy Japan Portugal UK USA 
    n (95%CI) n (95%CI) n (95%CI) n (95%CI) n (95%CI) n (95%CI) 
Esophageal cancer             
  Prevalence of ever drinkers and never smokers -2 0 0 0 -12 -2 
    (-10 ; 6) (-1 ; 1) (0 ; 0) (-2 ; 0) (-37 ; 12) (-5 ; 2) 
  Prevalence of ever smokers and never drinkers 1 0 0 0 0 -2 
    (-4 ; 4) (0 ; 0) (0 ; 1) (0 ; 0) (-16 ; 14) (-6 ; 1) 
  Prevalence of ever drinkers and ever smokers -2 2 3 0 -13 -11 
    (-13 ; 10) (0 ; 3) (-1 ; 4) (0 ; 0) (-47 ; 22) (-18 ; -3) 
  Prevalence of ever smokers 0 0 0 0 -14 -3 
    (-3 ; 3) (0 ; 0) (0 ; 0) (0 ; 0) (-32 ; 5) (-5 ; -1) 
  Prevalence of H. pylori infection -10 0 -2 0 0 -3 
    (-24 ; -1) (-1 ; 0) (-4 ; 1) (-1 ; 1) (-61 ; 67) (-9 ; 3) 
  Mean body mass index 25 -2 5 4 41 13 
    (14 ; 36) (-4 ; -2) (1 ; 7) (3 ; 6) (5 ; 78) (6 ; 16) 
  Mean fruit intake -41 1 -4 2 -24 8 
    (-63 ; -30) (0 ; 3) (-14 ; 6) (0 ; 3) (-61 ; 4) (4 ; 16) 
  Mean vegetable intake -2 0 0 0 110 13 
    (-8 ; 0) (-1 ; 1) (-1 ; 2) (0 ; 1) (89 ; 166) (1 ; 25) 
  Mean red meat intake 31 0 -7 0 -4 10 
    (23 ; 42) (0 ; 0) (-11 ; -5) (0 ; 0) (-14 ; 4) (8 ; 14) 
ESCC             
  Prevalence of ever drinkers and never smokers -2 0 0 0 -12 -2 
    (-10 ; 6) (-1 ; 1) (0 ; 0) (-2 ; 0) (-37 ; 12) (-5 ; 2) 
  Prevalence of ever smokers and never drinkers 1 0 0 0 0 -2 
    (-4 ; 4) (0 ; 0) (0 ; 1) (0 ; 0) (-16 ; 14) (-6 ; 1) 
  Prevalence of ever drinkers and ever smokers -2 2 3 0 -13 -11 
    (-13 ; 10) (0 ; 3) (-1 ; 4) (0 ; 0) (-47 ; 22) (-18 ; -3) 
  Mean body mass index 31 -2 5 5 74 16 
    (20 ; 42) (-4 ; -2) (1 ; 7) (4 ; 7) (44 ; 107) (10 ; 19) 
  Mean fruit intake -32 1 -4 2 -14 6 
    (-53 ; -21) (0 ; 2) (-13 ; 6) (0 ; 3) (-45 ; 7) (2 ; 14) 
  Mean vegetable intake -2 0 0 0 70 10 
    (-8 ; 0) (-1 ; 1) (-1 ; 2) (0 ; 1) (51 ; 114) (-1 ; 21) 
  Mean red meat intake 22 0 -7 0 -2 7 
    (16 ; 34) (0 ; 0) (-11 ; -5) (0 ; 0) (-11 ; 3) (5 ; 11) 
EAC             
  Prevalence of ever smokers 0 0 0 0 -14 -3 
    (-3 ; 3) (0 ; 0) (0 ; 0) (0 ; 0) (-32 ; 5) (-5 ; -1) 
2323)   Prevalence of H. pylori infection -10 0 -2 0 0 -3 
    (-24 ; -1) (-1 ; 0) (-4 ; 1) (-1 ; 1) (-61 ; 67) (-9 ; 3) 
  Mean body mass index -6 0 0 -1 -33 -3 
    (-9 ; -4) (0 ; 0) (0 ; 0) (-1 ; 0) (-53 ; -17) (-5 ; -2) 
  Mean fruit intake -9 0 0 0 -10 2 
    (-15 ; -5) (0 ; 1) (0 ; 1) (0 ; 1) (-33 ; 5) (0 ; 4) 
  Mean vegetable intake 0 0 0 0 40 3 
    (-2 ; 0) (0 ; 0) (0 ; 0) (0 ; 0) (25 ; 69) (-1 ; 6) 
  Mean red meat intake 9 0 0 0 -2 3 
    (3 ; 11) (0 ; 0) (-1 ; 0) (0 ; 0) (-6 ; 5) (1 ; 4) 
ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma; H. pylori: Helicobacter pylori; UK: United 
Kingdom; USA: United States of America. 
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GENERAL DISCUSSION 
 
 
Decision making towards cancer prevention and control requires monitoring of trends in cancer 
incidence and accurate estimation of its burden in different settings. This thesis aimed at the 
development of a model able to describe and predict esophageal cancer incidence, so that it 
could be used in countries with various incidence patterns and trends regarding its major 
subtypes, ESCC and EAC. The proposed model, to explain the past and to predict the future 
variations in esophageal cancer incidence relied on an extensive and detailed collection of data, 
from numerous sources. 
We started by describing esophageal cancer incidence in different countries, in order to perceive 
the diversity in trends across different contexts, which should be taken into consideration in the 
development of the model (Papers I-III). Very different patterns by cancer subtype were 
observed among the selected countries and between sexes. In Northern Europe, EAC ASIR rose 
substantially among men and surpassed ESCC, similarly to what had been observed in the USA 
and Australia[125], whereas among women ESCC remained the predominant histological type. 
Northern Portugal presented slight increases in ASIR among men and a downward trend among 
women, mostly reflecting the trends in the incidence of ESCC, which is the major histological 
type in the region for both sexes. 
In Europe, ESCC rates followed the trends in alcohol consumption, decreasing in southern 
countries and stabilizing in northern countries, while EAC followed more consistently the trends 
in overweight/obesity, with more appreciable increases in northern Europe than in southern 
countries. Thus, the limitation of one of these factors could lead to the avoidance of a substantial 
proportion of cases at a population level.  
In order to accommodate the current knowledge on the etiology of esophageal cancer in the 
model to be developed and to take into account the variations in exposure to risk factors such 
as alcohol consumption or excess BMI, an accurate assessment of the strength of association 
between each risk factor and the occurrence of esophageal cancer had to be performed. We 
then conducted a systematic review of published meta-analyses on the associations between 
the major risk factors for esophageal cancer subtypes (Paper IV), which allowed for the 
description of existing studies in a standardized format, facilitating the selection of the most 
adequate RR estimates to use in the risk factors’ model.  
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Prediction models heavily rely on the quality of information used, either regarding the exposures 
or the outcomes. In this thesis, we used information on cancer incidence from high-quality 
registries, which complied with quality requirements from the CI5 publications. For Portugal, 
data was retrieved from the RORENO; although data from this registry are not available in CI5-
plus, they were included in CI5-IX[116], which covers the period 1998-2002, a similar time frame 
to the one used in the present study, ensuring the quality of the data used. However, some 
limitations in data collected must be discussed, namely regarding esophageal cancer subtypes. 
The increasing awareness of EAC may have led to the increase in its incidence rates, through 
misclassification of gastric cardia cancers[81]. Since data on gastric cancer sub-locations is not 
available from CI5-plus, we assessed CI5-X to inspect the proportions of gastric cancer by 
subtype in each of the countries considered for the development of the risk factors’ model, 
namely Australia, Italy, Japan, the UK and the USA. In these settings, the proportion of gastric 
cancer cases of unspecified location often exceeded 30% and was higher than that observed for 
cardia cancer. In Northern Portugal, the proportion of unspecified cases was also higher than 
that observed for cardia and non-cardia cancers (Paper III). Therefore, and although the 
proportion of esophageal cancer cases of unspecified morphology was globally low in the 
countries considered, the extent to which the misclassification of cardia for EAC may have 
influenced EAC incidence trends could not be accurately quantified. 
Regarding methodological issues of the applied methods, an important matter relates to the 
number of cases included in analyses. While the DH models are usually based on at least six 
consecutive years of data with 50 cases/deaths (all ages) recorded per year[90], the naive and the 
risk factors’ models do not present a clear requirement on sample size. However, cancers 
presenting a low number of cases are also more prone to random variations, increasing the 
potential for deviations between the observed and the predicted incidence using either of these 
models. To attenuate the effect of random variations in predictions and increase stability in 
results provided by the latter methods, in Paper V we estimated the number of cases diagnosed 
in the years of interest (1995 and 2005) as the average of 3-year periods.  
As esophageal cancer presents much smaller numbers of cases than other tumors, more stable 
estimates using our proposed methodology may be obtained for other outcomes. Also, our 
model heavily relies on accuracy of the estimates on the levels of exposure to several risk factors, 
which varies widely with time and across countries. In fact, this was probably the most important 
determinant of the deviations between predicted and observed values in some settings. A series 
of surveys on nationally representative samples of the population would constitute the ideal 
basis for the collection of these data (Papers III and V). However, for most distant years, the 
process of accessing information from such surveys or similar sources of information is very 
time-consuming and, sometimes, unsuccessful, either because the data were not collected for 
the risk factor of interest on given years, or the level of detail provided was insufficient to allow 
for a good performance of the model, or data collected in two different periods were not 
comparable due to changes in coding or questions asked to participants. This was one of the 
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major difficulties observed for alcohol consumption, for instance, since different surveys in the 
same country often measured consumption differently (e.g., prevalence of consumption in the 
month/year before the survey, number of drinks consumed per day/week). The major limitation 
in data collection was, however, observed for GERD. Data on exposure to GERD were scarce and 
very heterogeneous, mainly because of the multiplicity of definitions across studies. Even 
though some systematic reviews have been performed on the prevalence of GERD, aiming to 
describe worldwide trends on this exposure[126, 127], few population-based studies were found 
allowing for this comparison, and fewer reported prevalence based on the same definition, not 
allowing for an accurate quantification of the variation in the prevalence of this condition. Since 
most studies focusing on this determinant were conducted since the 1990’s and changes in 
GERD-related therapies have been observed since then[128, 129], using recent exposure trends 
might yield contradicting results to the increasing trends expected for this risk factor in past 
decades. The non-inclusion of this risk factor is a likely explanation for the poor performance of 
the risk factors’ model for EAC in some settings. 
The performance of the proposed model varied widely across countries and between sexes, with 
no evident association with the patterns of trends observed in different settings. Globally, the 
proposed model yielded predictions closer to the observed number of cases than the naive 
assumption of constant rates from the past. As expected, the naive model presented lower 
deviations from the reality when no relevant variations in incidence trends were observed over 
time, while the risk factors’ model provided better estimates in the other situations. On account 
of this limitation of the naive model, the advantage of using the risk factors’ model may be 
further increased when considering longer-term predictions, since in these cases an assumption 
of constant rates is unlikely for most cancers and, in particular, for esophageal tumors. 
To test this hypothesis, and in order to allow for comparisons between the three prediction 
methods used in the course of this work (DH, naive and risk factors’ models), we predicted the 
number of incident cases in Northern Portugal for the years 2010 and 2020, at ages 15 years and 
older. For the DH model, we used data on incidence trends observed up to 2000 and 2009, 
respectively. For the other two models, we used the years 2000 and 2009, respectively, as the 
basis to perform predictions. The comparison between the three models for the year 2010 is 
presented in Table 3. 
Using the three models to perform predictions for 2010, the last year with available data from 
RORENO, the closest results to the values observed in 2010 were yielded by the risk factors’ 
model, with deviations of 1.1% among men and 10.5% among women. On the other hand, the 
DH model presented the least accurate estimates. Thus, as it was hypothesized, for longer-term 
predictions, the performance of the risk factors’ model was better that that of simpler methods. 
When performing predictions to 2020, the risk factors’ model yielded estimates of an increase 
in the number of cases of 6.0% among men and 9.7% among women, while the naive model 
estimated increases of 10.7% and 16.1%, respectively, and the DH model estimated increases of 
20.2% and 3.2%.  
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Table 3. Comparison of the prediction models for the year 2010 in Northern Portugal. 
    Men Women 
Cases observed 
  
2000 135 34 
2010 186 38 
Cases predicted  
for 2010 
Naive model (n) 197 48 
DH model  
n (95% confidence interval) 
229  
(146-311) 
69  
(21-117) 
Risk factors’ model  
n (95% credibility interval) 
188  
(177-203) 
42  
(37-45) 
% deviation from  
observed cases in 2010 
Naive model  5.9 26.3 
DH model  23.1 81.6 
Risk factors’ model 1.1 10.5 
DH: Dyba and Hakulinen methods   
 
The major strengths of the model proposed in this thesis were the incorporation of detailed 
information on the exposure to the different risk factors, the separate assessment of esophageal 
cancer by subtype to incorporate the knowledge on the etiology of the disease and the 
evaluation of esophageal cancer as a multifactorial disease. These should be regarded as 
important steps towards a proper evaluation of the burden of disease related to this cancer.  
It will be necessary to define the appropriate balance between the complexity of the model, 
namely regarding the number of risk factors and the type of exposure information to be used, 
and the accuracy of the predictions needed for planning of interventions and to define cancer 
control policies.  
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CONCLUSIONS 
 
 
A marked increase in esophageal cancer incidence was observed in Western countries over the last 
decades. In Europe, increasing EAC incidence trends were observed in most countries, while ESCC 
rates have been decreasing or stabilizing over the last few decades. Nordic countries and the UK 
registered the steepest increases in EAC trends among men, and EAC is now the predominant 
histological type in those settings. In central and southern Europe, smaller rises in EAC were observed 
and ESCC remains the predominant subtype among men. Among European women, ESCC remained 
the predominant subtype and rates increased in some countries. 
Numerous systematic reviews and meta-analyses have been published regarding the association 
between esophageal cancer’s major risk factors and its occurrence. For some risk factors, the 
strength of association with esophageal cancer varied notoriously between histological types (e.g., 
tobacco smoking), and for others the association was only found significant for one of the subtypes 
(e.g., alcohol consumption).  
In most settings, the prevalence of tobacco smoking has been decreasing among men and increasing 
among women, and mean BMI has been found increasing for both sexes. The prevalence of alcohol 
consumption and the mean daily intake of fruit, vegetables and red meat presented heterogeneous 
patterns across countries and between sexes. The prevalence of H. pylori infection decreased 
worldwide, although different rates of improvement were observed between countries. 
A model aiming to describe and predict the trends in esophageal cancer incidence, taking into 
account the changes in the exposures to risk factors, showed that the trends were mainly influenced 
by changes in fruit and red meat intake, and body mass index, although differences were observed 
across countries with different patterns of variation of incidence rates. In Northern Portugal, 
predictions using the proposed model yielded closer values to the ones observed than other 
methods. This thesis adds to previous research on this topic a framework for analysis of the 
contribution of the variation in the exposure to different factors known to be associated with 
esophageal cancer, as well as for long-term predictions of ESCC and EAC at a population level. The 
results obtained in this work show the potential of this model for the planning of interventions and 
to define cancer control policies, but future studies, performing longer-term predictions, while also 
using more accurate estimates of the variation in the exposure to the risk factors, are expected to 
improve the accuracy of predictions. 
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